AU742593B2 - Disubstituted bicyclic heterocycles, their production and use as medicaments - Google Patents

Disubstituted bicyclic heterocycles, their production and use as medicaments Download PDF

Info

Publication number
AU742593B2
AU742593B2 AU63991/98A AU6399198A AU742593B2 AU 742593 B2 AU742593 B2 AU 742593B2 AU 63991/98 A AU63991/98 A AU 63991/98A AU 6399198 A AU6399198 A AU 6399198A AU 742593 B2 AU742593 B2 AU 742593B2
Authority
AU
Australia
Prior art keywords
group
methyl
denotes
amide
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU63991/98A
Other versions
AU6399198A (en
AU742593C (en
Inventor
Norbert Hauel
Henning Priepke
Uwe Ries
Jean-Marie Stassen
Wolfgang Wienen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26034058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU742593(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19706229A external-priority patent/DE19706229A1/en
Priority claimed from DE1997151939 external-priority patent/DE19751939A1/en
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical BOEHRINGER INGELHEIM PHARMA
Publication of AU6399198A publication Critical patent/AU6399198A/en
Application granted granted Critical
Publication of AU742593B2 publication Critical patent/AU742593B2/en
Publication of AU742593C publication Critical patent/AU742593C/en
Assigned to BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG reassignment BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Request to Amend Deed and Register Assignors: BOEHRINGER INGELHEIM PHARMA KG
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/74—Sulfur atoms substituted by carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

1 S017002pct.200 WO 98/37075 PCT/EP98/00865 Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions The present invention relates to new disubstituted bicyclic heterocycles of general formula Ra A Het B Ar E the tautomers, stereoisomers and mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases which have valuable properties.
The compounds of general formula I above wherein E denotes a cyano group are valuable intermediates for preparing the other compounds of general formula I, and the compounds of general formula I above wherein E denotes an RbNH-C(=NH)group, and the tautomers and stereoisomers thereof have useful pharmacological properties, particularly a thrombininhibiting activity and the effect of extending thrombin time.
The present application thus relates to the new compounds of general formula I above and the preparation thereof, pharmaceutical compositions containing the pharmacologically active compounds and the use thereof.
In the above general formula A denotes a carbonyl or sulphonyl group linked to the S benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno 2 moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R, group, B denotes an ethylene group, wherein a methylene group, linked either to the group Het or Ar, may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, carbonyl or -NR, group, wherein
R
i denotes a hydrogen atom or a C 1 _,-alkyl group, E denotes a cyano or RbNH-C(=NH)- group wherein Rb denotes a hydrogen atom, a hydroxy group, a C_..-alkyl group or a group which may be cleaved in vivo, Ar denotes a phenylene or naphthylene group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C 1 _--alkyl or Cl_ 3 -alkoxy group, a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted in the carbon skeleton by a C 1 3 -alkyl group, Het denotes a bicyclic heterocycle of formula I ,wherein X is a nitrogen atom and Y is an oxygen or sulphur atom or a nitrogen atom optionally substituted by a C.
6 -alkyl or
C
3 _,-cycloalkyl group, whilst additionally one or two non-angular methyne groups in the phenyl moiety of the -3above-mentioned bicyclic heterocycle may each be replaced by a nitrogen atom, or X denotes a methyne group optionally substituted by the group wherein R, is as hereinbefore defined, and Y denotes a nitrogen atom optionally substituted by a
C
16 alkyl or C 3 7 ,-cycloalkyl group, or Het denotes a group of the formula
R
1 1
-^N
NN
J
N
R
1 S I N
R
1
Z
4
~~U~G
or
R
1 ;1 wh erein
R
1
R
1 is as hereinbefore defined, Z denotes an oxygen or sulphur atom, one of the groups D or G denotes a nitrogen atom and the other group D or G denotes a methyne group, and Ra denotes a C 1 6 -alkyl group, a C,,-cycloalkyl group optionally substituted by a C 1 3 -alkyl group, wherein the
C
1 alkyl group may additionally be substituted by a carboxyl group or by a group which may be converted in vivo into a carboxy group, or an R 2
NR
3 group wherein R, denotes a C 1 alkyl group, which may be substituted by a carboxy, C 1 alkyloxycarbonyl, benzyloxycarbonyl, Cl- 3 -alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, trifluorosulphonylamino, trifluorosulphonylaminocarbonyl or 1H-tetrazolyl group, a C 2 4 -alkyl group substituted by a hydroxy, phenyl-
C
1 3 -alkoxy, carboxy-C.
3 -alkylamino, C1- 3 alkoxycarbonyl-C_ 3 -alkylamino, N- (Cl--alkyl) -carboxy-
C
1 3 -alkylamino or N- (C 1 alkyl) -C 1 3 -alkoxycarbonyl-C-a 3 alkylamino group, whilst in the abovementioned groups 5 the carbon atom in the a-position relative to the adjacent nitrogen atom may not be substituted, or a piperidinyl group optionally substituted by a
C,
3 -alkyl group and
R
3 denotes a hydrogen atom, a C_,--alkyl group, a
C
3 7 -cycloalkyl group optionally substituted by a
CI.
3 -alkyl group, a C 3 alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R2NR 3 group, a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a Ci- 3 -alkyl or Ci- 3 -alkoxy 15 group, a benzyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, piperidinyl or imidazolyl group optionally substituted by a Ci- 3 -alkyl group or R. 2 and R 3 together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxy or C, -alkoxycarbonyl group, onto which a phenyl ring may 25 additionally be fused.
The compounds of the above general formula I which contain a group capable of being cleaved in vivo are thus prodrugs and compounds of general formula I which contain two groups capable of being cleaved in vivo are so-called double prodrugs.
The phrase "a group which may be converted in vivo into a carboxy group" denotes, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol, in which the alcoholic moiety is preferably a C- 6 ,-alkanol, a phenyl-C 1 3 -alkanol, a C3.9-cycloalkanol, wherein a
C
5 -cycloalkanol may additionally be substituted by one or 6 two C 1 3 -alkyl groups, a C,- 5 -cycloalkanol, in which a methylene group in the 3- or 4-position is replaced by an oxygen atom or by an imino group optionally substituted by a C 1 alkyl, phenyl-Cl- 3 -alkyl, phenyl-C,,-alkoxycarbonyl or S C2- 6 -alkanoyl group, and the cycloalkanol moiety may additionally be substituted by one or two C 1 3 -alkyl groups, a C 4 7 -cycloalkenol, a C 3 -s-alkenol, a phenyl-C- 5 -alkenol, a
C
3 5 _-alkynol or phenyl-C-s-alkynol, with the proviso that no bond to the oxygen atom emanates from a carbon atom which carries a double or triple bond, a
C
3 8 -cycloalkyl-Cl- 3 -alkanol, a bicycloalkanol having a total of 8 to 10 carbon atoms, which may additionally be substituted in the bicycloalkyl moiety by one or two
C,
1 3 -alkyl groups, a 1,3-dihydro-3-oxo-l-isobenzofuranol or an alcohol of formula
R
4
-CO-O-(R
5
CR
6
-OH,
wherein
R
4 denotes a C 1 alkyl, C 5 -,-cycloalkyl, phenyl or phenyl-C.
3 -alkyl group,
R
5 denotes a hydrogen atom, a C 1 3 -alkyl, C,--cycloalkyl or phenyl group and R, denotes a hydrogen atom or a C,- 3 -alkyl group, or the phrase "a group which may be cleaved in vivo from an imino or amino group" denotes for example a hydroxy group, an acyl group such as a benzoyl- or pyridinoyl group or a
C
1 16 -alkanoyl group such as the formyl-, acetyl-, propionyl-, butanoyl-, pentanoyl- or hexanoyl group, an allyloxycarbonyl group, a C1- 16 -alkoxycarbonyl group such as the methoxycarbonyl-, ethoxycarbonyl-, propoxycarbonyl-, isopropoxycarbonyl-, butoxycarbonyl-, tert.-butoxycarbonyl-, pentoxycarbonyl-, hexoxycarbonyl-, E4Voctyloxycarbonyl-, nonyloxycarbonyl-, decyloxycarbonyl-, 0 undecyloxycarbonyl-, dodecyloxycarbonyl- or hexadecyloxycarbonyl group, a phenyl-C 1 -6-alkoxycarbonyl group such as the benzyloxycarbonyl-, phenylethoxycarbonylor phenyipropoxycarbonyl group, a C 1 3 -alkylsulphonyl-
C
2 4 -alkoxycarbonyl-, C 1 3 -alkoxy-C 2 4 -alkoxy-
C
2 4 -alkoxycarbonyl- or R 4
CO-O-(R
5
CR
6 )-O-CO-group, wherein
R
4 to R 6 are as hereinbefore defined.
Examples of preferred prodrug groups for a carboxy group include a C 1 6 -alkoxycarbonyl group such as the methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, n-pentyloxycarbonyl, n-hexyloxycarbonyl or cyclohexyloxycarbonyl group or phenyl-C.
3 -alkoxycarbonyl group such as the benzyloxycarbonyl group and for an imino or amino group a Cl- 9 -alkoxycarbonyl group such as the methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, n-pentyloxycarbonyl, n-hexyloxycarbonyl, cyclohexyloxycarbonyl, n-heptyloxycarbonyl, n-octyloxycarbonyl or n-nonyloxycarbonyl group, a phenyl-C 1 3 -alkoxycarbonyl group such as the benzyloxycarbonyl group, a phenylcarbonyl group optionally substituted by a C 1 3 -alkyl group such as the benzoyl or 4-ethyl-benzoyl group, a pyridinoyl group such as the nicotinoyl group, a C 1 3 -alkylsulphonyln-C 2 3 -alkoxycarbonyl or C 1 3 -alkoxy-C 2 3 -alkoxy- C2- 4 -alkoxycarbonyl group such as the 2-methylsulphonylethoxycarbonyl or 2- (2-ethoxy) ethoxycarbonyl group.
Moreover, the saturated-alkyl and alkoxy moieties containing more than 2 carbon atoms as well as alkanoyl and unsaturated alkyl moieties containing more than 3 carbon 8 atoms as mentioned in the foregoing definitions also include the branched isomers thereof such as for example the isopropyl, tert.-butyl and isobutyl group, etc.
Preferred compounds of the above general formula I, however, are those wherein A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R i group, B denotes an ethylene group, in which a methylene group, linked either to the group Het or Ar, may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, carbonyl or group, wherein RI denotes a hydrogen atom or a C 1 _s-alkyl group, E denotes an RbNH-C(=NH)- group wherein Rb denotes a hydrogen atom, a hydroxy group, a
C
1 .3-alkyl group or a group which may be cleaved in vivo, Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl,
C
1 3 -alkyl or Cl, 3 -alkoxy group, a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted in the carbon skeleton by a C;_-alkyl group, Het denotes a bicyclic heterocycle of formula 9
X
I IJ ,wherein X is a nitrogen atom and Y is an oxygen or sulphur atom or a nitrogen atom optionally substituted by a C 1 _g-alkyl or
C
3 _.-cycloalkyl group, whilst additionally one or two non-angular methyne groups in the phenyl moiety of the above-mentioned bicyclic heterocycle may each be replaced by a nitrogen atom, or X denotes a methyne group optionally substituted by the group R 1 wherein R, is as hereinbefore defined, and Y denotes a nitrogen atom optionally substituted by a
C
16 -alkyl or C 37 -cycloalkyl group, or Het denotes a group of the formulae
R
1
^N^
10
R
1 -S I
N
G
R
i
N
R
1 wherein
R
i is as hereinbefore defined, Z denotes an oxygen or sulphur atom, one of the groups D or G denotes a nitrogen atom and the other group D or G denotes a methyne group, and Ra denotes a C 1 _.-alkyl group, a C 3 cycloalkyl group optionally substituted by a C 1 3 -alkyl group, wherein the
C
1 3 -alkyl group may additionally be substituted by a carboxyl group or by a group which may be converted in vivo into a carboxy group, or a R 2
NR
3 group wherein 11
R
2 denotes a -alkyl group, which may be substituted by a carboxy, -alkyloxycarbonyl, benzyloxycarbonyl, C,3-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, trifluorosulphonylamino, trifluorosulphonylaminocarbonyl or 1H-tetrazolyl group, a C, 4 -alkyl group substituted by a hydroxy, phenyl-
C
1 -alkoxy, carboxy-CI 3 -alkylamino, C,3alkoxycarbonyl C alkylamino, N- (C, 3 -alkyl) -carboxy-
C,-
3 -alkylamino or N-(C 1 3 -alkyl)-C, 3 -alkoxycarbonyl-C- 3 alkylamino group, whilst in the abovementioned groups :the carbon atom in the a-position relative to the *9* :adjacent nitrogen atom may not be substituted, or a piperidinyl group optionally substituted by a
C,
3 -alkyl group and 9**
R
3 denotes a hydrogen atom, a C,-6-alkyl group, a 20 C3-,-cycloalkyl group optionally substituted by a
C
1 3 -alkyl group, a C 3 6 -alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R 2 NR,- group, a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a C 1 3 -alkyl or C1-3-alkoxy group, a benzyl, oxazolyl, isoxazolyl,.thiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl or piperidinyl group optionally substituted by a C1-3-alkyl group or R, and R 3 together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxy or
C,-
4 -alkoxycarbonyl group, onto which a phenyl ring may additionally be fused, particularly those compounds wherein 12 Het denotes one of the abovementioned benzimidazolylene, benzothiazolylene, benzoxazolylene, indolylene, quinazolinylene, quinoxazolinonylene, imidazo[1,2-a]pyridinylene, thiazolo[5,4-b]pyridinylene or thieno[2,3-d]imidazolylene groups, the tautomers, the prodrugs, the double prodrugs, the stereoisomers and the salts thereof.
Particularly preferred compounds of general formula I above are those wherein A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R, group, B denotes an ethylene group in which the methylene group linked to the group Ar may be replaced by an oxygen or sulphur atom or by an group, wherein R. denotes a hydrogen atom or a C-.
4 -alkyl group, E denotes an RbNH-C(=NH)- group wherein Rb denotes a hydrogen atom, a hydroxy,
C
1 _9-alkoxycarbonyl, cyclohexyloxycarbonyl, phenyl- Cl-3-alkoxycarbonyl, benzoyl, p-C1- 3 -alkyl-benzoyl or pyridinoyl group, whilst the ethoxy moiety in the 2-position of the abovementioned Cl.
9 -alkoxycarbonyl group may additionally be substituted by a C1- 3 -alkylsulfonyl or 2-(C 1 3 -alkoxy)-ethyl group, 13 Ar denotes a 1,4-phenylene group optionally substituted by a chlorine atom or by a methyl, ethyl or methoxy group or it denotes a 2,5-thienylene group, Het denotes a 1-(C 1 3 -alkyl)-2,5-benzimidazolylene, 1cyclopropyl-2, 5-benzimidazolylene, 2, 1-(Cl..
3 -alkyl)-2,5-indolylene, l-(Cl 1 3 -alkyl)- 2,5-imidazo[4,5-blpyridinylene, 3-(Cl.
3 -alkyl)- 2,7-imidazo[1,2-alpyridinylen or 1-(Cl.
3 -alkyl)- 2, 5-thieno 3-d] imidazolylene group and Ra denotes an R 2
NR
3 group wherein R, is a 4 -alkyl group substituted by a carboxy, C 6 -alkyloxycarbonyl, benzyloxycarbonyl, Cl..
3 -alkylsulphonylaminocarbonyl or group, a C 2 4 -alkyl group substituted by a hydroxy, benzyloxy, carboxy-Cl-.
3 -alkylamino, C 1 3 -alkoxycarbonyl- Cl 1 3 -alkylamino, N- (C 1 3 -alkyl) -carboxy-Cl- 3 -alkylamino or N- (Cl 1 3 -alkyl) -CI- 3 -alkoxycarbonyl-C..
3 -alkylamino group, whilst in the abovementioned groups the carbon atom in the at-position to the adjacent nitrogen atom may not be substituted,
R
3 denotes a 7 -cycloalkyl group, a propargyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R 2
NR
3 group, a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, a pyrazolyl, pyridazolyl or pyridinyl group optionally substituted by a methyl group or 14
R
2 and R 3 together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxy or C1- 4 -alkoxycarbonyl group, to which a phenyl ring may additionally be fused, the tautomers, the stereoisomers and the salts thereof.
Most particularly preferred compounds of the above general formula I are those wherein A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R, group, B denotes an ethylene group in which the methylene group linked to the group Ar may be replaced by an oxygen or sulphur atom or by an group, wherein RI denotes a hydrogen atom or a methyl group, E denotes an RbNH-C(=NH)- group, wherein Rb denotes a hydrogen atom or a hydroxy,
C
1 -alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, p-C1- 3 -alkyl-benzoyl or nicotinoyl group, whilst the ethoxy moiety in the 2position of the abovementioned C 1 _,-alkoxycarbonyl group may additionally be substituted by a CI_ 3 alkylsulphonyl or 2-(C 13 -alkoxy)-ethyl group, Ar denotes a 1,4-phenylene group optionally substituted by a chlorine atom or by a methyl, ethyl or methoxy group, or it denotes a 2,5-thienylene group, 15 Het denotes a l-methyl-2,5-benzimidazolylene, 1- 1-methyl-2,5-indolylene, 1-methyl- 2,5-imidazo[4,5-b]pyridinylene, 3-methyl- 2,7-imidazo[1,2-a]pyridinylene or 1-methyl- 2,5-thieno[2,3-d]imidazolylene group and Ra denotes a R 2
NR
3 group wherein
R
2 denotes a C1_ 3 -alkyl group which may be substituted by a carboxy, Cl_6-alkyloxycarbonyl, benzyloxycarbonyl, methylsulphonylaminocarbonyl or 1H-tetrazol-5-yl group, a C 2 3 -alkyl group substituted by a hydroxy, benzyloxy, carboxy-C 1 -3-alkylamino, C 1 _3-alkoxycarbonyl- Cl_3-alkylamino, N-(C 1 3 -alkyl)-carboxy-C 1 3 -alkylamino or N-(C 1 3 -alkyl)-Cl_ 3 -alkoxycarbonyl-C 1 3 -alkylamino group, whilst in the abovementioned groups the carbon atom in the a-position to the adjacent nitrogen atom may not be substituted, and
R
3 denotes a propargyl group, wherein the unsaturated moiety may not be linked directly to the nitrogen atom of the R 2
NR
3 group, a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, or denotes a pyridinyl group, particularly those wherein A denotes a carbonyl group linked to the benzo or thieno moiety of the group Het, B denotes an ethylene group wherein the methylene group attached to the group Ar may be replaced by an -NR 1 group, wherein 0 -16 R, denotes a hydrogen atom or a methyl group, E denotes an RbNH-C(=NH)- group wherein Rb is a hydrogen atom, a hydroxy, C 1 9 -alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, p-Cl 1 3 -alkyl-benzoyl or nicotinoyl group, whilst the ethoxy moiety in the 2-position of the abovementioned Cl- 9 -alkoxycarbonyl group may additionally be substituted by a methylsulfonyl or 2-ethoxy-ethyl group, Ar denotes a 1,4-phenylene group optionally substituted by a methoxy group, or denotes a 2,5-thienylene group, Het denotes a 2, 5-benzothiazolylene, l-methyl-2, 5-indolylene or 1-methyl- 2,5-thieno[2,3-d] imidazolylene group and Ra denotes an R 2
NR
3 group wherein
R
2 denotes a C 1 3 -alkyl group which may be substituted by a carboxy, C 1 6 -alkyloxycarbonyl, benzyloxycarbonyl, methylsulfonylaminocarbonyl or 1H-tetrazol-5-yl group, a C 2 3 -alkyl group substituted by a hydroxy, benzyloxy, carboxy-C...
3 -alkylamino, 3 -alkoxycarbonyl- Cl..
3 -alkylamino, N- (C 1 3 -alkyl) -carboxy-C..
3 -alkylamino or N- (Cl..
3 -alkyl) -C 1 3 -alkoxycarbonyl-CI-.
3 -alkylamino group, whilst in the abovementioned groups the carbon atom in the cx-position to the adjacent nitrogen atom may not be substituted, and 17
R
3 denotes a phenyl group optionally substituted by a fluorine atom, or denotes a 2-pyridinyl group, the tautomers, stereoisomers and the salts thereof.
The following are mentioned as examples of particularly preferred compounds: 2- (4-amidinophenyl) -aminomethyl] -benzthiazoleadid-N-phenyl-N- (2-carboxyethyl) -amide, 2- (4-midinophenyl) -N-methyl-aminomethyl] acid-N-phenyl-N- (2hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N-phenyl-N- (2hydroxycarbonylethyl) -amide, l-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N-phenyl- N- hydroxycarbonylpropyl) -amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) N- (hydroxycarbonylmethyl) -amide, l-Methyl-2- (2-amidinothiophen-5-yl)ethyl] benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide, 18 1-Methyl-2- (4-amidinophenyl)ethyl] yl-carboxylic acid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl)ethyl] yl-carboxylic acid-N-phenyl-N- (2-hydroxycarbonylethyl) amide, 1-Methyl-2- (4-amidinophenyl) ethyl] yl-carboxylic acid-N-phenyl-N- (1H-tetrazol-5-yl)ethyl] amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N-phenyl-N- (11tetrazol-5-yl) ethyl] -arnide, l-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] acid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide, (in) 1-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] acid-N- (3-pyridyl) (2hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] acid-N-phenyl-N- (2hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] benzimidazol-5-yl-carboxylic acid-N-phenyl-N- hydroxycarbonylethyl-N-methyl) -2-aminoethyl] -amide, 1-Methyl-2- (4-amidinophenyl) -aniinomethyl] acid-N- (3-f luorophenyl) (2hydroxycarbonylethyl) -amide, 0 -19 1-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N- (4-f luorophenyl) (2hydroxycarbonylethyl) -amide, l-Methyl-2- (4-amidino-2-methoxy-phenyl) aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2 -hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidino-2-methoxy-phenyl) aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-hydroxycarbonylethyl) -amide, l-Methyl-2- (4-amidinophenyl) aminomethyl] carboxylic acid-N-phenyl-N- (2-methoxycarbonylethyl) -amide and 1-Methyl-2- (4-amidinophenyl) aminomethyl] thieno [2 .3-dI imidazol-5-yl-carboxylic acid-N-phenyl-N- (2hydroxycarbonylethyl) -amide, the tautomers, prodrugs, double prodrugs, stereoisomers and the salts thereof.
The new compounds may be prepared by methods known per se, for example by the following methods: a. In order to prepare a compound of general formula I, wherein E denotes an RbNI-C group, wherein Rb is a hydrogen atom, a hydroxy or C 1 alkyl group: By reacting a compound of general formula Ra A Het B Ar C
II
optionally formed in the reaction mixture, 20 wherein A, B, Ar, Het and Ra are as hereinbefore defined and Z denotes an alkoxy or aralkoxy group such as the methoxy, ethoxy, n-propoxy, isopropoxy or benzyloxy group or an alkylthio or aralkylthio group such as the methylthio, ethylthio, n-propylthio or benzylthio group, with an amine of general formula
H
2 N Rb ,(III) wherein Rb' denotes a hydrogen atom or a hydroxy or C 1 _--alkyl group.
The reaction is conveniently carried out in a solvent such as methanol, ethanol, n-propanol, water, methanol/water, tetrahydrofuran or dioxane at temperatures between 0 and 150 0 C, preferably at temperatures between 20 and 120 0
C,
with a compound of general formula III or with a corresponding acid addition salt such as ammonium carbonate, for example.
A compound of general formula II may be obtained, for example, by reacting a compound of general formula I wherein E denotes a cyano group, with a corresponding alcohol such as methanol, ethanol, n-propanol, isopropanol or benzyl alcohol in the presence of an acid such as hydrochloric acid or by reacting a corresponding amide with a trialkyloxonium salt such as triethyloxoniumtetrafluoroborate in a solvent such as methylene chloride, tetrahydrofuran or dioxane at temperatures between 0 and 0 C, but preferably at 20 0 C, or a corresponding nitrile with hydrogen sulphide, appropriately in a solvent such as pyridine or dimethylformamide and in the presence of a base such as triethylamine and subsequent alkylation of the resulting thioamide with a corresponding alkyl or aralkyl halide.
21 b. In order to prepare a compound of general formula I wherein the Ra-A- group and E are as hereinbefore defined, with the proviso that the Ra-A- group contains a carboxy group and E as hereinbefore defined or that the Ra-A- group is as hereinbefore defined and E denotes an NH 2 group, or that the group contains a carboxy group and E denotes an NH 2 group: Converting a compound of general formula Ra' A Het B Ar C E' ,(IV) wherein A, B, Ar and Het are as hereinbefore defined and the Ra'-A- group and E' have the meanings given for the Ra-A- group and E hereinbefore, with the proviso that the Ra'-A- group contains a group which may be converted into a carboxyl group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis and E is as hereinbefore defined or E' denotes a group which may be converted into an NH 2 group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis and the Ra'-A- group has the meanings given for the Ra-A- group hereinbefore or the Ra'-A- group contains a group which may be converted into a carboxyl group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis and E' denotes a group which may be converted into an NH 2 group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis, is converted by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis into a compound of general formula I, wherein the Ra-A- group and E are as hereinbefore defined, with the proviso that the Ra-A- group contains a carboxy group and E is as hereinbefore defined or the Ra-A- group has the meanings given above and E 22 denotes an NH 2 group or the Ra-A- group contains a carboxy group and E denotes an NH 2 group.
Examples of groups which may be converted into a carboxy group include a carboxyl group protected by a protecting group and the functional derivatives thereof, e.g. the unsubstituted or substituted amides, esters, thioesters, trimethylsilylesters, orthoesters or iminoesters which may conveniently be converted into a carboxyl group by hydrolysis, the esters thereof with tertiary alcohols, e.g. the tert.butylester, which are conveniently converted into a carboxyl group by treatment with an acid or by thermolysis, and the esters thereof with aralkanols, e.g. the benzylester, which are conveniently converted into a carboxyl group by hydrogenolysis.
The hydrolysis is expediently carried out either in the presence of an acid such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid or mixtures thereof or in the presence of a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent such as water, water/methanol, water/ethanol, water/isopropanol, methanol, ethanol, water/tetrahydrofuran or water/dioxane at temperatures between -10 and 120 0 C, e.g. at temperatures between room temperature and the boiling temperature of the reaction mixture.
If the Ra'-A- group and/or E' in a compound of formula IV contains the tert.-butyl or tert.-butyloxycarbonyl group, for example, these may also be cleaved by treating with an acid such as trifluoroacetic acid, formic acid, pk toluenesulphonic acid, sulphuric acid, hydrochloric acid, 23 phosphoric acid or polyphosphoric acid, optionally in an inert solvent such as methylene chloride, chloroform, benzene, toluene, diethylether, tetrahydrofuran or dioxane, preferably at temperatures between -10 and 120 0 C, e.g. at temperatures between 0 and 60 0 C, or thermally optionally in an inert solvent such as methylene chloride, chloroform, benzene, toluene, tetrahydrofuran or dioxane and preferably in the presence of a catalytic quantity of an acid such as p-toluenesulphonic acid, sulphuric acid, phosphoric acid or polyphosphoric acid, preferably at the boiling temperature of the solvent used, e.g. at temperatures between 40 and 120 0
C.
If the group and/or E' in a compound of formula IV contains the benzyloxy or benzyloxycarbonyl group, for example, these may also be cleaved by hydrogenolysis in the presence of a hydrogenation catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethanol/water, glacial acetic acid, ethyl acetate, dioxane or dimethylformamide, preferably at temperatures between 0 and 50 0 C, e.g. at room temperature, under a hydrogen pressure of 1 to 5 bar.
c. In order to prepare a compound of general formula I wherein the Ra-A- group contains one of the ester groups mentioned in the definition of the Ra-A- group hereinbefore: Reaction of a compound of general formula Ra" A Het B Ar E wherein B, E, Ar and Het are as hereinbefore defined and the group has the meanings given for the Ra-A- group hereinbefore, with the proviso that the Ra"-A- group 24 contains a carboxyl group or a group which may be converted into a corresponding ester group by means of an alcohol, with an alcohol of general formula HO R7 ,(VI) wherein
R
7 is the alkyl moiety of one of the above-mentioned groups which may be cleaved in vivo, with the exception of the
R
4 -CO-O-(RsCR 6 group for a carboxyl group, or with the formamide acetals thereof.
o. r with a compound of general formula Z2 R (VII) S* wherein
R
8 denotes the alkyl moiety of one of the above-mentioned groups which may be cleaved in vivo, with the exception of the R 4 -CO-O-(RsCR 6 group for a carboxyl group and eeo 20 Z 2 denotes a leaving group such as a halogen atom, e.g. a chlorine or bromine atom.
The reaction with an alcohol of general formula VI is conveniently carried out in a solvent or mixture of solvents such as methylene chloride, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, but preferably in an alcohol of general formula VI, optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, e.g. in the presence of isobutylchloroformate, thionyl chloride, trimethylchlorosilane, hydrochloric acid, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid, phosphorus trichloride, phosphorus pentoxide, N,N'dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/Nhydroxysuccinimide, N,N'-carbonyldiimidazole or N,N'thionyldiimidazole, triphenylphosphine/carbon tetrachloride or triphenylphosphine/diethylazodicarboxylate, optionally 25 in the presence of a base such as potassium carbonate, Nethyl-diisopropylamine or N,N-dimethylamino-pyridine, conveniently at temperatures between 0 and 150 0
C,
preferably at temperatures between 0 and 80 0
C.
With a compound of general formula VII the reaction is usefully carried out in a solvent such as methylene chloride, tetrahydrofuran, dioxane, dimethylsulphoxide, dimethylformamide or acetone, optionally in the presence of a reaction accelerator such as sodium or potassium iodide and preferably in the presence of a base such as sodium carbonate or potassium carbonate or in the presence of a tertiary organic base such as N-ethyl-diisopropylamine or N-methyl-morpholine, which may act as solvent at the same 15 time, or optionally in the presence of silver carbonate or silver oxide at temperatures between -30 and 100 0 C, but preferably at temperatures between -10 and 80 0
C.
d. In order to prepare a compound of general formula I 20 wherein Rb denotes a group which may be cleaved in vivo: Reacting a compound of general formula Ra A Het B Ar C(=NH) NH 2
(VIII)
wherein Ra, A, Het, B and Ar are as hereinbefore defined, with a compound of general formula Z2 R7 (IX) wherein R- denotes a group which may be cleaved in vivo and
Z
2 denotes a nucleofugic leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom.
26 The reaction is preferably carried out in a solvent such as methanol, ethanol, methylene chloride, tetrahydrofuran, toluene, dioxane, dimethylsulphoxide or dimethylformamide, optionally in the presence of an inorganic or tertiary organic base, preferably at temperatures between 20 0 C and the boiling temperature of the solvent used.
With a compound of general formula IX, wherein Z, denotes a nucleofugic leaving group, the reaction is preferably carried out in a solvent such as methylene chloride, acetonitrile, tetrahydrofuran, toluene, dimethylformamide or dimethylsulphoxide, optionally in the presence of a base such as sodium hydride, potassium carbonate, potassium tert.-butoxide or N-ethyl-diisopropylamine at temperatures between 0 and 60 0
C.
e. In order to prepare a compound of general formula I wherein B denotes an ethylene group, in which a methylene group is replaced by a sulphinyl or sulphonyl group: Oxidation of a compound of general formula Ra A Het B' Ar E wherein A, E, Ar, Het and R a are as hereinbefore defined and B' denotes an ethylene group, wherein a methylene group is replaced by a sulphenyl or sulphinyl group.
The oxidation is preferably carried out in a solvent or mixture of solvents, e.g. in water, water/pyridine, acetone, methylene chloride, glacial acetic acid, glacial acetic acid/acetic anhydride, dilute sulphuric acid or trifluoroacetic acid, and depending on the oxidising agent used, at temperatures between -80 and 100 0
C.
27 In order to prepare a corresponding sulphinyl compound of general formula I oxidation is conveniently carried out with one equivalent of the oxidising agent used, e.g. with hydrogen peroxide in glacial acetic acid, trifluoroacetic acid or formic acid at 0 to 20 0 C or in acetone at 0 to 0 C, with a peracid such as performic acid in glacial acetic acid or trifluoroacetic acid at 0 to 50 0 C or with mchloroperbenzoic acid in methylene chloride, chloroform or dioxane at -20 to 80 0 C, with sodium metaperiodate in aqueous methanol or ethanol at -15 to 25 0 C, with bromine in glacial acetic acid or aqueous acetic acid, optionally in the presence of a weak base such as sodium acetate, with Nbromosuccinimide in ethanol, with tert.-butylhypochlorite in methanol at -80 to -30 0 C, with iodobenzodichloride in aqueous pyridine at 0 to 50 0 C, with nitric acid in glacial acetic acid at 0 to 20 0 C, with chromic acid in glacial acetic acid or in acetone at 0 to 20 0 C and with sulphuryl chloride in methylene chloride at -70 0 C, the resulting thioether chlorine complex is conveniently hydrolysed with aqueous ethanol.
In order to prepare a sulphonyl compound of general formula I, oxidation is carried out starting from a corresponding sulphinyl compound, conveniently with one or more equivalents of the oxidising agent used, or starting from a corresponding sulphenyl compound, conveniently with two or more equivalents of the oxidising agent used, e.g. with hydrogen peroxide in glacial acetic acid/acetic anhydride, trifluoroacetic acid or in formic acid at 20 to 100 0 C or in acetone at 0 to 60 0 C, with a peracid such as performic acid or with m-chloroperbenzoic acid in glacial acetic acid, trifluoroacetic acid, methylene chloride or chloroform at temperatures between 0 and 60°C, with nitric acid in glacial acetic acid at 0 to 20 0 C, with chromic acid or 28 potassium permanganate in glacial acetic acid, water/sulphuric acid or in acetone at 0 to 20 0 C. Thus, by carrying out oxidation, for example, starting from a corresponding sulphenyl compound, preferably in methylene chloride, by treating with a corresponding amount of mchloroperbenzoic acid at temperatures between 20 0 C and the reflux temperature of the reaction mixture, a corresonding sulphonyl compound of general formula I is obtained which may still contain a small amount of the corresponding sulphinyl compound.
f. In order to prepare a compound of general formula I wherein E is a cyano group and B is an ethylene group in which a methylene group linked either to group Het or to Ar is replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, carbonyl or group: Reacting a compound of general formula Ra A Het U (XI) a with a compound of general formula V Ar CN ,(XII) wherein Ra, A, Ar and Het are as hereinbefore defined, one of the groups U or V denotes an HO-, HS-, HOSO-, HOSO2or HNR,- group and the other group denotes a Z 3
CH
2 group, wherein R 1 is as hereinbefore defined and Z 3 denotes a nucleofugic leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom.
The reaction is preferably carried out in a solvent such as methanol, ethanol, methylene chloride, tetrahydrofuran, toluene, dioxane, dimethylsulphoxide or dimethylformamide, optionally in the presence of an inorganic or a tertiary 29 organic base, preferably at temperatures between 20 0 C and the boiling temperature of the solvent used.
g. In order to prepare a compound of general formula I, wherein E is a cyano group and Ra denotes an R 2
NR
3 group: Reacting a compound of general formula H A Het B Ar CN ,(XIII) wherein A, B, Het and Ar are as hereinbefore defined, with an amine of general formula /R2 H N ,(XIV)
R
3 wherein
R
2 and R 3 are as hereinbefore defined, or with the reactive derivatives thereof.
The reaction of an acid of general formula XIII is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane or in a corresponding amine of general formula III, optionally in the presence of a dehydrating agent, e.g. in the presence of isobutylchloroformate, tetraethylorthocarbonate, trimethylorthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide,
N,N'-
dicyclohexylcarbodiimide/N-hydroxysuccinimide,
N,N'-
dicyclohexylcarbodiimide/l-hydroxy-benzotriazole, 2-(1Hbenzotriazol-l-yl)-1,1,3,3-tetramethyluroniumtetrafluoroborate, 2-(IH-benzotriazol-l-yl)-1,1,3,3- Stetramethyluronium-tetrafluoroborate/1-hydroxybenzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride and optionally with the addition of a base such as pyridine, 4-dimethylaminopyridine, N-methyl-morpholine or triethylamine, conveniently at temperatures between 0 and 150 0
C,
preferably at temperatures between 0 and 100 0
C.
The reaction of a corresponding reactive compound of general formula XIII such as the esters, imidazolides or halides thereof with an amine of general formula XIV is preferably carried out in a corresponding amine as solvent, optionally in the presence of another solvent such as methylene chloride or ether and preferably in the presence of a tertiary organic base such as triethylamine, N-ethyldiisopropylamine or N-methyl-morpholine at temperatures between 0 and 150 0 C, preferably at temperatures between and 100 0
C.
h. In order to prepare a benzimidazolyl, benzothiazolyl or benzoxazolyl compound of general formula I wherein B denotes an ethylene group: Reacting a compound of general formula Ra A 2 (XV)
YH
wherein Ra, A and Y are as hereinbefore defined, with a compound of general formula 30 HO-CO
CH
2
CH
2 Ar E
(XVI)
wherein Ar and E are as hereinbefore defined, or with the reactive N derivatives thereof.
31 The reaction is conveniently carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, optionally in the presence of a dehydrating agent, e.g. in the presence of isobutylchloroformate, tetraethylorthocarbonate, trimethylorthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/Nhydroxysuccinimide, N,N'-dicyclohexylcarbodiimide/1hydroxy-benzotriazole, 2-(1H-benzotriazol-l-yl)-1,1,3,3tetramethyluronium-tetrafluoroborate, 2-(1H-benzotriazol-lyl)-1,1,3,3-tetramethyluronium tetrafluoroborate/1-hydroxybenzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, and optionally with the addition of a base such as pyridine, 4-dimethylaminopyridine, N-methyl-morpholine or triethylamine, appropriately at temperatures between 0 and 150 0
C,
preferably at temperatures between 0 and 100 0
C.
The reaction of a corresponding reactive compound of general formula XVI such as the esters, imidazolides or halides thereof with an amine of general formula XV is preferably carried out in a solvent such as methylene chloride, ether or tetrahydrofuran and preferably in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine, which may simultaneously be used as solvents, at temperatures between 0 and 150 0 C, preferably at temperatures between 50 and 100°C.
i. In order to prepare a quinoxalin-2-one compound of the general formula: 32 Reacting a compound of general formula
NH
2
R
a A 2 (XVII)
NR
1
H
wherein Ra, R 1 and A are as hereinbefore defined, with a compound of general formula HO-CO COCH 2 Ar E ,(XVIII) wherein Ar and E are as hereinbefore defined, or with the reactive derivatives thereof.
The reaction is conveniently carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran, ethanol or dioxan, optionally in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexylcarbodiimide/1-hydroxy-benzotriazole, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumtetrafluoroborate, 2-(1H-benzotriazol-l-yl)-1,1,3,3tetramethyluronium-tetrafluoroborate/1-hydroxybenzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, and optionally with the addition of a base such as pyridine, 4-dimethylaminopyridine, N-methyl-morpholine or triethylamine, appropriately at temperatures of between 0 and 1500C, preferably at temperatures of between 0 and 100oc.
33 However, it is particularly preferred to carry out the reaction with a corresponding reactive compound of general formula XVIII such as the esters, imidazolides or halides thereof with an amine of general formula XVII in a solvent such as methylene chloride, ether, ethanol or tetrahydrofuran and optionally in the presence of a tertiary organic base such as triethylamine, N-ethyldiisopropylamine or N-methyl-morpholine, which may simultaneously serve as solvent, at temperatures of between 0 and 150 0 C, preferably at temperatures of between 50 and 1000C.
j. In order to prepare a compound of general formula I wherein R 2 denotes a C 1 _4-alkyl group substituted by an alkylsulphonylaminocarbonyl group: Reacting a compound of general formula
R'
\N A Het B Ar E ,(IXX) wherein
R
3 A, B, E, and Het are as hereinbefore defined and
R
2 denotes a C 1 _4-alkyl group substituted by a carboxy group, or the reactive derivatives thereof, with a salt of a compound of general formula
C
1 -3-Alkyl-SO 2
-NH
2
(XX).
The reaction is preferably carried out with a corresponding reactive compound of general formula IXX such as the esters, imidazolides or halides thereof with a salt of a compound of general formula XX, preferably with an alkali metal salt thereof such as a sodium salt, in a solvent such as methylene chloride, ether, ethanol, tetrahydrofuran or 34 dimethylformamide at temperatures between 0 and 150 0
C,
preferably at temperatures of between 50 and 1000C.
In the reactions described hereinbefore, any reactive groups present such as hydroxy, carboxy, amino, alkylamino or imino groups may be protected during the reaction by means of conventional protecting groups which are removed by cleaving after the reaction.
For example, the protecting group for a hydroxy group may be the trimethylsilyl, acetyl, benzoyl, tert.butyl, trityl, benzyl or tetrahydropyranyl group, the protecting group for a carboxyl group may be the trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group, and the protecting group for an amino, alkylamino or imino group may be the acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert.-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and for the amino group the phthalyl group may also be considered.
The optional subsequent cleaving of a protecting group may, for example, be carried out hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide or by ether cleaving, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 100 0
C,
preferably at temperatures between 10 and 50 0
C.
However, a benzyl, methoxybenzyl or benzyloxycarbonyl group may for example be cleaved hydrogenolytically, e.g. using hydrogen in the presence of a catalyst such as 35 palladium/charcoal in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid, at temperatures between 0 and 50 0 C, but preferably at room temperature, under a hydrogen pressure of 1 to 7 bar, preferably 3 to 5 bar.
A methoxybenzyl group may also be cleaved in the presence of an oxidising agent such as cerium(IV) ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile/water at temperatures between 0 and 50 0 C, but preferably at room temperature.
However, a 2,4-dimethoxybenzyl group is preferably cleaved in trifluoroacetic acid in the presence of anisole.
A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treatment with an acid such as trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxane, or ether.
A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxane, at temperatures between 20 and 50 0
C.
An allyloxycarbonyl group is cleaved by treating with a catalytic amount of tetrakis-(triphenylphosphine)palladium(O), preferably in a solvent such as tetrahydrofuran and preferably in the presence of an excess of a base such as morpholine or 1,3-dimedone, at temperatures between 0 and 100 0 C, preferably at room temperature and under inert gas, or by treating with a catalytic amount of tris-(triphenylphosphine)-rhodium(I)chloride, in a solvent such as aqueous ethanol and optionally in the presence of a base such as 1,4- 36 diazabicyclo[2.2.2]octane, at temperatures between 20 and 0
C.
The compounds of general formulae II to XX used as starting materials, some of which are known from the literature, may be obtained by methods known from the literature and moreover their production is described in the Examples.
Thus, for example, a compound of general formula II is obtained by reacting a corresponding nitrile which in turn is conveniently obtained by processes f to h, with a corresponding thio or alcohol in the presence of hydrogen chloride or bromide.
A compound of general formulae IV, V, VIII, X and IXX used as starting material is conveniently obtained according to a process of the present invention.
A starting compound of general formula XI in which U denotes a halomethyl group is conveniently obtained by cyclisation of a corresponding ester which is substituted in the o-position by a suitable halogen atom and a methoxyacetamido group, to form a corresponding bicyclic 2alkoxymethyl compound, optionally subsequent hydrolysis and optionally subsequent amidation of a resulting carboxylic acid with a corresponding amine, converting the alkoxymethyl compound thus obtained into the corresponding halomethyl compound, which can if necessary be subsequently converted into the desired compound by means of a suitable compound. If the cyclisation is carried out with a suitable carbonic acid derivative, a starting compound of general formula XI is obtained wherein U denotes a hydroxy, mercapto or amino group.
A starting compound of general formula XIII is obtained by cyclisation of a corresponding o-disubstituted ester, followed by saponification of the resulting ester and 37 subsequent amidation of the carboxylic acid thus obtained with a corresponding amine.
Furthermore, an imidazopyridine substituted in the position by a methyl group and obtained by cyclisation can be converted, via the corresponding N-oxide, into the corresponding hydroxymethyl compound which is-converted by oxidation into the desired carboxylic acid of general formula XIII.
The compounds of general formulae III, VI, VII, IX and XII used as starting materials are obtained by conventional methods, for example by reducing an aromatic ester substituted in the o-position by an optionally substituted amino group and a nitro group, and optionally subsequent cyclisation of the resulting o-diamino compound with a corresponding carboxylic acid.
Furthermore, the compounds of general formula I obtained may be separated into their enantiomers and/or diastereomers.
Thus, for example, the compounds of general formula I obtained which occur in racemate form may be separated by methods known per se (see Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes, and compounds of general formula I having at least 2 asymmetric carbon atoms may be separated on the basis of their physical-chemical differences using known methods, e.g. by chromatography and/or fractional crystallisation, into the diastereomers thereof, which, if they occur in racemic form, may subsequently be separated into the enantiomers as mentioned above.
The separation of enantiomers is preferably effected by column separation on chiral phases or by recrystallisation 38 from an optically active solvent or by reacting with an optically active substance, especially acids and the activated derivatives thereof or alcohols, which forms salts or derivatives such as e.g. esters or amides with the racemic compound, and separation of the diastereomeric salt mixture or derivative thus obtained, e.g. on the basis of their different solubilities, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Particularly common, optically active acids are, for example, the D- and L-forms of tartaric acid, and dibenzoyltartaric acid, di-otolyl tartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid and quinaldic acid. Examples of optically active alcohols include for example or (-)-menthol and examples of optically active acyl groups in amides include, for example, or (-)-menthyloxycarbonyl.
Moreover, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof with inorganic or organic acids. Examples of suitable acids include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
In addition, the new compounds of formula I thus obtained, if they contain a carboxyl group, may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, more particularly, for pharmaceutical use, into the physiologically acceptable salts thereof.
Examples of suitable bases include for example sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
S-39- As already mentioned, the new compounds of general formula I and the salts thereof have valuable properties. Thus, the compounds of general formula I wherein E denotes a cyano group are valuable intermediate products for preparing the other compounds of general formula I and the compounds of general formula I wherein E denotes an RbNH-C(=NH)- group and the tautomers, the stereoisomers and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly a thrombininhibiting effect, an effect of prolonging the thrombin time and an inhibitory effect on related serine proteases such as e.g. trypsin, urokinase factor VIIa, factor Xa, factor IX, factor XI and factor XII, whilst a few compounds such as for example the compound of Example 16 simultaneously also have a slight inhibitory effect on thrombocyte aggregation.
For example, the following compounds: A 2-[N-(4-amidinophenyl)-aminomethyl]-benzthiazoleacid-N-phenyl-N-(2-carboxyethyl)-amide, B 1-methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazolacid-N-phenyl-N-(3-hydroxycarbonylpropyl)-amide, C l-methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazolacid -N-phenyl-N-(hydroxycarbonylmethyl)-amide, D l-methyl-2-[N-(4-amidinophenyl)-aminomethyl]acid-N-phenyl-N-(2hydroxycarbonylethyl)-amide, E l-methyl-2-[N-(4-amidinophenyl)-aminomethyl]acid-N-(2-pyridyl)- SN- (hydroxycarbonylmethyl) -amide, 40 F 1-methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5yl-carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5yl)ethyl]-amide and G l-methyl-2-[N-(4-amidinophenyl)-aminomethyl]acid-N-(2-pyridyl)-N-(2hydroxycarbonylethyl)-amide were investigated as follows for their effects on thrombin time: Materials: plasma, from human citrated blood.
Test thrombin (bovine), 30U/ml, Behring Werke, Marburg Diethylbarbiturate acetate buffer, ORWH 60/61, Behring Werke, Marburg Biomatic B10 coagulometer, Sarstedt Method: The thrombin time was determined using a Biomatic coagulometer made by Messrs. Sarstedt.
As the test substance, 0.1 ml of human citrated plasma and 0.1 ml diethylbarbiturate buffer (DBA buffer) were added to the test strip prescribed by the manufacturer. The mixture was incubated for one minute at 37 0 C. The clotting reaction was started by the addition of 0.3 U test thrombin in 0.1 ml DBA buffer. The time is measured using the apparatus from the addition of the thrombin up to the clotting of the mixture. Mixtures to which 0.1 ml of DBA buffer were added were used as the controls.
According to the definition, a dosage-activity curve was used to determine the effective concentration of the 41 substance, i.e. the concentration at which the thrombin time is double compared with the control.
The Table which follows contains the results found: Substance Thrombin time
(ED
200 in jM).
A 0.04 B 0.06 C 0.15 D 0.03 E 0.09 F 0.03 G 0.03 By way of example, no acute toxic side effects were observed when compounds A, D, E and G were administered to rats in doses of up to 10 mg/kg i.v. The compounds are thus well tolerated.
In view of their pharmacological properties the new compounds and the physiologically acceptable salts thereof are suitable for the prevention and treatment of venous and arterial thrombotic diseases, such as for example the treatment of deep leg vein thrombosis, for preventing reocclusions after bypass operations or angioplasty and occlusion in peripheral arterial diseases such as pulmonary embolism, disseminated intravascular coagulation, for preventing coronary thrombosis, stroke and the occlusion of shunts or stents. In addition, the compounds according to the invention are suitable for antithrombotic support in thrombolytic treatment, such as for example with rt-PA or streptokinase, for preventing long-term restenosis after PT(C)A, for preventing metastasis and the growth of clot-dependent tumours and fibrin-dependent inflammatory processes.
S-42- The dosage required to achieve such an effect is appropriately 0.1 to 30 mg/kg, preferably 0.3 to 10 mg/kg by intravenous route, and 0.1 to 50 mg/kg, preferably 0.3 to 30 mg/kg by oral route, in each case administered 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, with one or more inert conventional carriers and/or diluents, e.g.
with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The Examples which follow are intended to illustrate the invention: 43 Preliminary remarks Unless otherwise specified, the R, values were always determined using polygram silica gel plates produced by Messrs. E. Merck of Darmstadt.
The EKA mass spectra (electrospray mass spectra of cations) are described, for example, in "Chemie unserer Zeit 6, 308-316 (1991) Example 1 3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid -N-phenyl-N-(2ethoxycarbonylethyl)-amide a) Methyl 1.6 g (7.4 mMol) of methyl 6-chloro-5-nitro-nicotinate (see Bernie et al. in J. Chem. Soc. 1951, 2590) were stirred in 20 ml of 40% aqueous methylamine solution at room temperature for 30 minutes. The reaction mixture was then diluted with ice water, the yellow precipitate formed was filtered off and dried.
Yield: 1.2 g (80 of theory), Rf value: 0.66 (silica gel; ethyl acetate/ethanol/glacial acetic acid 90:5:5) b) Methyl 5-amino-6-methylamino-nicotinate To a solution of 3.1 g (15 mMol) of methyl 6-methylamino- 5-nitro-nicotinate in 100 ml of ethanol/dichloromethane was added 1 g of palladium on charcoal and the resulting suspension was hydrogenated at room temperature under 5 bar of hydrogen pressure for 1.5 hours. The catalyst was then filtered off and the solvent was distilled off in vacuo. The crude oily product obtained was further reacted directly.
Yield: 2.4 g (92 of theory), 44 Rf value: 0.44 (silica gel; ethyl acetate/ethanol/ammonia 90:10:1) c) Methyl 5-[2-(4-cyanophenyl)ethylcarbonylamino]- 6-methylamino-nicotinate A solution of 2.6 g (15 mMol) of 3-(4-cyanophenyl)propionic acid in 25 ml of absolute tetrahydrofuran was mixed with 2.4 g (15 mMol) of N,N'-carbonyldiimidazole and stirred for minutes at room temperature. Then the imidazolide was mixed with a solution of 2.3 g (13 mMol) of methyl 6-methylamino-nicotinate in 25 ml of dimethylformamide and heated for 3 hours to 100 0 C. After the removal of the solvent in vacuo the crude product obtained was taken up in ethyl acetate, the organic phase was washed with water and after drying over sodium sulphate it was again freed from solvent. The residue obtained was purified by flash chromatography (silica gel; gradient: dichloromethane to dichloromethane/ethanol 19:1).
Yield: 2.1 g (50 of theory) of beige solid Rf value: 0.54 (silica gel; ethyl acetate/ethanol/ammonia 90:10:1) d) Methylyl 3-methvl-2-[2- (4-cyanophenyl)ethyll imidazo 4,5-b]pyridine-6-carboxvlate A solution of 2.0 g (5.9 mMol)of methyl cyanophenyl)ethylcarbonylamino] -6-methylamino-nicotinate in ml glacial acetic acid was heated to 1000C for one hour.
After removal of the solvent the residue was taken up in dichloromethane, washed with sodium hydrogen carbonate solution, dried with sodium sulphate and the solvent was distilled off again.
Yield: 1.7 g brown solid (89 of theory), Rf value: 0.50 (silica gel; ethyl acetate/ethanol/ammonia 90:10:1) 45 e) 3-Methyl-2-[2-(4-cyanophenyl)ethyllimidazo 4.5-b]pyridine-6-carboxylic acid A solution of 3.2 g (10 mMol) of methyl 3-methyl-2-[2-(4cyanophenyl)ethyl] -imidazo[4.5-b] pyridine-6-carboxylate in 150 ml methanol was mixed with a solution of 1.5 g lithium hydroxide in 20 ml water and stirred for 24 hours at room temperature. Then the mixture was diluted with 50 ml of water, the alcohol was distilled off and the aqueous phase was washed with ethyl acetate. After acidification with dilute hydrochloric acid the mixture was extracted several times with dichloromethane/methanol the organic phase was dried with sodium sulphate and the solvent was distilled off.
Yield: 2.1 g beige solid (70 of theory), Rf value: 0.38 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) f) 3-Methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxvlic acid-N-phenvl-N-(2-ethoxycarbonylethyl)-amide A solution of 2.0 g (6.5 mMol) of 3-methyl-2-[2- (4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid in 100 ml dichloromethane was mixed with 20 ml thionyl chloride and refluxed for 2 hours. After the liquid components had been distilled off the crude product was taken up twice more in dichloromethane and the solvent was distilled off each time. The crude acid chloride thus obtained (2 g) was suspended in 100 ml of tetrahydrofuran and mixed with 1.2 g (6.5 mMol) of N-(2-ethoxycarbonylethyl)aniline. Then within 5 minutes 0.73 g (7,2 mMol) of triethylamine were added dropwise. After 1 hour's stirring the solvent was distilled off in vacuo, the residue was taken up in ethyl acetate, the organic phase was washed with water and dried with sodium sulphate. After distillation of the solvent and flash chromatography (silica gel; dichloromethane to dichloromethane/ethanol 49:1) the desired compound was isolated as a brownish oil.
S- 46- Yield: 1.9 g (65 of theory), R, value: 0.44 (silica gel; ethyl acetate/ethanol/ammonia 90:10:1) g) 3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide 1.8 g (3.7 mMol) of 3-methyl-2-[2-(4-cyanophenyl)ethyl]imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide were stirred into 100 1 of ethanol saturated with hydrogen chloride for 16 hours first at 0°C and then at room temperature until no more starting material could be detected by thin layer chromatography.
Then the solvent was distilled off, the oily residue was taken up in 50 ml of absolute ethanol and mixed with 3.6 g (37 mMol) of ammonium carbonate. After 4 hours the solvent was distilled off in vacuo, the crude product obtained was purified by flash chromatography (silica gel; gradient: dichloromethane/ethanol 19:1 to 4:1) and evaporated down again.
Yield: 1.6 g of beige solid (80 of theory), Rf value: 0.30 (silica gel; ethyl acetate/ethanol/ammonia 90:5:5) Example 2 3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2hydroxycarbonylethyl)-amide A solution of 535 mg (1.0 mMol) of 3-methyl-2-[2-(4amidinophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide in 10 ml ethanol was mixed with 5 ml of 2N sodium hydroxide solution and stirred for 2 hours at room temperature. Then the mixture was diluted with 10 ml water, the alcohol was distilled off, the aqueous phase was washed with 20 ml 47 ethyl acetate and acidified with concentrated hydrochloric acid, whereupon the desired compound was precipitated in the form of white crystals.
Yield: 375 mg (74 of theory), Rf value: 0.23 (silica gel; ethyl acetate/ethanol/ammonia 90:5:5)
C
2 6
H
2 6
N
6 0 3 (470.54) Mass spectrum: (M+H) 471 Example 3 3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5b]pyridin-6-yl-carboxylic acid-N- (2-pyridyl)-N-(2methoxycarbonylethyl)-amide-hydrochloride Prepared analogously to Example 1 from 3-methyl-2-[2-(4cyanophenyl)ethyl]-imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide, methanolic hydrochloric acid, methanol and ammonium carbonate.
Yield: 75 of theory,
C
2 6
H
2 7
N
7 0 3 (485.55) Rf value: 0.31 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: 486 Example 4 3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5b] pyridin-6-yl-carboxylic acid-N-phenyl-Nethoxycarbonylmethyl-amide-hydrochloride Prepared analogously to Example 1 from 3-methyl-2-[2-(4cyanophenyl) ethyl] -imidazo pyridin-6-yl-carboxylic acid-N-phenyl-N-ethoxycarbonylmethyl-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
VT
yy4 'V& 48 Yield: 84 of theory,
C
27
H
28
N
6 0 3 (484.56) R, value: 0.44 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: (M+H) 485 Example 3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5b]pyridin-6-yl-carboxylic acid-N-phenyl-Nhydroxycarbonylmethyl-amide-hydrochloride Prepared analogously to Example 2 from 3-methyl-2-[2-(4amidinophenyl)ethyl]-imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-ethoxycarbonylmethyl-amide-hydrochloride and sodium hydroxide solution.
Yield: 85 of theory,
C
25
H
24
N
6 0 3 (456.51) Rf value: 0.19 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: (M+H) 457 Example 6 2-[2-(4-amidinophenyl)ethyl]-3-methyl-6-(2-methoxycarbonyl- 2,3-dihydroindol-l-yl-carbonyl)-imidazo[4,5-b]pyridinehydrochloride Prepared analogously to Example 1 from cyanophenyl)ethyl]-3-methyl-6-(2-methoxycarbonyl- 2,3-dihydroindol-l-yl-carbonyl)-imidazo[4,5-b]pyridine, methanolic hydrochloric acid, methanol and ammonium carbonate.
Yield: 20 of theory,
C
27
H
26
N
6 0 3 (482.54) Rf value: 0.30 (silica gel; ethyl acetate/ethanol/ammonia 49 50:45:5) EKA mass spectrum: 483 Example 7 2-[2-(4-amidinophenyl)ethyl]-3-methyl-6-(2-carboxy- 2,3-dihydroindol-l-yl-carbonyl)-imidazo[4,5-b pyridinehydrochloride Prepared analogously to Example 2 from amidinophenyl)ethyl]-3-methyl-6-(2-methoxycarbonyl- 2,3-dihydroindol-l-yl-carbonyl)-imidazo[4,5-b]pyridinehydrochloride and sodium hydroxide solution.
Yield: 90 of theory,
C
26
H
24
N
6 0 3 (468.52) R, value: 0.24 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: (M+H) 469 (M+Na) 491 Example 8 l-Methyl-2-[(4-amidinophenyl)oxymethyl]imidazo[4,5-b]pyridin-5-yl-carboxylic acid-N-(2-pyridyl)-N- (2-ethoxycarbonylethyl)-amide a) 2-Amino-3-methylamino-6-methyl-pyridine 8.35 g (50 mMol) of 2-Methyl-5-methylamino-6-nitro-pyridine (Heterocycles 38, 529 (1994)) were dissolved in 300 1 ethyl acetate and hydrogenated with 1.5 g Raney nickel for hours at room temperature. Then the catalyst was filtered off and the filtrate was evaporated down. After crystallisation of the resulting residue from petroleum ether, 5.75 g (84 of theory) were obtained as olive-green crystals.
C
7
H
1 1
N
3 (137.20) 50 Melting point: 112-1130C b) 1,5-Dimethyl-2-[(4-cyanophenyl)oxymethyll- 11.4 g (63 mMol) of 4-cyano-phenoxyacetic acid were dissolved in 200 ml of absolute tetrahydrofuran and mixed at room temperature with 10.2 g (63 mMol) of N,N'-carbonyldiimidazole. After 15 minutes at 60 0 C, 5.70 g (41.5 mMol) of 2-amino-3-methylamino-6-methyl-pyridine were added. After 2 hours at 60 0 C the solvent was distilled off and the crystalline residue was mixed with water, washed with water and dried. After crystallisation from ethanol 9.95 g (91 of theory) were obtained in the form of white crystals.
C
16
H
14
N
4 0 (278.32) Mass spectrum: M+ 278 c) 1,5-Dimethyl-2-[(4-cyanophenyl)oxymethyl]imidazo[4,5-b]pyridin-4-N-oxide 2.62 g (10 mMol) of 1,5-dimethyl-2-[(4-cyanophenyl)were suspended in 125 ml dichloromethane and mixed with 2.62 g (12.7 mMol) of m-chloroperbenzoic acid, whereupon a clear solution was obtained. After 2 hours at room temperature the solvent was distilled off and the residue obtained was mixed with a sodium hydrogen carbonate solution. After 30 minutes the white crystalline product obtained was suction filtered, washed with water and dried at 400C.
Yield: 2.45 g (83 of theory),
C
1 6
H
1 4
N
4 0 2 (294.30) Mass spectrum: M+ 294 d) l-Methyl-2-[(4-cvanophenyl)oxymethl] 2.40 g (8.2 mMol) of 1,5-dimethyl-2-[(4-cyanophenyl)oxymethyl]-imidazo[4,5-b]pyridin-4-N-oxide were suspended s in 75 ml dichloromethane and mixed with 2.4 ml of 51 trifluoroacetic acid anhydride (16.9 mMol), whereupon a clear solution was obtained. After 16 hours at room temperature the solvent was distilled off, the viscous residue obtained was taken up in 50 ml dichloromethane and covered with 50 ml of 2M sodium hydrogen carbonate solution. After 3 hours' vigorous stirring the precipitate formed was suction filtered, washed with water and dried at 0
C.
Yield: 1.85 g white powder (78 of theory),
C
16
H
14
N
4 0 2 (294.30) Melting point: ,172°C e) l-Methyl-2-[(4-cyanophenyl)oxymethyl]-imidazo[4,5-b]- 3.65 g (12.5 mMol) of 1-methyl-2-[(4-cyanophenyl)oxymethyl]-5-hydroxymethyl-imidazo[4,5-b]pyridine were dissolved in 500 ml dichloromethane and mixed with 15.0 g of manganese dioxide. After 96 hours at room temperature the mixture was filtered through kieselgur and the solvent was distilled off. The filtrate obtained was evaporated down, the crystalline precipitate was triturated with ether, suction filtered and dried.
Yield: 3.05 g white powder (84 of theory),
C
16
H
12
N
4 0 2 (292.30) Melting point: 231-234°C f) l-Methyl-2-[(4-cyanophenyl)oxymethyll-5-carboxy-imidazo- 1.25 g (4.3 mMol) of 1-methyl-2-[(4-cyanophenyl)oxymethyl]imidazo[4,5-b]pyridine-5-carbaldehyde were dissolved in ml formic acid and mixed at 0°C with 1.0 ml hydrogen peroxide (33% strength). After 12 hours at 4°C the white precipitate formed was suction filtered, washed with water and dried at 40 0
C.
Yield: 0.81 g (61 of theory),
C
16
H
12
N
4 0 3 (308.7) 52 g) 1-Methyl-2- [(4-cyanophenyl)oxymethvl imidazo[4,5-blpyridin-5-vl-carboxylic acid-N-(2-pyridyl)-N- (2-methoxycarbonvlethyl)-amide 308 mg (1.0 mMol) of 1-methyl-2-[(4-cyanophenyl)oxymethyl]- 5-carboxy-imidazo[4.5-blpyridine were suspended in 5 ml of dimethylformamide and mixed with 303 mg (3.0 mMol) of N-methyl-morpholine and 321 mg (1.0 mMol) of O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium tetrafluoroborate. After 10 minutes at room temperature a solution of 215 mg (1.2 mMol) of methyl N-(2-pyridyl)- 3-amino-propionate in 2 ml of dimethylformamide was added, whereupon a clear solution was obtained. After 12 hours at room temperature the reaction solution was stirred into ice-water. After extracting 3 times with ethyl acetate the combined organic extracts were washed with a saline solution, dried over sodium sulphate and evaporated down.
The residue obtained was chromatographed on silica gel with dichloromethane/ethanol (90:1 to 25:1).
Yield: 165 mg of white powder (35 of theory),
C
25 H1 2
N
6 0 4 (407.50) Melting point: 139-140 0
C
h) l-Methyl-2-[(4-amidinophenvl)oxymethvll-imidazo[4.5-b] acid-N- (2-pyridyl)-N-(2ethoxycarbonyl-ethyl) -amide Prepared by reacting 140 mg (0.3 mMol) of 1-methyl- 2-[(4-cyanophenyl)oxymethyl]-imidazo[4,5-b]pyridin-5-ylcarboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl) amide with ethanol saturated by hydrogen chloride and with ammonium carbonate/ethanol analogously to Example Ig. The resulting product was purified by chromatography over silica gel with dichloromethane/ethanol (19:1 to 4:1).
Yield: 48 mg of white powder (36 of theory),
C
2 6
H
2 7
N
7 0 4 (501.57) Mass spectrum: (M+H) 502 53 Example 9 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazole-5carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl) -amide a) Ethyl 4-fluoro-3-methoxyacetamido-benzoate A solution of 2.8 g (15.3 mMol) of ethyl 3-amino-4-fluorobenzoate (cf. L.S. Fosdick, A.F. Dodds in J. Amer. Chem.
Soc. 65, 2305 (1943)) and 1.56 ml (1.85 g 17.0 mMol) of methoxyacetylchloride in 50 ml chlorobenzene was stirred for 1 hour at 50 0 C and then refluxed for 15 minutes. Then the solvent was distilled off in vacuo and the crude product obtained was purified by flash chromatography (silica gel; dichloromethane/ethanol 100:1). The desired compound, initially oily, solidified within a few days.
Yield: 3.8 g (98 of theory), R, value: 0.38 (silica gel; dichloromethane/ethanol 19:1) b) A mixture of 3.0 g (11.7 mMol) of 4-fluoro-3methoxyacetamido-benzoic acid and 2.1 g (5.2 mMol) of Lawesson's reagent was refluxed for 6 hours in 90 ml toluene, mixed with 1.0 g Lawesson's reagent and heated to 1200C for another 6 hours. After the solvent was replaced with xylene the mixture was heated to 180°C for a further 8 hours in a pressurised vessel. Then the solvent was distilled off in vacuo, the crude product obtained was purified by flash chromatography (silica gel; ethyl acetate/petroleum ether 5:95) and evaporated down again.
Yield: 2.1 g of yellow crystals (72 of theory), R, value: 0.55 (silica gel; ethyl acetate/petroleum ether 3:7) c) 2-Methoxymethvl-benzothiazole-5-carboxylic acid A mixture of 2.1 g (8.36 mMol) of ethyl 2-methoxymethyland 16 ml of 2N sodium hydroxide solution was stirred into 60 ml ethanol for 1 54 hour at room temperature. Then the alcohol was distilled off, the crude product was taken up in 20 ml water, washed with 50 ml diethylether and the aqueous phase was acidified with concentrated hydrochloric acid whilst being cooled with ice. The pinkish-beige compound thereby precipitated was suction filtered, washed with water and dried.
Yield: 1.6 g (86 of theory), R, value: 0.12 (silica gel; dichloromethane/ethanol 29:1) d) 2-Methoxymethyl-benzothiazole-5-carboxylic acid-Nphenyl-N-(2-ethoxycarbonylethyl)-amide A suspension of 1.6 g (7.2 mMol) of 2-methoxymethylacid in 60 ml dichloromethane was mixed with 1.6 ml (22 mMol) of thionyl chloride and refluxed for 1 hour. The solid dissolved after 20 minutes.
After distillation of the liquid components the crude product was taken up in dichloromethane twice more and each time the solvent was distilled off. The crude acid chloride thus obtained was taken up in 50 ml of tetrahydrofuran, added dropwise to a mixture of 1.4 g (7.2 mMol) of N-(2-ethoxycarbonylethyl)aniline and 3.0 ml (21 mMol) of triethylamine in 50 ml of tetrahydrofuran and stirred overnight at room temperature. Then the solvent was distilled off in vacuo, the residue was taken up in ml of dichloromethane, this solution was washed with water and dried with sodium sulphate. After distillation of the solvent and flash chromatography (silica gel; gradient: dichloromethane/ethanol 98.5:1.5 to 80:20) the desired compound was isolated as a brownish oil.
Yield: 2.05 (72 of theory), Rf value: 0.40 (silica gel; ethyl acetate/petroleum ether 1:1) e) 2-[N-(4-Cyanophenyl)-aminomethyll-benzothiazole- 5-carboxylic acid-N-phenvl-N-(2-ethoxycarbonvlethyl)-amide A mixture of 2.05 g (5.14 mMol) of 2-methoxymethylacid-N-phenyl-N-(2- 55 ethoxycarbonylethyl)-amide and 5.7 ml (5.7 mMol) of a 1M solution of boron tribromide in dichloromethane was dissolved in a further 60 ml of dichloromethane and stirred for 16 hours at room temperature. Then the mixture was washed with 40 ml of saturated sodium hydrogen carbonate solution, the organic phase was dried with sodium sulphate and the solvent was distilled off. The crude acid-N-phenyl- N-(2-ethoxycarbonylethyl)-amide thus obtained (2.4 g) was taken up in 5.0 ml of N,N-diisopropyl-ethylamine and mixed with 0.64 g (5.4 mMol) of 4-amino-benzonitrile. After 1 hour's heating to 130 0 C the solvent was distilled off in vacuo and the crude product obtained was purified by flash chromatography (silica gel; gradient: ethyl acetate/petroleum ether 1:3 to whilst an orange foam was obtained when the eluates were evaporated down.
Yield: 1.1 g (44 of theory), R, value: 0.35 (silica gel; ethyl acetate/petroleum ether 7:3) f) 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazoleacid-N-phenvl-N-(2-ethoxvcarbonylethyl)-amide 1.1 g (2.27 mMol) of 2-[N-(4-cyanophenyl)-aminomethyl]acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide was stirred in 100 ml of ethanol saturated with hydrogen chloride for 5 hours first at 0°C and then at room temperature until no more starting material could be detected by thin layer chromatography.
Then the solvent was distilled off at a maximum bath temperature of 30 0 C and the oily residue was taken up in 100 ml of absolute ethanol and mixed with 1.6 g (22 mMol) of ammonium carbonate. After 18 hours stirring at room temperature the solvent was distilled off in vacuo and the crude product was purified by flash chromatography (silica gel; gradient: water/methanol 19:1 to When the eluates are evaporated down the desired compound is obtained as a white foam.
56 Yield: 0.77 g (63 of theory), R, value: 0.19 (silica gel; dichloromethane/ethanol 3:7)
C
27
H
27
N
5 0 3 S (501.60) Mass spectrum: 502 Example 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazoleacid-N-phenyl-N-(2-carboxyethyl)-amide 0.45 g (0.84 mMol) of 2-[N-(4-amidinophenyl)-aminomethyl]acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide were dissolved in 15 ml of ethanol, mixed with 2 ml of 2N sodium hydroxide solution and stirred for 4 hours at room temperature. Then the mixture was acidified with 3 ml of 2N hydrochloric acid and the solvent was distilled off. The crude product obtained was taken up in 5 ml dichloromethane/ethanol and filtered to remove the insoluble sodium chloride. After the distillation of the solvent the desired compound was obtained as a yellow foam.
Yield: 0.26 g (67 of theory), Rf value: 0.47 (silica gel; methanol/5 aqueous sodium chloride 6:4)
C
25
H
23
N
5 0 3 S (473.55) Mass spectrum: (M+H) 474 Example 11 2-[N-(4-amidinophenyl)-aminomethyl]benzothiazol-5-ylcarboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)amide-dihydrochloride Prepared analogously to Example 9 from cyanophenyl)-aminomethyl]benzothiazol-5-yl-carboxylic acid- N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide, methanolic hydrochloric acid, methanol and ammonium carbonate.
57 Yield: 68 of theory,
C
25
H
24
N
6 0 3 S (488.57) R, value: 0.13 (silica gel; methylene chloride/ethanol 4:1 +a few drops of acetic acid) EKA mass spectrum (M+H) 489 Example 12 2-[2-(4-amidinophenyl)ethyl]-benzothiazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-amidedihydrochloride Prepared analogously to Example 9 from acid-N-(2pyridyl)-N-(ethoxycarbonylmethyl)-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 95 of theory,
C
26
H
25
N
5 0 3 S (487.58) Rf value: 0.20 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: 488 Example 13 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazol-5-ylcarboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)amide-dihydrochloride Prepared analogously to Example 9 from acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 68 of theory,
C
25
H
24
N
6 0 3 S (488.57) R, value: 0.14 (silica gel; methylene chloride/ethanol 58 4:1 a few drops of acetic acid) EKA mass spectrum: 489 Example 14 2- (4-amidinophenyl) -aminomethyl] carboxylic acid-N- (2-pyridyl) (hydroxycarbonylmethyl) amide -dihydrochioride Prepared analogously to Example 10 from amidinophenyl) -aminomethyll acid-N- (2-pyridyl) (ethoxycarbonylmethyl) -amidedihydrochloride and sodium hydroxide solution.
Yield: 90 of theory,
C
23
H
20
N
6 0 3 S (460.52) Rf value: EKA mass spectrum: 461 483 253 Example 2- (4-amidinophenyl) -N-methyl-aminomethyl] -benzothiazolacid-N-phenyl-N- (2-ethoxycarbonylethyl) amide-hydrochloride a) 2- (4-Cvanophenvl) -N-methvl-aminomethvll -benzothiazolacid-N-phenvl-N- (2-ethoxcycarbonylethyl) amide Prepared analogously to Example 9e from 4-cyano-N-methylaniline and acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide.
Yield: 57 of theory, Rf value: 0.46 (silica gel; dichloromethane/ethanol= 19:1).
59 b) 2- (4-amidinophenyl) -N-methyl-aminomethyll acid-N-phenvl-N- (2ethoxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 9 from cyanophenyl) -N-methyl-aminomethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 73 t of theory,
C
28
H
29
N
5 0 3 S (515.64) Rf value:0.29 (silica gel; methylene chloride /ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: 516 Example 16 2- (4-amidinophenyl) -N-methyl-aminomethyl] -benzothiazolacid-N-phenyl-N- (2-hydroxycarbonylethyl) amide -hydrochloride Prepared analogously to Example 10 from amidinophenyl) -N-methyl-aminomethyl] carboxylic acid-N-phenyl-N- (2 -ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 96 of theory,
C
26
H
25
N
5 0 3 S (487.58) Rf value: 0.48 (Merck RP-8, methanol/51i NaCl solution 6:4) EKA mass spectrum: 488 266.5 60 Example 17 2-[(4-amidinophenyl)thiomethyl]-benzothiazol-5-ylcarboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl)-amidehydrochloride Prepared analogously to Example 9 from acid- N-phenyl-N-(2-ethoxycarbonylethyl)-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 61 of theory,
C
27
H
26
N
4 0 3
S
2 (518.66) Rf value: 0.27 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: 519 Example 18 2-[(4-amidinophenyl)thiomethyl]-benzothiazol-5-ylcarboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amidehydrochloride Prepared analogously to Example 10 from acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.
Yield: 95 of theory,
C
25
H
22
N
4 0 3
S
2 (490.61) Rf value: 0.25 (Merck RP-8, methanol/5% NaCl solution 6:4) EKA mass spectrum: (M+H) 491 513 61 Example 19 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazol-5-ylcarboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amidehydrochloride Prepared analogously to Example 9 from acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 82 of theory,
C
26
H
25
N
5 0 3 S (487.58) Rf value: 0.21 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: (M+H) 488 Example 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazol-5-ylcarboxylic acid-N-phenyl-N-(hydroxycarbonylmethyl)-amidehydrochloride Prepared analogously to Example 10 from acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide-hydrochloride and sodium hydroxide solution.
Yield: 75 of theory,
C
24
H
21
N
5 0 3 S (459.53) R, value: 0.14 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: (M+H) 460 482 62 Example 21 2-[2-(4-amidinophenyl)ethyl] acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride Prepared analogously to Example 9 from acid-Nphenyl-N-(2-ethoxycarbonylethyl)-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 80 of theory,
C
28
H
28
N
4 0 3 S (500.62) R, value: 0.30 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: 501 Example 22 2-[2-(4-amidinophenyl)ethyl]-benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amidehydrochloride Prepared analogously to Example 10 from acid-Nphenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.
Yield: 77 of theory,
C
2 6
H
2 4
N
4 0 3 S (472.57) Rf value: 0.18 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: (M+H) 473 495 (M+H+Na) 259 0- 63 Example 23 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazol-5-ylcarboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)amide-hydrochloride Prepared analogously to Example 9 from acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 83 of theory,
C
24
H
29
N
5 0 3 (467.59) R, value: 0.31 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: (M+H) 468 935 Example 24 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazol-5-ylcarboxylic acid-N-(n-propyl)-N-(2-hydroxycarbonylethyl)amide-hydrochloride Prepared analogously to Example 10 from acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amidehydrochloride and sodium hydroxide solution.
Yield: 75 of theory,
C
22
H
25
N
5 0 3 S (439.54) Rf value: 0.14 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: (M+H) 440 (M+H+Na) 231.6 W- 64 Example l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol- 5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide-hydrochloride a) 4-Methylamino-3-nitro-benzoic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide To a solution of 24.7 g (0.115 mol) of 4-methylamino-3nitro-benzoic acid chloride and 22.3 g (0.115 mol) of N-(2-ethoxy-carbonylethyl)-aniline in 300 ml of tetrahydrofuran, 13.1 g (0.13 mol) of triethylamine were added dropwise in 15 minutes, with stirring, at room temperature. After 2 hours stirring the solvent was distilled off in a water-jet vacuum and the residue was mixed with 700 ml of water with stirring. The mixture was extracted 3 times with 200 ml of dichloromethane, the organic extract was washed twice with 200 ml of 2N hydrochloric acid and twice with 300 ml of water and dried over sodium sulphate. The solvent was then distilled off and the oily product thus obtained was purified by column chromatography (1 kg silica gel; eluant: petroleum ether/ethyl acetate 2:1).
Yield: 35.0 g (82 of theory), R, value: 0.28 (silica gel; dichloromethane/ethanol 50:1) b) 3-Amino-4-methylamino-benzoic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide 12.1 g (0.0326 mol) of 4-methylamino-3-nitro-benzoic acid- N-phenyl-N-(2-ethoxycarbonylethyl)-amide were hydrogenated in 300 ml ethanol and 150 ml dichloromethane after the addition of about 4 g of palladium/charcoal at room temperature and under a hydrogen pressure of 5 bar. Then the catalyst was filtered off and the filtrate was evaporated down. The crude product thus obtained was reacted without further purification.
65 Yield: 10.6 g (95 of theory), Rf value: 0.19 (silica gel; dichloromethane/ethanol 50:1) c) l-Methyl-2-[N-(4-cyanophenyl)-aminomethyll-benzimidazol- 5-yl-carboxylic acid-N-phenyl-N-(2-ethoxvcarbonvlethyl)amide 6.17 g (0.035 mol) of N-(4-cyanophenyl)glycine and 5.68 g (0.035 mol) of N,N'-carbonyldiimidazole were refluxed in 300 ml of tetrahydrofuran for 30 minutes, then 10.6 g (0.032 mol) of 3-amino-4-methylamino-benzoic acid-N-phenyl- N-(2-ethoxycarbonylethyl)-amide were added and the mixture was refluxed for a further five hours. Then the solvent was distilled off in vacuo, the residue was dissolved in 150 ml of glacial acetic acid and refluxed for one hour.
Then the glacial acetic acid was distilled off in vacuo, the residue was dissolved in about 300 ml of dichloromethane, the solution was washed twice with about 150 ml water and then dried over sodium sulphate. After evaporation of the solvent the crude product thus obtained was purified by column chromatography (800 g silica gel; eluant: dichloromethane with 1-2 ethanol).
Yield: 8.5 g (57 of theory), Rf value: 0.51 (silica gel; dichloromethane/ethanol 19:1) d) l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide-hydrochloride 1.2 g (2.49 mMol) of l-methyl-2-[N-(4-cyanophenyl)acid-N-phenyl-N- (2-ethoxycarbonylethyl)-amide were stirred in 100 ml of saturated ethanolic hydrochloric acid for 6 hours at room temperature. Then the mixture was evaporated to dryness in vacuo, the residue was dissolved in 100 ml of ethanol, mixed with 2.5 g (26 mMol) of ammonium carbonate and stirred overnight at room temperature. After distillation of the solvent the crude product thus obtained was purified by column chromatography (100 g silica gel; eluant: 66 dichloromethane/ethanol By concentrating the eluates the desired compound was obtained as a white, amorphous solid.
Yield: 1.10 g (83 of theory), R, value: 0.18 (silica gel; dichloromethane/ethanol 4:1)
C
28
H
30
N
6 0 3 x HC1 (498.6) EKA mass spectrum: 499 (M+2H) 250 261 Example 26 l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazolacid-N-phenyl-N-(2-hydroxycarbonylethyl)amide A mixture of 300 mg (0.56 mMol) of l-methyl-2-[N-(4acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amidehydrochloride, 15 ml of ethanol, 4 ml of water and 120 mg mMol) of sodium hydroxide was stirred for two hours at room temperature. Then the mixture was diluted with about ml of water and made weakly alkaline with glacial acetic acid. The product which crystallised out was suction filtered, washed with water and dried at 600C in vacuo.
Yield: 250 mg (95 of theory),
C
26
H
26
N
6 0 3 (470.5) EKA mass spectrum: (M+H) 471 247 258 67 Example 27 1-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-ylcarboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)amide-hydrochloride a) 4-Methvlamino-3-chloracetamido-benzoic acid-N-(npropyl)-N-(2-ethoxycarbonylethyl)-amide A solution of 1.8 g (5.9 mMol) of 3-amino-4-methylaminobenzoic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide [prepared analogously to 3-amino-4-ethylamino-benzoic acid- N-phenyl-N-(2-ethoxycarbonylethyl)-amide], 1.lg (6.8 mMol) of N,N'-carbonyldiimidazole and 0.65 g (6.9 mMol) of chloroacetic acid in 75 ml tetrahydrofuran was stirred for 1 hour at room temperature. Then the solvent was distilled off in vacuo, and the crude product was purified by flash chromatography (silica gel; methylene chloride/ethanol 49:1).
Yield: 1.7 g (77% of theory) yellow oil, Rf value: 0.58 (silica gel; ethyl acetate/ethanol/ammonia 90:10:1) b) acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide 1.6 g (4.3 mMol) of 4-methylamino-3-chloracetamido-benzoic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide were heated to 100 0 C in 25 ml of acetic acid for 30 minutes.
Then the solvent was distilled off, the crude product was taken up in 40 ml methylene chloride/ethanol and washed with 20 ml saturated sodium hydrogen carbonate solution. The organic phase was dried with sodium sulphate and evaporated down.
Yield: 1.5 g (100% of theory) of brown oil, R, value: 0.63 (silica gel; ethyl acetate/ethanol/ammonia 90:10:1) 68 c) l-Methyl-2-[(4-cyanophenyl)thiomethyl]-benzimidazol-5yl-carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)amide A mixture of 1.5 g (4.1 mMol) of 2-chloromethyl-1-methylbenzimidazol-5-yl-carboxylic acid-N-(n-propyl)-N- (2-ethoxycarbonylethyl)-amide and 0.65 g (4.8 mMol) of pcyanothiophenol was heated in 10 ml of dimethylformamide and 10 ml of diisopropylethylamine for 1 hour to 100 0
C.
The solvent was distilled off in vacuo, the crude product was dissolved in 30 ml ethyl acetate, washed with 30 ml water, and after concentration purified by flash chromatography (silica gel; methylene chloride/ethanol (49:1 to 19:1).
Yield: 1.5 g (79% of theory) of brown oil, R, value: 0.65 (silica gel; ethyl acetate/ethanol/ammonia 90:10:1) d) l-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5yl-carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)amide-hydrochloride 1.4 g (3.01 mMol) of l-methyl-2-[(4-cyanophenyl)acid-N-(n-propyl)- N-(2-ethoxycarbonylethyl)-amide were stirred in 50 ml of ethanol saturated with hydrogen chloride for 5 hours first at 0°C, later at room temperature, until no more starting material could be detected by thin layer chromatography.
Then the solvent was distilled off at a maximum bath temperature of 30 0 C, the oily residue was taken up in 40 ml of absolute ethanol and mixed with 2.8 g of ammonium carbonate. After 18 hours the solvent was distilled off in vacuo and the crude product was purified by flash chromatography (silica gel; methylene chloride/ethanol 19:1 to 4:1).
Yield: 1.3 g (83% of theory) as a light beige solid, Rf value: 0.29 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) 69
C
25
H
31
N
6 0 3 S (481.62) EKA mass spectrum: (M+H) 482 Example 28 l-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-ylcarboxylic acid-N-(n-propyl)-N-(2-hydroxycarbonylethyl)amide-hydrochloride 0.52 g (1.0 mMol) of 1-Methyl-2-[(4-amidinophenyl)acid-N-(n-propyl)- N-(2-ethoxycarbonylethyl)-amide-hydrochloride was dissolved in 15 ml ethanol, mixed with 5 ml of 2N sodium hydroxide solution and stirred for 2 hours at room temperature. Then 5 ml of water were added, the alcohol was distilled off, and it was acidified with concentrated hydrochloric acid.
The water was distilled off in vacuo, and the crude product was taken up in 5 ml of ethanol and filtered to remove the insoluble sodium chloride. After the solvent had been distilled off the title compound was obtained as a white solid.
Yield: 0.43 g (88% of theory), R, value: 0.19 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5)
C
23
H
27
N
5 0 3 S (453.57) EKA mass spectrum: (M+H) 454 476 Example 29 l-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-ylcarboxylic acid-N-(2-methylpropyl)-N-(2ethoxycarbonylethyl)-amide-hydrochloride Prepared analogously to Example 27 from 1-methyl-2-[(4acid- (N-(2-methylpropyl-N-(2-ethoxycarbonylethyl)-amide, 70 ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 83 of theory,
C
2 5
H
3 1
N
6 0 3 S (495.65) R, value: 0.30 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: 496 Example l-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-ylcarboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl) -amidehydrochloride Prepared analogously to Example 27 from l-methyl-2-[(4acid- N-phenyl-N-(2-ethoxycarbonylethyl)-amide, and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 90 of theory,
C
28
H
29
N
5 0 3 S (515.64) Rf value:0.24 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: (M+H) 516 269.7 Example 31 1-Methyl-2- (4-amidinophenyl) thiomethyl] carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl) -amidehydrochloride Prepared analogously to Example 28 from 1-methyl-2-[(4acid- N-phenyl-N- (2-ethoxycarbonylethyl) -amide-hydrochloride and sodium hydroxide solution.
Yield: 76 of theory, 71
C
26
H
25
N
5 0 3 S (487.58) R, value: 0.31 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: (M+H) 488 510 Example 32 l-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-ylsulphonic acid-N-(l-methyl-piperidin-4-yl)-N-methyl-amidehydrochloride a) 4-Chloro-3-nitrobenzenesulphonic acid-N-(1-methylpiperidin-4-yl)-N-methyl-amide To a solution of 2.2 ml (15 mMol) of l-methyl-4methylamino-piperidine in 60 ml pyridine, 3.8 g (15 mMol) of 4-chloro-3-nitro-benzenesulphonic acid chloride were added, in batches, whilst cooling with ice. The mixture was then stirred for two hours with cooling, then evaporated to dryness, the residue was mixed with about 50 ml of water and made alkaline with concentrated ammonia whilst stirring vigorously. The crude product precipitated was suction filtered and purified by column chromatography (250 g silica gel, eluant: dichloromethane with 1.5% ethanol).
Yield: 1.6 g (31% of theory),
C
13
H
18 C1N 3 0 4 S (347.8) Rf value: 0.19 (silica gel; dichloromethane/ethanol 19:1) b) 4-Methylamino-3-nitrobenzenesulphonic acid-N-methyl-N- (l-methvlpiperidin-4-vl) -amide 1.6 g (4.6 mMol) of 4-chloro-3-nitrobenzenesulphonic acid- N-methyl-N-(l-methyl-piperidin-4-yl)-amide was mixed with ml of 40% methylamine solution and stirred in a sealed flask for four hours at room temperature. Then the mixture was diluted with about 40 ml of water, the product precipitated was suction filtered, washed with water and it dried.
72 Yield: 1.5 g (95% of theory),
C
14
H
22
N
4 0 4 S (343.4) R, value: 0.45 (silica gel; dichloromethane/ethanol 4:1) c) 3-Amino-4-methylaminobenzenesulphonic acid-N-methyl-N- (1-methylpiperidin-4-yl)-amide g (4.4 mMol) of 4-methylamino-3-nitrobenzenesulphonic acid-N-methyl-N-(l-methyl-piperidin-4-yl)-amide were dissolved in 100 ml methanol and catalytically hydrogenated at room temperature and under 5 bar hydrogen pressure palladium on charcoal). Then the catalyst was filtered off and the filtrate was evaporated down. The resulting oily product was further reacted without any purification.
Yield: 1.4 g (100% of theory),
C
14
H
24
N
4 0 2 S (312.4) Rf value: 0.33 (silica gel; dichloromethane/ethanol 4:1) d) l-Methyl-2-[(4-cyanophenvl)oxymethvll-benzimidazol-5-vlsulfonic acid-N-methyl-N-(l-methyl-piperidin-4-yl)-amide 532 mg (3.0 mMol) of 4-cyanophenyloxyacetic acid and 486 mg mMol) of l,l'-carbonyldiimidazole were dissolved in ml of tetrahydrofuran and refluxed for 15 minutes. Then 700 mg (2.24 mMol) of 3-amino-4-methylaminobenzenesulphonic acid-N-methyl-N-(l-methyl-piperidin-4-yl)-amide were added and boiling was continued for a further eight hours. Then the mixture was evaporated down and the resulting oily residue was refluxed in 30 ml of glacial acetic acid for one hour. The glacial acetic acid was distilled off, the residue was mixed with about 30 ml of water and made alkaline with concentrated ammonia, and the solution was extracted three times with about 20 ml of dichloromethane.
The organic phases were dried and evaporated down. The resulting product was further reacted without any purification.
Yield: 400 mg (39% of theory),
C
23
H
27
N
5 0 3 S (453.6) Rf value: 0.37 (silica gel; dichloromethane/ethanol 4:1) 73 e) 1-Methvl-2- [(4-amidinophenyl) oxymethyll yl-sulphonic acid-N-methyl-N- (l-methylpiperidin-4-yl) amide -hydrochloride Prepared analogously to Example 25d from 400 mg of 1methyl-2- [(4-cyanophenyl) oxymethyl] sulphonic acid-N-methyl-N- (l-methylpiperidin-4-yl) -amide with ethanolic hydrochloric acid and ammonium carbonate.
Yield: 370 mg (83-01 of theory),
C
23
H
30
N
6 0 3 S (470.6) EKA mass spectrum: 471 236 Example 33 l-Methyl-2- [(4-amidinophenyl) oxymethyl] sulphonic acid-N-methyl -N-phenyl -amide -hydrochloride Prepared analogously to Example 32 from l-methyl-2-[(4cyanophenyl) -oxymethyl] -benzimidazol-5-yl-sulphonic acid-Nmethyl-N-phenyl-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 46 of theory,
C
23
H
23
N
5 0 3 S (449.5) EKA mass spectrum: 450 (M+H+Methanol)+ 482 223 Example 34 1-Methyl-2- [(4-amidinophenyl) oxymethyll sulphonic acid-N- (3-ethoxycarbonyl-n-propyl) -N-phenylamide -hydrochloride Prepared analogously to Example 32 from 1-methyl-2-[(4cyanophenyl) oxymethyl] -benzimidazol-5-yl-sulphonic acid-N-
R
4 (0 0 -74 (3-ethoxycarbonyl-n-propyl) -N-phenyl-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 57 91 of theory,
C
28
H
31
N
5 0 5 S (549.7) EKA mass spectrum: 550 Example 1-Methyl-2- [(3-amidinophenyl) oxymethyll sulphonic acid-pyrrolidide-hydrochioride Prepared analogously to Example 32 from l-methyl-2-[(3cyanophenyl) oxymethyl] -benzimidazol-5-yl-sulphonic acidpyrrolidide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 71 *1 of theory,
C
20
H
23
N
5 0 3 S (413.5) EKA mass spectrum: 414 Example 36 l-Methyl-2- (4-amidinophenyl) ethyl] carboxylic acid-N-phenyl-N- (3 -met hoxycarbonylpropyl) -amidedihydrochioride Prepared analogously to Example 25d from i-methyl-2-[2-(4cyanophenyl) ethyl] -benzimidazol-5-yl--carboxylic acid-Nphenyl-N- (3-tert.butyloxycarbonylpropyl) -amide and methanolic hydrochloric acid, methanol and ammonium carbonate.
Yield: 83.5 of theory, R, value: 0. 17 (silica gel; dichloromethane /ethanol 4: 1)
C
29
H
31
N
5 0 3 (497.6) EKA mass spectrum: 498 (M+H+Na) 260.7 75 Example 37 1-Methyl-2- (4-arnidinophenyl) ethyl] carboxylic acid-N-phenyl-N- (3-hydroxycarbonylpropyl) -amidehydrochloride Prepared analogously to Example 26 from 1-methyl-2-[(4amidinophenyl) aminomethyl] acid-N-phenyl (3 -methoxycarbonylpropyl) -amide dihydrochloride and sodium hydroxide solution.
Yield: 92 0-1 of 'theory, Rf value: 0.09 (silica gel; dichloromethane /ethanol 4:1)
C
28
H
29
N
5 0 3 (483.6) EKA mass spectrum: 484 506 253.7 Example 38 l-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-phenyl-N- (3-ethoxycarbonylpropyl) amide -dihydrochloride a) l-Methvl-2- (4-cyanophenyl) -aminomethyll -benzimidazol- 5-vl-carboxylic acid-N-phenvl-N- (3-tert .butyloxvcarbonylpropvl) -amide Prepared analogously to Example 25c from N-(4-cyanophenyl)glycine and 3 -amino-4-methylamino-benzoic acid-N-phenyl- N- (3-tert .butyloxycarbonylpropyl) -amide.
Yield: 65 ?c of theory, Rf value: 0.17 (silica gel; dichloromethane /methanol- 19:1) b) 1-Methyl-2- fN- (4-amidinophenyl) -aminomethyl] benzimidazol-5-yl-carboxvylic acid-N-phenvl- N- (3 -ethoxycarbonvlpropvl) -amide-dihvdrochloride 76 Prepared analogously to Example 25d from l-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N-phenyl-N- (3-tert .butyloxycarbonylpropyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 68 of theory, Rf value: 0.12 (silica gel; dichioromethane/ethanol 4:1)
C
29
H
32
N
6 0 3 (512.6) EKA mass spectrum: 513 268 Example 39 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazol- 5-yl-carboxylic acid-N-phenyl-N- (3-hydroxycarbonylpropyl) amide-hydrochloride Prepared analogously to Example 26 from i-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl-N- (3-ethoxycarbonyipropyl) -amidedihydrochloride and sodium hydroxide solution.
Yield: 73.5 of theory,
C
2 7
H
2 8
N
6 0 3 (484.6) EKA mass spectrum: 485 243 254 Example 1-Methyl-2- (4-amidinophenyl) ethyl] carboxylic acid-N-phenyl-N- (ethoxycarbonylmethyl) -amidehydrochloride Prepared analogously to Example 25d from i-methyl-2-[ 2 4 cyanophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-N- 77 phenyl-N-(ethoxycarbonylmethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 73 1 of theory, Rf value: 0.15 (silica gel; dichloromethane/ethanol 4:1)
C
28
H
2 9
N
5 0 3 (483.6) EKA mass spectrum: 484 253.7 Example 41 l-Methyl-2-[2-'(4-amidinophenyl)ethyl]-benzimidazol-5-ylcarboxylic acid-N-phenyl-N-(hydroxycarbonylmethyl)-amidehydrochloride Prepared analogously to Example 26 from l-methyl-2-[2-(4acid-Nphenyl-N-(ethoxycarbonylmethyl)-amide-hydrochloride and sodium hydroxide solution.
Yield: 97 of theory,
C
2 6
H
2 5
N
5 0 3 (455.5) EKA mass spectrum: 456 478 250.6 Example 42 l-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-ylcarboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amidehydrochloride Prepared analogously to Example 25d from i-methyl-2-[(4cyanophenyl) oxymethyl] -benzimidazol-5-yl-carboxylic acid-Nphenyl-N-(ethoxycarbonylmethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 76 of theory, Rf value: 0.17 (silica gel; dichloromethane/ethanol 4:1) 78
C
27
H
27
N
5 0 4 (485.6) EKA mass spectrum: 486 254.7 Example 43 l-Methyl-2- [(4-amidinophenyl) oxymethyl] carboxylic acid-N-phenyl-N- (hydroxycarbonylmethyl) -amidehydrochloride Prepared analogously to Example 26 from 1-methyl-2-[(4amidinophenyl) oxymethyl] -benzimidazol-5-yl-carboxylic acid- N-phenyl-N- (ethoxycarbonylmethyl) -amide-hydrochloride and sodium hydroxide solution.
Yield: 58 of theory,
C
25
H
23
N
5 0 4 (457.5) EKA mass spectrum: 458 480 251.6 Example 44 l-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-phenyl-N- (ethoxycarbonylmethyl) amide-hydrochloride Prepared analogously to Example 25d from l-methyl-2- [N- (4-cyanophenyl) -aminomethyl] acid-N-phenyl-N- (ethoxycarbonylmethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 74 1; of theory, Rf value: 0.12 (silica gel; dichloromethane/ethanol 4:1)
C
27
H
28
N
6 0 3 (484.6) EKA mass spectrum: 485 254 79 Example 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-phenyl-N- (hydroxycarbonylmethyl) amide-hydrochioride Prepared analogously to Example 26 from 1-methyl-2- (4amidinophenyl) -aminomethyl] acid-N-phenyl (ethoxycarbonylmethyl) -amide -hydrochloride and sodium hydroxide solution.
Yield: 84 11 of theory,
C
2 _9H 2 4
N
6 0 3 (456.5) EKA mass spectrum: 457 479 251 Example 46 1-Methyl-2- (4-amidinophenyl)oxymethyl] carboxylic acid-N- (4-pyrimidyl) (2 -ethoxycarbonyl ethyl) amide -hydrochloride Prepared analogously to Example 25d from 1-methyl-2- (4 -cyanophenyl) oxymethyl]I -benz imidazol 5-yl -carboxyl ic acid-N- (4-pyrimidyl) (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 14 t o f theory,
C
26
H
27
N
7 0 4 (501.6) Mass spectrum: 502 80 Example 47 1-Methyl-2- [(4-amidinophenyl)oxymethyl] carboxylic acid-N- (2-pyridyl) (ethoxycarbonylmethyl) amide-dihydrochioride Prepared analogously to Example 25d from 1-methyl-2- [(4-cyanophenyl) oxymethyl] acid-N- (2-pyridyl) (ethoxycarbonylmethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 44 of theory, Rf value: 0.12 (silica gel; dichioromethane/ethanol 4:1)
C
26
H
26
N
6 0 4 (486.5) EKA mass spectrum: 487 (M+2H) 244 255 Example 48 1-Methyl-2- [(4-amidinophenyl) oxymethyl] carboxylic acid-N- (2-pyridyl) (hydroxycarbonylmethyl) amide -hydrochloride Prepared analogously to Example 26 from 1-methyl-2-[(4amidinophenyl) oxymethyl] -benzimidazol-5-yl-carboxylic acid- N- (2-pyridyl) (ethoxycarbonylmethyl) -amidedihydrochloride and sodium hydroxide solution.
Yield: 85 of theory,
C
24
H
22
N
6 0 4 (458.5) EKA mass spectrum: 459 481 252 81 Examvle 49 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N- (2-pyridyl) N- (ethoxycarbonylmethyl) -amide-dihydrochioride a) 1-Methvl-2- (4-cyanophenyl) -aminomethyll -benzimidazolacid-N- (2-pyridyl) -N-ethoxvcarbonvlmethvlamide Prepared analogously to Example 25c from N-(4-cyanophenyl)glycine and 3-amino-4-methylamino-benzoic acid- N- (2-pyridyl) -N-ethoxycarbonylmethyl-amide.
Yield: 24 of theory, Rf value: 0.56 (silica gel; dichloromethane/methanol 4:1) b) I-Methvl-2- (4-amidinop~henyl) -aminomethyll acid-N- (2-pyridyl) N- (ethoxvcarbonvlmethvl) -amide -dihvdrochloride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N- (2-pyridyl) (ethoxycarbonylmethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 70 of theory, Rf value: 0.16 (silica gel; dichloromethane/ethanol 4:1)
C
26
H
27
N
7 0 3 (485.6) EKA mass spectrum: 486 243.7 254.6 82 Example 1-Methyl-2- (4-amidinophenyl) -aminomethyll-benzimidazolacid-N- (2-pyridyl) N- (hydroxycarbonylmethyl) -amide -hydrochloride Prepared analogously to Example 26 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (ethoxycarbonylmethyl) -amidedihydrochloride and sodium hydroxide solution.
Yield: 91 of theory,
C
24
H
23
N
7 0 3 (457.5) EKA mass spectrum: 458 480 251.7 Example 51 l-Methyl-2- (4-amidinophenyl) ethyl] carboxylic acid-N- (2-pyridyl) (ethoxycarbonylmethyl) amide -dihydrochioride Prepared analogously to Example 25d from l-methyl-2-[2-(4cyanophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (ethoxycarbonylmethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 90 t of theory, Rf value: 0.17 (silica gel; di chioromethane /ethanol 4:1)
C
27
H
28
N
6 0 3 (484.6) EKA mass spectrum: 485 243 254 83 Example 52 l-Methyl-2- (4-amidinophenyl) ethyl] carboxylic acid-N- (2 -pyridyl) (hydroxycarbonylmethyl) amide-hydrochioride Prepared analogously to Example 26 from l-methyl-2-[2-(4amidinophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (ethoxycarbonylmethyl) -amide-dihydrochioride and sodium hydroxide solution.
Yield: of theory,
C
25
H
24
N
6 0 3 (456.5) EKA mass spectrum: 457 479 Example 53 l-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-phenyl-N- (2-methoxyarbonylethyl) amide-hydrochloride Prepared analogously to Example 25d from l-methyl-2- [N- (4-cyanophenyl) -aminomethyl] acid-N-phenyl (2-ethoxycarbonylethyl) -amide and methanolic hydrochloric acid, methanol and ammonium carbonate.
Yield: 87 of theory, Rf value: 0.11 (silica gel; dichioromethane /ethanol 4:1)
C
27
H
28
N
6 0 3 (484.6) EKA mass spectrum: 485 243 254 84 Example 54 1-Methyl-2- [(4-amidinophenyl) oxymethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amidehydrochloride Prepared analogously to Example 25d from 1-methyl-2- [(4-cyanophenyl) oxymethyll acid-N-phenyl (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 79.5 t of theory,
C
28
H
29
N
5 0 4 (499.6) Rf value: 0.15 (silica gel; dichioromethane/ethanol 4:1) EKA mass spectrum: 500.0 261.7 Example 1-Methyl-2- (4-amidinophenyl) oxymethyl] carboxylic acid-N-phenyl-N- (2-hydroxycarbonylethyl) -amidehydrochloride Prepared analogously to Example 26 from 1-methyl-2-[(4amidinophenyl) oxymethyl] -benzimidazol-5-yl-carboxylic acid- N-phenyl (2 -ethoxycarbonyl ethyl) -amide -hydrochloride and sodium hydroxide solution.
Yield: 82 t~ of theory,
C
26
H
25
N
5 0 4 (471.5) Rf value: 0.11 (silica gel; .di chloromethane /ethanol 4:1) EKA mass spectrum: 472 247.6 494 258.6 85 Example 56 1-Methyl-2- (2-amidinothiophen-5-yl) ethyl] -benzimidazol- 5-yl-carboxylic acid-N- (2-pyridyl) (2ethoxycarbonylethyl) -amide-hydrochioride a) 1-Methvl-2- (2-cyanothiophen-5-vl) -ethyl] acid-N- (2-Pyridyl) (2ethoxycarbonylethyl) -amide Prepared analogously to Example 25c from 3-(2- -propionic acid and 3-amino- 4-methylamino-benzoic acid-N- (2-pyridyl) N- (2-ethoxycarbonylethyl) amide.
Yield: 18 *1 of theory, Rf value: 0.66 (silica gel; dichloromethane /methanol 9:1) b) 1-Methvl-2- (2-amidinothiophen-5-vl) ethyl] acid-N- (2-pyridyl) (2ethoxvcarbonylethyl) -amide-hvdrochloride Prepared analogously to Example 25d from l-methyl-2-[2-(2ethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 53 of theory,
C
26
H
28
N
6 0 3 S (504.6) Rf value: 0.22 (silica gel; dichloromethane/methanol 5:1) EKA mass spectrum: 505 264 86 Example 57 1-Methyl-2- (2-amidinothiophen-5-yl) ethyl] -benzimidazolacid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl-2-[2-(2ethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 98 of theory,
C
24
H
24
N
6 0 3 S (476.6) EKA mass spectrum: 477 (M-iNa)+ 499 239 Example 58 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazol- 5-yl-carboxylic acid-N- (2-pyridyl) (2ethoxycarbonylethyl) -amide-hydrochioride a) 1-methvl-2- (4-cyanophenyl) -aminomethyll -benzimidazolacid-N- (2-Pyridyl) (2ethoxvcarbonylethyl) -amide Prepared analogously to Example 25c from N-(4-cyanophenyl)glycine and 3-amino-4-methylamino-benzoic acid-N- (2pyridyl) (2-ethoxycarbonylethyl) -amide.
Yield: 61 t of theory, Rf value: 0.62 (silica.,gel; dichioromethane/methanol- 19:1) b) 1-Methvl-2- (4-amidinophenyl) -aminomethyll acid-N- (2-pyridyl) (2ethoxcycarbonylethyl) -amide-hydrochloride >Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyanophenyl) -aminomethyl] 87 acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 71 of theory,
C
27
H
29
N
7 0 3 (499.6) Rf value: 0.28 (silica gel; dichioromethane /methanol =5:1) EKA mass spectrum: 500 261.8 250.8 Example 59 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 91 t of theory,
C
25
H-
25
N
7 0 3 (471.5) EKA mass spectrum: 472 247.6 236.7 258.6 Example 1-Methyl-2- (4-amidinophenyl) ethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide -hydrochloride a) 1-Methvl-2- (4-cyanophenyl) -ethyll carboxvlic acid-N- (2-ovridvl) (2-ethoxvcarbonvlethvl) amide 0 -88 Prepared analogously to Example 149a from 3-(4cyanophenyl) -propionic acid and 3 -amino-4-methylaminobenzoic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide.
Yield: 22 t of theory, Rf value: 0.68 (silica gel; dichioromethane /methanol= 19:1) b) 1-methvl-2- 12- (4-amidinophenyl) ethyll -benzimidazol-S-vlcarboxylic acid-N- (2-pyridyl) (2-ethoxvycarbonylethvl) amide-hvdrochloride Prepared analogously to Example 25d from 1-methyl-2-[2-(4cyanophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 85 t of theory,
C
28
H
30
N
6 0 3 (498.6) Rf value: 0.30 (silica gel; dichloromethane /methanol 5:1) EKA mass spectrum: 499 261 Example 61 l-Methyl-2- (4-amidinophenyl) ethyl] carboxylic acid-N- (2-pyridyl) (2-hydroxycarbonylethyl) amide Prepared analogously to Example 26 from l-methyl-2- (4amidinophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (2 -ethoxycarbonyl ethyl) -amide -hydrochloride and sodium hydroxide solution.
Yield: 97 t of theory,
C
26
H
26
N
6 0 3 (470.5) EKA mass spectrum: 471 247 493 89 Example 62 1-Methyl-2- (4-amidinophenyl)ethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amidehydrochloride Prepared analogously to Example 25d from l-methyl-2-[2-(4cyanophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-Nphenyl-N- (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 86 26 of theory,
C
2 9
H
3 1
N
5 0 3 (497.6) Rf value: 0.11 (silica gel; di chloromethane /ethanol 4:1) EKA mass spectrum: 498 249.8 Example 63 l-Methyl-2- (4-amidinophenyl)ethyl] carboxylic acid-N-phenyl-N- (2-hydroxycarbonylethyl) -amidehydrochloride Prepared analogously to Example 26 from l-methyl-2-[2-(4amidinophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-Nphenyl (2-ethoxycarbonylethyl) -amide-hydrochloride and sodium hydroxide solution.
Yield: 71 15 of theory,
C
27 11 27
N
5 0 3 (469.6) EKA mass spectrum: 470 246.6 (M-iNa)+ 492 235.6 90 Example 64 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazolacid-N-(2-pyridyl)-N- (methoxycarbonylmethyl) -amide-dihydrochioride Prepared analogously to Example 25d from 1-methyl-2-[N-(4acid-N-(2-pyridyl)-N-(methoxycarbonylmethyl)-amide and methanolic hydrochloric acid, methanol and ammonium carbonate.
Yield: 73 of theory,
C
25
H
25
N
7 0 3 (471.5) Rf value: 0.12 (silica gel; dichl oromethane /ethanol 4: 1) EKA mass spectrum: 472 247.8 Example 1-Methyl-2- (4-amidinophenyl) -aminomethyl -benz imidazolacid-N-(2-pyridyl)-N-(2methoxycarbonylethyl)-amide-hydrochloride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyanophenyl) -aminomethyll acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide and methanolic hydrochloric acid, methanol and ammonium carbonate.
Yield: 78 of theory,
C
2 6H 27
N
7 0 3 (485.6) Rf value: 0.31 (silica gel; dichioromethane /methanol 5:1) EKA mass spectrum: 486 254.8 91 Example 66 1-Methyl-2- (4-amidinophenyl) ethyl] carboxylic acid-N-phenyl-N- (lH-tetrazol-5-yl) ethyl] amide-hydrochioride a) l-Methvl-2- (4-cyanophenvl)ethyll carboxylic acid-N-phenyl-N- F2- (lH-tetrazol-5-yl) ethyl] amide Prepared analogously to Example 25c from 3-(4-cyanophenyl)propionic acid and 3-amino-4-methylamino-benzoic acid- N-phenyl-N- (lH-tetrazol-5-yl) ethyl] -amide.
Yield: 67 15 of theory, IR Mass spectrum characteristic bands at 3439.5 cm- 1 2235.5 cm- 1 1631.6 cm- 1
(C=O)
b) 1-Methyl-2- (4-amidinolphenyl) ethyl] carboxylic acid-N-iphenyl-N- r2- (1H-tetrazol-5-vl) ethyl] amide -hydrochloride Prepared analogously to Example 25d from l-methyl-2-[2-(4cyanophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-Nphenyl-N- (lH-tetrazol-5-yl) ethyl] -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 92 t of theory,
C
27 11 27
N
9 0 (493.6) EKA mass spectrum: 494 516 258.7 92 Example 67 1-Methyl-2-[N-(4-amidinophenyl);-aminomethyl]-benzimidazolyl)ethyl]-amide-hydrochloride Prepared analogously to Example 25d from 1-methyl-2-[N-(4acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 29 of theory,
C
26
H
26
N
10 0 (494.6) EKA mass spectrum: (M+H) 495 Example 68 l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazolacid-N-(2-pyridyl)-N-(2-nhexyloxycarbonylethyl)-amide-hydrochloride 0.60 g (1.1 mMol) of l-methyl-2-[N-(4-amidinophenyl)acid-N-(2pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride were added to about 30 ml of n-hexanol saturated with hydrogen chloride and the mixture was stirred for 19 hours at room temperature. Then the hexanol was distilled off in vacuo, the residue was mixed with about 5 ml of IN ammonia solution with stirring and evaporated down once more. The crude product thus obtained was purified by column chromatography (silica gel, dichloromethane/methanol 5:1).
Yield: 53 of theory,
C
31
H
37
N
7 0 3 (555.7) Rf value: 0.36 (silica gel; dichloromethane/methanol 5:1 93 EKA mass spectrum: 556 Example 69 1-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyll acid-N- (2-pyridyl) (2ethoxycarbonylethyl) -amide-hydrochioride a) l-Methyl-2- (4-cyanophenyl) -N-methyl-aminomethyl] benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (2ethoxvcarbonylethyl) -amide Prepared analogously to Example 25c from N-(4-cyanophenyl)- N-methylglycine and 3 -amino-4-methylamino-benzoic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide.
Yield: 71 of theory, Rf value: 0.66 (silica gel; dichloromethane /methanol- 19 :1) b) l-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (2ethoxycarbonylethyl) -amide -hydrochloride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyanophenyl) -N-methyl-aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 77 t of theory,
C
28 11 31
N
7 0 3 (513.6) EKA mass spectrum: 514 268.7 94 Example l-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] acid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl-2-[N-(4amidinophenyl) -N-methyl-aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide-hydrochloride and sodium hydroxide solution.
Yield: 66 %k of theory,
C
26
H
27
N
7 0 3 (485.6) EKA mass spectrum: 486 508 265.6 Example 71 l-Methyl-2- (4-amidinophenyl) ethyl] carboxylic acid-N-cyclopentyl-N- (2-ethoxycarbonylethyl) amide -hydrochloride Prepared analogously to Example 25d from i-methyl-2-[2-(4cyanophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-Ncyclopentyl (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 65 t of theory,
C
28
H
35
N
5 0 3 (489.6) EKA mass spectrum: 490 0 -95 Example 72 1-Methyl-2- (4-amidinophenyl) ethyl] carboxylic acid-N-cyclopentyl-N- (2-hydroxycarbonylethyl) amide Prepared analogously to Example 26 from 1-methyl-2-[2-(4amidinophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-Ncyclopentyl (2 -ethoxycarbonylethyl) amide -hydrochloride and sodium hydroxide solution.
Yield: 89 of theory,
C
26
H
31
N
5 0 3 (461.6) EKA mass spectrum: 462 242.6 is 484 231.6 Example 73 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-cyclopentyl-N- (2ethoxycarbonylethyl) -amide-hydrochloride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N-cyclopentyl (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 60 01 of theory,
C
27
H
34
N
6 0 3 (490.6) EKA mass spectrum: 491 96 Example 74 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-cyclopentyl-N- (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-cyclopentyl-N- (2-ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 45 of theory,
C
25
H
30
N
3 0 4 (462.6) EKA mass spectrum: 463 243 485 254 Example 1-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] acid-N- (2-pyridyl) -N- (ethoxycarbonylmethyl) -amide-hydrochloride Prepared analogously to Example 25d from l-methyl-2-[N-(4cyanophenyl) -N-methyl-aminomethyl] carboxylic acid-N- (2-pyridyl) (ethoxycarbonylmethyl) amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 54 ?6 of theory,
C
27
H
29
N
7 0 3 (499.6) EKA mass spectrum: 500 (M+2H 250.7 0 -97 Example 76 l-Methyl-2- (4-amidinophenyl)-N-methyl-aminomethyl] acid-N- (2-pyridyl) -N- (hydroxycarbonylmethyl) -amide Prepared analogously to Example 26 from l-methyl-2-[N-(4amidinophenyl) -N-methyl-aminomethyl] carboxylic acid-N- (2-pyridyl) (ethoxycarbonylmethyl) amide-hydrochloride and sodium hydroxide solution.
Yield: 68 t of theory,
C
25
H
25
N
7 0 3 (471.5) EKA mass spectrum: 472 494 258.6 Example 77 l-Methyl-2- (4-amidinophenyl) -ethyl] carboxylic acid-N- (3-pyridyl) (2-ethoxycarbonylethyl) amide -hydrochloride Prepared analogously to Example 25d from l-methyl-2-[2-(4cyanophenyl) -ethyl] -benzimidazol-5-yl-carboxylic acid-N- (3pyridyl) (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 91 t of theory,
C
28 11 30
N
6 0 3 (498.6) R. value: 0. 19 (silica gel; dichloromethane /ethanol 4: 1) EKA mass spectrum: 499 98 Example 78 l-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N- (3-pyridyl) (2ethoxycarbonylethyl) -amide-dihydrochioride Prepared analogously to Example 25d from l-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N- (3-pyridyl) (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 86 Ilk of theory,
C
27 11 29
N
7 0 3 (499.6) Rf value: 0.09 (silica gel; dichioromethane/ethanol 4:1 EKA mass spectrum: 500 Example 79 l-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazol- 5-yl-carboxylic acid-N- (3-pyridyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (3-pyridyl) (2-ethoxycarbonylethyl) -amidedihydrochloride and sodium hydroxide solution.
Yield: 85 0- of theory,
C
25
H
25
N
7 0 3 (471.5) EKA mass spectrum: 472 236.6 258.6 0~ -99- Example 1-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] acid-N- (3-pyridyl) (2ethoxycarbonylethyl) -amide -hydrochloride Prepared analogously to Example 25d from 1-Methyl-2-[N-(4cyanophenyl) -N-methyl-aminomethyl] carboxylic acid-N- (3-pyridyl) (2-ethoxycarbonylethyl) amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 64 t of theory,
C
28 11 31
N
7 0 3 (513.6) EKA mass spectrum: 514 Example 81 1 -Methyl 2- (4 -amidinophenyl) -N-methyl -aminomethyl] acid-N- (3-pyridyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-Methyl-2-[N-(4amidinophenyl) -N-methyl-aminomethyll carboxylic acid-N- (3-pyridyl) (2-ethoxycarbonylethyl) amide -hydrochloride and sodium hydroxide solution.
Yield: 70 of theory,
C
26
H
27
N
7 0 3 (485.6) EKA mass spectrum: 486 508 265.6 100 Example 82 1-Methyl-2- (4-amidinopheny1),-N-methy1-aminomethy1] acid-N-phenyl-N- (2ethoxycarbonylethyl) -amide-hydrochioride a) l-Methvl-2- (4-cyanophenyl) -N-methvl-aminomethvll acid-N-phenyl-N- (2-pvridv1) -Nethoxvcarbonylethyl) -amide Prepared analogously to Example 25c from N-(4-cyanophenyl)- N-methylglycine and 3-amino-4-methylamino-benzoic acid- N-phenyl (2-ethoxycarbonylethyl) -amide.
Yield: 71 t of theory, R, value: 0.38 (silica gel; dichloromethane /methanol- 19:1) b) 1-Methvl-2- (4-amidinophenyl) -N-methyl-aminomethvll acid-N-phenyl-N- (2ethoxvcarbonylethvl) -amide-hydrochloride Prepared analogously to Example 25d from l-methyl-2-[N-(4cyanophenyl) -N-methyl-aminomethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 74 t of theory,
C
29
H
32
N
6 0 3 (512.6) EKA mass spectrum: 513 268 257 101 Example 83 l-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] acid-N-phenyl-N- (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from l-methyl-2-[N-(4amidinophenyl) -N-methyl-aminomethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 80 -1 of'theory,
C
27
H
28
N
6 0 3 (484.6) EKA mass spectrum: 485 254 507 (M+2Na)+ 265 Example 84 l-ethyl-2- (4-amidinophenyl) -aminomethyl] yl-carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide -hydrochloride Prepared analogously to Example 25d from l-ethyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 85 t of theory,
C
28
H
31
N
7 0 3 (513.6) Rf value: 0.21 (silica gel; dichloromethane /methanol 5:1) EKA mass spectrum: 514 268.6 257.7 102 Example 1-ethyl-2- (4-amidinophenyl) -aminomethyl] yl-carboxylic acid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-ethyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and 2N sodium hydroxide solution.
Yield: 49 t of theory,
C
26
H
27
N
7 0 3 (485.6) EKA mass spectrum: 486 254.6 243.6 265.7 Example 86 l-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N- (2-f luorophenyl) (2ethoxycarbonylethyl) -amide-hydrochloride Prepared analogously to Example 25d from l-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N- (2-f luorophenyl) (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 88 t of theory,
C
28
H
29
FN
6 0 3 (516.6) R, value: 0.08 (silica gel; dichloromethane/ethanol 4:1) EKA mass spectrum: 517 270 (M+2H) 259 103- Example 87 1-Methyl-2- [N-(4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-(2-fluorophenyl)-N-(2hydroxycarbonylethyl)-amide Prepared analogously to Example 26 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-(2-fluorophenyl)-N-(2-ethoxycarbonylethyl)-amidehydrochloride and sodium hydroxide solution.
Yield: 45 of theory,
C
26
H
25
FN
6 0 3 (488.5) Rf value: 0.05 (silica gel; dichloromethane /ethanol 4: 1) EKA mass spectrum: 489 267 256 Example 88 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazolacid-N-(3-methyiphenyl)-N-(2ethoxycarbonylethyl)-amide-hydrochloride Prepared analogously to Example 25d from i-methyl-2-[N-(4acid-N-(3-methylphenyl)-N-(2-ethoxycarbonylethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 79 of theory,
C
2 9
H
32
N
6 0 3 (512.6) Rf value: 0.10 (silica gel; dichloromethane/ethanol 4:1) EKA mass spectrum: 513 268 104 Example 89 l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazolacid-N-(3-methylphenyl)-N-(2hydroxycarbonylethyl)-amide Prepared analogously to Example 26 from l-methyl-2-[N-(4acid-N-(3-methylphenyl)-N-(2-ethoxycarbonylethyl)-amidehydrochloride and sodium hydroxide solution.
Yield: 62 of theory,
C
2 7
H
2 8
N
6 0 3 (484.6) EKA mass spectrum: 485 254 507 265 Example l-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl] acid-N-phenyl-N- (2-ethoxycarbonylethyl)-amide 1.1 g (2.06 mMol) of l-methyl-2-[N-(4-amidinophenyl)aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl)-amide-hydrochloride was dissolved in a mixture of 40 ml of tetrahydrofuran and 10 ml of water, then 570 mg (4.12 mMol) of potassium carbonate and 362 mg (2.2 mMol) of n-hexyl chloroformate were added and stirred for two hours at room temperature. The solvent was then distilled off, the residue was mixed with about 50 ml of saturated saline solution and the resulting solution was extracted three times with 20 ml of dichloromethane. The extracts were dried over sodium sulphate and evaporated down. The crude product thus obtained was purified by column chromatography (100 g silica gel; dichloromethane 5% ethanol).
105 Yield: 78 of theory,
C
35
H
42
N
6 0 5 (626.8) R, value: 0.49 (silica gel; dichlorornethane/ethanol 19:1) E KA mass spectrum: 627 325 314 Example 91 l-Methyl-2- (N-methoxycarbonylamidino)phenyl] -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl -ethoxycarbonyl ethyl) amide -hydrochloride and methyl chioroformate.
Yield: 41 of theory,
C
30
H
32
N
6 0 5 (556.6) Rf value: 0.85 (silica gel; dichloromethane /ethanol =4:1) EKA mass spectrum: 557 290 579 Example 92 1-Methyl-2- (N-ethoxycarbonylamidino) phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2 -methoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl (2-methoxycarbonylethyl) -amidehydrochloride and ethyl chioroformate.
Yield: 62 of theory, X C 30
H
32
N
6 0 5 (556.6) 0 -106 Rf value: 0.51 (silica gel; dichloromethane/ethanol =19:1) EKA mass spectrum: 557 290 (M+2H) 279 Example 93 l-Methyl-2- (N-cyclohexyloxycarbonylamidino)phenyl) aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl-N- (2-methoxycarbonylethyl) -amidehydrochloride and cyclohexyl chloroformate.
Yield: 25 of theory,
C
34
H
38
N
6 0 5 (610.7) Rf value: 0.44 (silica gel; dichloromethane /ethanol 19:1) EKA mass spectrum: 611 306 Example 94 l-Methyl-2- (methylsulphonyl)ethyloxycarbonyl] amidino] phenyl] -aminomethyl] acid-N-phenyl (2 -ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl (2-ethoxycarbonylethyl) amide -hydrochloride and 2- (methylsulphonyl) -ethyl chloroformate.
Yield: 66 1; of theory,
C
32
H
36
N
6 0 7 S (648.8) Rf value: 0.44 (silica gel; dichloromethane /ethanol 19:1) EKA mass spectrum: 649 4 336 107 (M+2H) 325 Example 1-Methyl-2-[N-[4-(N-n-octyloxycarbonylamidino)phenyl]acid-N-phenyl-N- (2-methoxycarbonylethyl)-amide Prepared analogously to Example 90 from l-methyl-2-[N-(4acid-N-phenyl-N-(2-methoxycarbonylethyl)-amidehydrochloride and n-octyl chloroformate.
Yield: 41 of theory,
C
36
H
44
N
6 0 5 (640.8) Rf value: 0.43 (silica gel; dichloromethane/ethanol 19:1) EKA mass spectrum: (M+H) 641 (M+Na) 663 Example 96 l-Methyl-2-[N-[4-(N-hydroxylamidino)phenyl]-aminomethyl acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide 1.44 g (3.0 mMol) of l-methyl-2-[N-(4-cyanophenyl)acid-N-phenyl-N- (2-ethoxycarbonylethyl)-amide, 0.625 g (9.0 mMol) of hydroxylamine hydrochloride and 0.425 g (4.0 mMol) of sodium carbonate were dissolved in 80 ml of ethanol and refluxed for 7 hours. Then a further 210 mg of hydroxylamine hydrochloride and 170 mg of sodium carbonate were added, the mixture was boiled for a further 5 hours and then evaporated down in vacuo. The residue was dissolved in about 30 ml of dichloromethane, the solution obtained was washed with 20 ml of water, the organic phase was dried and evaporated down. The crude product thus 108 obtained was purified by column chromatography (200 g silica gel, dichloromethane 4% ethanol).
Yield: 39 t of theory,
C
28
H
30
N
6 0 4 (514.6) Rf value: 0.15 (silica gel; dichloromethane /ethanol 19:1) EKA mass spectrum: 515 537 1029 (2M+Na)+ 1051 Example 97 1-Methyl-2- (N-n-heptyloxycarbonylamidino)phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl (2-methoxycarbonylethyl) -amidehydrochloride and n-heptyl chioroformate.
Yield: 43 t of theory,
C
35
H
42
N
6 0 5 (626.8) R. value: 0.40 (silica gel; dichloromethane /ethanol 19:1) EKA mass spectrum: 627 325 649 Example 98 1-Methyl-2- (N-benzoylamidino)phenyl] -aminomethyl] acid-N-phenyl-N- (2methoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] 109 acid-N-phenyl (2-methoxycarbonylethyl) -amidehydrochloride and benzoyl chloride.
Yield: 88 %1 of theory,
C
34
H
32
N
6 0 4 (588.7) Rf value: 0.37 (silica gel; dichioromethane /ethanol 19:1) 1 H-NMR spectrum (D 6 -DMSO): 2.61 3.54 3.76 4.10 4.61 6.83 7.05 to 7.55 (m,12H),8.03 8.25 (dd,2H), 8.98 10.48 (s,1H) Example 99 1-Methyl-2- (N-n-hexyloxycarbonylamidino)phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl-N- (2-methoxycarbonylethyl) -amidehydrochloride and n-hexyl chioroformate.
Yield: 54 11 of theory,
C
34
H
40
N
6 0 5 (612.7) Rf value: 0.45 (silica gel; dichioromethane /ethanol 19:1) EKA mass spectrum: 613 Example 100 1-Methyl-2- (N-n-hexyloxycarbonylamidino) phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2 -n-propyloxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl-N- (2-n-propyloxycarbonylethyl) -amidehydrochloride and n-hexyl chloroformate.
SYield: 31 of theory, 110
C
36
H
44
N
6 0 5 (640.8) Rf value: 0.42 (silica gel; dichioromethane /ethanol 19:1) EKA mass spectrum: 641 332 663 Example 101 1-Methyl-2- (N-ethoxycarbonylamidino)phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-methoxycarbonylethyl) -amidehydrochloride and ethyl chloroformate.
Yield: 72 *1 of theory,
C
29
H
31
N
7 0 5 (557.6) Rf value: 0.58 (silica gel; dichloromethane/methanol= 9:1) EKA mass spectrum: 558 290.8 580 Example 102 1-Methyl-2- (N-n-octyloxycarbonylamidino)phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2- (4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-methoxycarbonylethyl) -amidehydrochloride and n-octyl chioroformate.
Yield: 57 of theory,
C
35
H
43
N
7 0 5 (641.8) 0 ill R. value: 0.60 (silica gel; di chloromethane /methanol 9:1) EKA mass spectrum: 642 332.8 664 sT F< 112 Example 103 l-Methyl-2-[N-[4-(N-methoxycarbonylamidino)phenyl]-aminoacid-N-(2-pyridyl)- N-(2-ethoxycarbonylethyl)-amide Prepared analogously to Example 90 from l-methyl-2-[N-(4acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amidehydrochloride and methyl chloroformate.
Yield: 48 of theory,
C
29
H
31
N
7 0 5 (557.6) Rf value: 0.62 (silica gel; dichloromethane/methanol 9:1) EKA mass spectrum: 558 290.7 (M+Na) 580 Example 104 1-Methyl-2-[N-[4-(N-n-octyloxycarbonylamidino)phenyl]acid-N-(2pyridyl)-N-(2-hydroxycarbonylethyl)-amide 0.7 g (1.1 mMol) of l-methyl-2-[N-[4-(N-noctyloxycarbonylamidino) -phenyl] -aminomethyl] -benzimidazolacid-N-(2-pyridyl)-N-(2methoxycarbonylethyl)-amide was stirred in a mixture of 0.12 g (3.0 mMol) of sodium hydroxide, 5 ml of water and ml of methanol for one hour at room temperature. Then the mixture was diluted with 20 ml of water and adjusted to pH 6 with glacial acetic acid. Then about 5 ml of diethylether were added and the mixture was vigourously stirred for one hour. The product thus precipitated was suction filtered, washed with a little water, then with diethylether and dried.
Yield: 80 of theory, 113
C
34
H
41
N
7 0 5 (627.8) EKA mass spectrum: 628 325.7 (M+Na) 650 (M-42Na)++ 337.7 Example 105 1-Methyl-2- (2-methylsulphonylethyloxycarbonyl) amidino] -phenyl] -aminomethyl] acid-N- (2-pyridyl) N- (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and 2- (methylsuiphonyl) -ethyl chioroformate.
Yield: 65 01; of theory,
C
31 11 35
N
7 0 7 S (649.7) Rf value: 0.54 (silica gel; dichloromethane /methanol =9:1) EKA mass spectrum: 650 336.6 672 347.6 Example 106 1 -Methyl 2- [4 (N-n-butyloxycarbonylamidino) phenyl]I aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-methoxycarbonylethyl) -amidehydrochloride and n-butyl chloroformate.
7.
114 Yield: 30 lk of theory,
C
31
H
35
N
7 0 5 (585.7) Rf value: 0.62 (silica gel; dichloromethane /methanol 9:1) EKA mass spectrum: 586 304.7 293.7 Example 107 1-Methyl-2- (N-n-hexyloxycarbonylamidino)phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-methoxycarbonylethyl) -amidehydrochloride and n-hexyl chloroformate.
Yield: 51 of theory,
C
33
H
39
N
7 0 5 (613.7) R. value: 0.56 (silica gel; dichloromethane /methanol =9:1) EKA mass spectrum: 614 318.7 307.6 Examvle 108 1-Methyl-2- (N-n-heptyloxycarbonylamidino) -phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2- (4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-methoxycarbonylethyl) -amidehydrochloride and n-heptyl chloroformate.
Yield: 21 of theory,
C
34
H
41
N
7 0 5 (627.8) 0 -115 R, value: 0.60 (silica gel; dichioromethane /methanol 9:1) EKA mass spectrum: 628 325.7 314.7 Example 109 1-Methyl-2- (N-n-pentyloxycarbonylamidino) -phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-methoxycarbonylethyl) -amidehydrochloride and n-pentyl chloroformate.
Yield: 66 of theory,
C
32
H
37
N
7 0 5 (599.7) Rf value: 0.58 (silica gel; dichloromethane /methanol 9:1) EKA mass spectrum: 600 311.7 622 Example 110 1 -Methyl 2- [4 (N-n-nonyloxycarbonylamidino) phenyl]I aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-methoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2- (4amidinophenyl) -aminomethyll acid-N- (2-pyridyl) (2 -methoxycarbonyl ethyl) -amidehydrochloride and n-nonyl chloroformate.
Yield: 60 of theory,
C
36 11 45
N
7 0 5 (655.8) Rf value: 0.48 (silica gel; dichloromethane /methanol 9:1) EKA mass spectrum: 656 116 339.8 678 0 -117 Example 111 1l-Methyl 2- [4 (N-benzoylamidino) phenyl] -aminomethyl] acid-N- (2-pyridyl) (2methoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-methoxycarbonylethyl) -amidehydrochloride and benzoyl chloride.
Yield: 62 of,'theory,
C
33
H
31
N
7 0 4 (589.7) Rf value: 0.50 (silica gel; dichloromethane /methanol 9:1) EKA mass spectrum: 590 612 Example 112 1 -Methyl 2- [4 (N-nicot inoylamidino) phenyl]I aminomethyl]I benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (2methoxycarbonylethyl) -amide Prepared analogously to Example 90 from i-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2 -methoxycarbonyl ethyl) -amidehydrochloride and nicotinic acid chloride.
Yield: 40 11 of theory,
C
32
H
30
N
8 0 4 (590.7) Rf value: 0.47 (silica gel; dichloromethane/methanol 9:1) EKA mass spectrum: 591 307 613 0- 118 Example 113 1-Methyl-2- (N-n-hexyloxycarbonylamidino)phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and n-hexyl chloroformate.
Yield: 51 of theory,
C
34
H
41
N
7 0 5 (627.8) Rf value: 0.53 (silica gel; dichloromethane /methanol 9:1) EKA mass spectrum: 628 325.7 314.7 Example 114 l-Methyl-2- (N-n-octyloxycarbonylamidino)phenyl] aminomethyll -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and n-octyl chloroformate.
Yield: 57 of theory,
C
36 11 45
N
7 0 5 (655.8) Rf value: 0.46 (silica gel; dichloromethane /methanol 9:1) EKA mass spectrum: 656 339.7 328.7 0 -119 Example 115 l-Methyl-2- (2-methylsulphonylethyloxycarbonyl)amidino] -phenyl] -aminomethyl] benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -Nethoxycarbonylmethyl -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) -N-ethoxycarbonylmethyl-amidehydrochloride and 2- (methylsulphonyl) -ethyl chloroformate.
Yield: 72 of theory,
C
30
H
33
N
7 0 7 S (635.7) Rf value: 0.23 (silica gel; dichloromethane /ethanol 19:1) EKA mass spectrum: 636 (M+H-iNa) 329.8 Example 116 l-Methyl-2- (N-cyclohexyloxycarbonylamidino) phenyl] aminomethyll -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) -N-methoxycarbonylmethyl -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2 -pyridyl) -N-methoxycarbonylmethyl-amidehydrochloride and cyclohexyl chloroformate.
Yield: 40 of theory,
C
32
H
35
N
7 0 5 (597.7) Rf value: 0.26 (silica gel; dichioromethane /ethanol =19:1) EKA mass spectrum: 598 620 120 Example 117 1-Methyl-2- (N-methoxycarbonylamidilo) -phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) -N-ethoxycarbonylmethyl-amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) -N-ethoxycarbonylmethyl-amidehydrochloride and methyl chioroformate.
Yield: 62 11 of theory,
C
28
H
29
N
7 0 5 (543.6) R. value: 0.19 (silica gel; dichloromethane/ethanol 19:1) EKA mass spectrum: 544 283.8 566 Example 118 1-Methyl-2- (N-ethoxycarbonylamidino) -phenyl] -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl)
-N-
methoxycarbonylmethyl -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2 -pyridyl) -N-methoxycarboflylmethyl -amide hydrochloride and ethyl chloroformate.
Yield: 42 of theory,
C
28
H
29
N
7 0 5 (543.6) Rf value: 0.20 (silica gel; dichloromethane /ethanlol 19:1) EKA mass spectrum: 544 121 Example 119 l-Methyl-2- (N-n-octyloxycarbonyl-amidino) phenyll aminomethyll -benzimidazol-5-yl-carboxylic acid-N- (3pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (3-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and n-octyl chioroformate.
Yield: 35 of-theory,
C
36
H
45
N
7 0 5 (655.8) Rf value: 0.28 (silica gel; dichloromethane /ethanol 19:1) EKA mass spectrum: 656 328.7 Example 120 l-Methyl-2- (N-n-hexyloxycarbonylamidino) -phenyl] N-methyl-aminomethyl] -benzimidazol-5-yl-carboxylic acid- N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from i-methyl-2-[N-(4amidinophenyl) -N-methyl-aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide-hydrochioride and n-hexyl chioroformate.
Yield: 58 of theory,
C
35
H
43
N
7 0 5 (641.2) Rf value: 0.42 (silica gel; dichloromethane /ethanol 19:1) EKA mass spectrum: 642 332.7 122 Example 121 l-Methyl-2- (N-n-octyloxycarbonylamidino) -phenyl] N-methyl-aminomethyl] -benzimidazol-5-yl-carboxylic acid- N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -N-methyl-aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide-hydrochloride and n-octyl chioroformate.
Yield: 36 of theory,
C
37
H
47
N
7 0 5 (669.8) EKA mass spectrum: 670 346.8 335.6 Example 122 1-Methyl-2- (N-n-butyloxycarbonylamidino) -phenyl] N-methyl-aminomethyl] -benzimidazol-5-yl-carboxylic acid- N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -N-methyl -aminomethyl] -benzimidazol -5 -yl carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide-hydrochloride and n-butyl chioroformate.
Yield: 34 %of theory,
C
33 11 39
N
7 0 5 (613.7) EKA mass spectrum: 614 318.7 636 123 Example 123 l-Methyl-2-[N-[4-(N-benzoylamidino)phenyl]-N-methyl-aminoacid-N-(2-pyridyl)- N-(2-ethoxycarbonylethyl)-amide Prepared analogously to Example 90 from l-methyl-2-[N-(4carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide-hydrochloride and benzoyl chloride.
Yield: 63 of-theory,
C
3 5
H
3 5
N
7 0 4 (617.7) EKA mass spectrum: (M+H) 618 320.7 640 Example 124 l-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl- (1-ethoxycarbonylmethyl-cyclohex-1-yl) -ketone-hydrochloride a) 4-Chlorophenl- (l-hydroxycarbonvlmethyl-cyclohex-l-vl)ketone 8.4 g (40 mMol) of 3-(4-chlorobenzoyl)-propionic acid were dissolved in 300 ml of tetrahydrofuran and 5.8 g (120 mMol) of sodium hydride (50-60% suspension in paraffin oil) were added in batches. Then the mixture was refluxed for hours with stirring, after which 8.9 ml (60 mMol) of diiodopentane were added dropwise and boiling was continued for a further three hours. After cooling the solution was stirred into 200 ml of ice-water, then the tetrahydrofuran was distilled off in vacuo, the resulting aqueous solution was acidified with 2N hydrochloric acid and extracted three times with 150 ml of dichloromethane. The organic phase was dried and evaporated down, the crude product thus obtained was purified by column chromatography (500 g silica gel; eluant: dichloromethane with 1-2% ethanol).
124 Yield: 6.2 g (55% of theory) of oily product,
C
15
H
17 C10 3 (280.8) R, value: 0.56 (silica gel; dichloromethane/ethanol 19:1) b) 4-Chloro-3-nitrophenvl-(l-hydroxycarbonylmethylcyclohex-1-yl)-ketone g (25 mMol) of 4-chlorophenyl-(1-hydroxycarbonylmethylcyclohex-l-yl)-ketone were added in batches, with stirring, at -5 to -100C, to 80 ml of fuming nitric acid.
The solution was then stirred for a further 10 minutes, then stirred into 200 ml of ice-water, the precipitated product was then washed with water and dried.
Yield: 7.8 g (96% of theory),
C
15
H
16 C1N0 5 (325.8) Rf value: 0.41 (silica gel; petroleum ether/ethyl acetate 4:6) c) 4-Methylamino-3-nitrophenyl-(l-hydroxycarbonylmethylcyclohex-l-yl)-ketone 7.8 g 23.9 mMol) of 4-chloro-3-nitrophenyl-(1hydroxycarbonylmethyl-cyclohex-l-yl)-ketone were stirred in 100 ml of a 40% aqueous methylamine solution at room temperature for 14 hours, then diluted with about 150 ml of water and made slightly acidic with glacial acetic acid.
The precipitated product was suction filtered, washed with water and dried.
Yield: 7.1 g (93% of theory),
C
16
H
20
N
2 0 5 (320.4) Rf value: 0.34 (silica gel; dichloromethane/ethanol 19:1) d) 4-Methylamino-3-nitrophenyl-(1-methoxycarbonvlmethvlcyclohex-1-yl)-ketone 4.9 g (15 mMol) of 4-methylamino-3-nitrophenyl-(1hydroxycarbonylmethyl-cyclohex-1-yl)-ketone were dissolved in 100 ml of tetrahydrofuran, 2.4 g (15 mMol) of 1,1'carbonyl-diimidazole were added and the mixture was refluxed for 15 minutes. Then the solvent was evaporated 125 off, 30 ml of methanol were added and the mixture was boiled for three hours with stirring. After the methanol had been distilled off the crude product thus obtained was purified by column chromatography (250 g silica gel, eluant: dichloromethane with 1 to 5% ethanol).
Yield: 2.4 g (48% of theory),
C
17
H
22
N
2 0 5 (334.4) Rf value: 0.76 (silica gel; dichloromethane/ethanol 19:1) e) 3-Amino-4-methylaminophenvl-(1-methoxycarbonvlmethylcyclohex-l-yl)-ketone 2.4 g (7.2 mMol) of 4-methylamino-3-nitrophenyl-(1methoxycarbonylmethyl-cyclohex-1-yl)-ketone were catalytically hydrogenated in 100 ml of methanol at room temperature under 5 bar hydrogen pressure (10% palladium on charcoal). The crude product thus obtained was further reacted without purification.
Yield: 2.1 g (96% of theory), Rf value: 0.34 (silica gel; dichloromethane/ethanol 19:1) f) 3-(4-Cyanophenyloxyacetylamino)-4-methylaminophenyl- (1-methoxycarbonylmethyl-cyclohex-l-yl)-ketone 620 mg (3.5 mMol) of 4-cyanophenyloxyacetic acid and 570 mg mMol) of l,1'-carbonyl-diimidazole were refluxed in 50 ml of tetrahydrofuran for 15 minutes. Then 1.0 g (3.28 mMol) of 3-amino-4-methylaminophenyl-(1-methoxycarbonylmethyl-cyclohex-l-yl)-ketone were added and the mixture was boiled for a further 4 hours. Then the solvent was evaporated off and the crude product thus obtained was purified by column chromatography (150 g silica gel; eluant: dichloromethane with 0 to 2% ethanol).
Yield: 1.4 g (93% of theory),
C
26
H
29
N
3 0 5 (463.5) Rf value: 0.44 (silica gel; dichloromethane/ethanol 19:1) 126 g) 1-Methvl-2- [(4-cvanop~henvl)oxvmethvll (l-methoxvcarbonvlmethyl-cvclohex-l-vl) -ketone 1.4 g (3.02 mMol) of 3-(4-cyanophenyloxyacetylamino)-4methylaminophenyl- (1-methoxycarbonylmethyl-cyclohex-1-yl) ketone were ref luxed in 50 ml of glacial acetic acid for one hour. Then the glacial acetic acid was distilled off, the residue was mixed with 20 ml of water and made alkaline with concentrated ammonia. This solution was extracted three times with 20 ml of dichloromethane, the organic extracts were dried and evaporated down. The crude product thus obtained was purified by column chromatography (100 g silica gel; eluant: dichloromethane with 0 to 2%0 ethanol).
Yield: 700 mg (5201 of theory),
C
2 6
H
2 7
N
3 0 4 (445.5) h) 1-Methvl-2- [(4-amidinophenvl) oxvmethyll yi- (1-ethoxvycarbonvlmethvl-cvclohex-l-vl) -ketonehydrochloride Prepared analogously to Example 25d from 700 mg (1.57 mMol) of l-methyl-2- (4-cyanophenyloxymethyl) (l-methoxycarbonylmethyl-cyclohex-l-yl) -ketone with ethanolic hydrochloric acid and ammonium carbonate.
Yield: 390 mg (50% of theory),
C
27
H
32
N
4 0 4 (476.6) EKA mass spectrum: 477 1 H-NMR spectrum(d 6 -DMSO) 1.10 1.0-2.15 (m,lOH) 3. 36 3H) 3. 90 2H1); 3. 94 2H) 5. 60 2H) 7.25-7.40 3H) 7.56-7. 75 2H) 7. 90 2H) 9.20 (broad s,4H) ppm.
127 Example 125 l-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazol- .butyl-ketone-hydrochloride Prepared analogously to Example 25d from 1-methyl-2-[(N- (4cyanophenyl) -aminomethyl] -benzimidazol-5-yl-tert .butylketone, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 59 of theory,
C
21 11 25
N
5 0 (363.5) EKA mass spectrum: 364 Example 126 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazol- (l-methylcyclopent-l-yl) -ketone-hydrochloride Prepared analogously to Example 25d from l-methyl-2-[N-(4cyanophenyl) -aminomethyl] -benzimidazol-5-yl- (1methylcyclopent-1-yl) -ketone, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 63.5 21 of theory,
C
23
H
27 NS0 (389.5) EKA mass spectrum: 390 128 Example 127 2-[(4-amidinophenyl)sulphinylmethyl]-benzothiazol-5-ylcarboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amidehydrochloride A solution of 0.15 g (0.27 mMol) of acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride in 10 ml of acetic acid was mixed with 0.09 ml (about 0.81 mMol) of 30% hydrogen peroxide solution and stirred at room temperature. After 4 days a further 0.18 ml of hydrogen peroxide solution was added and the resulting mixture was stirred for a further two days. After removal of the solvent in vacuo the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol 10:1 to 4:1).
Yield: 58 of theory,
C
27
H
26
N
4 0 4
S
2 (534.66) R, value: 0.24 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: 535 Example 128 l-Methyl-2-[(4-amidinophenyl)sulphonylmethyl]-benzimidazolacid-N-(n-propyl)-N-(2ethoxycarbonylethyl)-amide-hydrochloride A solution of 0.40 g (0.70 mMol) of l-methyl-2-[(4acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amidehydrochloride in 10 ml of formic acid was mixed with 2 ml of 30% hydrogen peroxide solution and the mixture was stirred for 16 hours at room temperature. Then the solvent N was distilled off in vacuo, whereupon the desired compound 0 129 was obtained as a beige solid (contaminated with some l-methyl-2-[(4-amidinophenyl)sulfinylmethyl]-benzimidazolacid-N-(n-propyl)-N-(2ethoxycarbonylethyl)-amide-hydrochloride).
Yield: 95 %of theory,
C
25
H
31
N
6 0 5 S (513.62) Rf value: 0.50 (silica gel; ethyl acetate/ethanol/lN hydrochloric acid 50:45:5) EKA mass spectrum: 514 Example 129 2-[N-(4-amidinophenyl)-aminomethyl]-thiazolo[5,4-b]pyridin- 6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide-hydrochloride a) Methyl 5-amino-6-chloro-nicotinate A solution of 1.08 g (5.00 mMol) of methyl nitro-nicotinate (see A.H. Berrie, G.T. Newbold, F.S.
Spring in J. Chem. Soc., 2590, 1951) in 25 ml of absolute ethanol was mixed successively with 0.53 ml (29 mMol) of water, 3.2 g (57 mMol) of iron powder and 0.030 ml of concentrated hydrochloric acid and heated to boiling for one hour. Then equal quantities of water, iron powder and hydrochloric acid were added and the mixture was heated to boiling for 30 minutes. The precipitate formed on cooling was filtered off and washed with ethanol and the solvent was distilled off in vacuo.
Yield: 0.75 g (81% of theory) of greenish-yellow solid, R, value: 0.31 (silica gel;ethyl acetate/petroleum ether 1:4)
C
7
H
7 C1N 2 0 2 (186.60) YEF- Mass spectrum: M+ 186 and 188 (chlorine isotopes).
130 b) Methyl A solution of 0.75 g (4.02 mMol) of methyl 5-amino-6chloro-nicotinate and 0.43 g 0.35 ml (4.5 mMol) of methoxyacetylchloride in 20 ml of chlorobenzene was stirred for one hour at 1100C. After the solvent had been removed in vacuo the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol 100:1), evaporated down again in vacuo and then digested with petroleum ether.
Yield: 0.55 g (53% of theory) light yellow amorphous solid, R, value: 0.33 (silica gel; ethyl acetate/petroleum ether 1:4) c) Methyl 2-methoxymethyl-thiazolo 5,4-b]pyridin-6-ylcarboxylate A mixture of 0.53 g (2.05 mMol) of methyl methoxyacetamido-nicotinate and 0.42 g (1.0 mMol) of Lawessons reagent was refluxed for 16 hours in 25 ml of xylene. After the solvent had been removed in vacuo the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol 100:1) and evaporated down again in vacuo.
Yield: 0.33 g (67% of theory) of yellow amorphous solid, Rf value: 0.52 (silica gel; ethyl acetate/petroleum ether 1:4) d) 2-Methoxymethyl-thiazolo[5,4-b]pyridin-6-yl-carboxylic acid A mixture of 1.1 g (4.62 mMol) of methyl 2-methoxymethylthiazolo[5,4-b]pyridine-6-carboxylate and 9.2 ml of 2N sodium hydroxide solution were stirred into 50 ml of ethanol for one hour at room temperature. Then 9.2 ml of 2N hydrochloric acid were added, the alcohol was distilled off, and it was diluted with 20 ml of water. The aqueous phase was acidified with concentrated hydrochloric acid 131whilst cooling with ice, the beige precipitate formed was filtered off, then washed with water and dried.
Yield: 1.03 g (100% of theory), Rf value: 0.10 (silica gel; ethyl acetate/petroleum ether 3:7) e) 2-Methoxymethyl-thiazolo[5,4-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonvlethvl)-amide A suspension of 1.03 g (4.62 mMol) of 2-methoxymethylthiazolo[5,4-b]pyridin-6-yl-carboxylic acid in 40 ml of methylene chloride was mixed with 1.6 g 1.0 ml (13.5 mMol) of thionyl chloride and refluxed for 90 minutes, during which time the solid gradually dissolved. After the liquid components had been distilled off the crude product was taken up twice more in methylene chloride and concentrated again. The resulting crude acid chloride (1.2 g) was taken up in 40 ml of tetrahydrofuran, added dropwise to a mixture of 0.94 g (4.86 mMol) of N-(2-ethoxycarbonylethyl)aniline and 2.1 ml (13.8 mMol) of triethylamine in 30 ml of tetrahydrofuran and stirred for 2 hours at room temperature. Then it was diluted with 200 ml of ethyl acetate, washed with 100 ml of 14% saline solution and the organic phase was dried with sodium sulphate.
After the solvent had been removed in vacuo the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol 100:1).
Yield: 1.57 g (87% of theory)of yellow oil, R, value: 0.55 (silica gel; methylene chloride/ethanol 19:1) f) 2-[N-(4-Cvanophenyl)-aminomethyl]-thiazolo[5,4-b pyridin-6-yl-carboxvlic acid-N-phenyl-N-(2ethoxycarbonylethvl)-amide A mixture of 1.54 g (3.85 mMol) of 2-methoxymethylthiazolo[5,4-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide and 4.3 ml (4.3 mMol) of a 1 Smolar solution of boron tribromide in methylene chloride 132 was dissolved in a further 30 ml of methylene chloride and stirred for 5 hours at room temperature. Then the mixture was washed with 40 ml of saturated sodium hydrogen carbonate solution, the organic phase was dried with sodium sulphate and the solvent was distilled off. The crude product (1.9 g) was taken up in 15.0 ml of N,N-diisopropylethylamine, mixed with 0.50 g (4.2 mMol) of 4-aminobenzonitrile and heated to boiling for one hour.
Then the solvent was distilled off in vacuo, the crude product was taken up in 100 ml of methylene chloride, the organic phase was washed with 100 ml of water and dried with sodium sulphate. After the solvent had been removed in vacuo the crude product obtained was purified by flash chromatography (silica gel; ethyl acetate/petroleum ether 35:65 to 1:1) and evaporated down again in vacuo.
Yield: 0.45 g (24% of theory) of yellow amorphous solid, Rf value: 0.34 (silica gel; ethyl acetate/petroleum ether 1:1) g) 2-[N-(4-amidinophenyl)-aminomethyl]-thiazolo[5,4-b pvridin-6-yl-carboxylic acid-N-phenvl-N-(2ethoxycarbonvlethyl)-amide-hvdrochloride 0.39 g (0.803 mMol) of 2-[N-(4-cyanophenyl)-aminomethyl]thiazolo[5,4-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide were stirred in 40 ml of ethanol saturated with hydrogen chloride for 5 hours first at 0 C and then at room temperature, until no more starting material could be detected by thin layer chromatography.
Then the solvent was distilled off at a maximum bath temperature of 300C, the oily residue was taken up in 40 ml of absolute ethanol and mixed with 0.5 g ammonium carbonate. After 18 hours the solvent was removed in vacuo and the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol 9:1 to 4:1).
!s Yield: 78 of theory of yellow foam, 133
C
26
H
26
N
6 0 3 S (502.60) R, value: 0.19 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: (M+H) 503 Example 130 l-Methyl-2-[(4-amidinophenyl)methylthio]-benzimidazol-5-ylcarboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amidehydrochloride a) l-Methyl-2-mercapto-benzimidazol-5-vl-carboxvlic acid-Nphenyl-N-(2-ethoxycarbonylethyl)-amide A solution of 6.5 g (19 mMol) of 3-amino-4-methylaminobenzoic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide and g (22.8 mMol) of N,N'-thiocarbonyldiimidazole were dissolved in 100 ml of tetrahydrofuran under a nitrogen atmsphere, the solution was heated to 90 0 C for 4 hours and left to stand for 16 hours at room temperature. After removal of the solvent in vacuo the crude product obtained was purified by flash chromatography (silica gel; petroleum ether/ethyl acetate 100:0 to 65:35).
Yield: 6.8 g (93 of theory) of beige crystalline solid, Rf value: 0.55 (silica gel; ethyl acetate) b) l-Methyl-2-[(4-cyanophenyl)methylthio]-benzimidazol-5yl-carboxylic acid-N-phenyl-N-(2-ethoxvcarbonvlethvl)-amide A solution of 1.30 g (3.4 mMol) of l-methyl-2-mercaptobenzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide, 0.52 g (3.74 mMol) of potassium carbonate and 0.66 g (3.4 mMol) of 4-bromomethylbenzonitrile were dissolved in 40 ml of absolute ethanol, stirred for 4 hours at 60 0 C and 16 hours at room temperature. Then the solvent was distilled off in vacuo, the crude product was taken up in 30 ml of methylene chloride, washed with 40 ml of water and dried with sodium 134 sulphate. After filtration and distillation of the solvent the desired compound was obtained as a beige-white solid.
Yield: 1.8 g (100 of theory),.
Rf value: 0.64 (silica gel; ethyl acetate) c) l-Methyl-2-[(4-amidinophenyl)methylthio]-benzimidazol-5yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide-hydrochloride g (3.0 mMol) of l-methyl-2-[(4-cyanophenyl)methylthio]benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide were stirred in 80 ml of ethanol saturated with hydrogen chloride for 6.5 hours first at 0°C, then at room temperature, until no more starting material could be detected by thin layer chromatography.
Then the solvent was distilled off at a maximum bath temperature of 30 0 C, the oily residue taken up in 80 ml of absolute ethanol and mixed with 1.0 g (10.5 mMol) of ammonium carbonate. After 18 hours the solvent was distilled off in vacuo and the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol 19:1 to 10:1).
Yield: 78 of theory of light beige solid,
C
2 8H 29
N
5 0 3 S (515.63) R, value: 0.19 (silica gel; methylene chloride/ethanol 4:1) EKA mass spectrum: (M+H) 516 269.7 258.7 Example 131 l-Methyl-2-[(4-amidinophenyl)methylthio]-benzimidazol-5-ylcarboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amidehydrochloride 135 Prepared analogously to Example 10 from 1-methyl-2-[(4amidinophenyl) methylthio] acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide-hydrochloride and sodium hydroxide solution.
Yield: 57 11 of theory,
C
26
H
25
N
5 0 3 S (487.58) Rf value: 0.23 (Reversed Phase silica gel RP-8; saline solution 6:4) EKA mass spectrum: 488 510 255.6 Example 132 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-propargyl-N- (2-ethoxycarbonylethyl) amide -hydrochloride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N-propargyl-N- (2-ethoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 81 t of theory,
C
25
H
28
N
6 0 3 (460.6) Rf value: 0.094 (silica gel; dichioromethane /ethanol 4:1) EKA mass spectrum: 461 242 231 Example 133 1-Methyl-2- (N-nhexyloxycarbonylamidino) phenyl] ethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide 136 Prepared analogously to Example 90 from 1-methyl-2-[2-(4acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide-hydrochloride and n-hexyl chloroformate.
Yield: 72 of theory,
C
3 5
H
4 2
N
6 0 5 (626.8) Rf value: 0.54 (silica gel; dichioromethane /methanol 9:1) EKA mass spectrum: 627 649 Example 134 l-Methyl-2-[2-[4-(N-benzoylamidino)phenyl]ethyl]acid-N-(2-pyridyl)-N-(2ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from 1-methyl-2-[2-(4acid-N- (2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochioride and benzoyl chloride.
Yield: 79 of theory,
C
35
H
34
N
6 0 4 (602.7) Rf value: 0.52 (silica gel; dichl oromethane /methanol 9:1) EKA mass spectrum: 603 625 Example 135 l-Methyl-2-[2-[4-(N-nicotinoylamidino)phenyl]ethyl]benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl) (2ethoxycarbonylethyl)-amide Prepared analogously to Example 90 from 1-methyl-2-[2-(4acid-N- (2-pyridyl) -N-(2-ethoxycarbonylethyl) -amide-hydrochloride and nicotinic acid chloride.
137 Yield: 56 t of theory,
C
34
H
33
N
7 0 4 (603.7) Rf value: 0. 52 (silica gel; dichioromethane /methanol 9: 1) EKA mass spectrum: 604 626 Example 136 1-Cyclopropyl-2- (4-amidinophenyl) -aminomethyl] acid-N-phenyl-N- (2ethoxycarbonylethyl) -amide-hydrochloride Prepared analogously to Example 25d from l-Cyclopropyl-2- (4-cyanophenyl) -aminomethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 31 t of theory,
C
30
H
33
N
6 0 3 (524.6) Rf value: 0.40 (silica gel; di chl oromethane /methanol =5:1) EKA mass spectrum: 525 274 263 Example 137 1-Cyclopropyl-2- (4-amidinophenyl) -aminomethyl] acid phenyl (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from l-cyclopropyl-2- [N- (4-amidinophenyl) -aminomethyl] acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide -hydrochloride and sodium hydroxide solution.
Yield: 64 t of theory, 138
C
28
H
2 8
N
6 0 3 (496.6) EKA mass spectrum: 497 260 519 271 139 Examrple 138 1-Methyl-2- (4-amidinophenyl) (n-butyl) -aminomethyl] acid-N-phenyl-N- (2ethoxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyanophenyl) (n-butyl) -aminomethyl] carboxylic acid-N-phenyl-N- (2 -ethoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 62 of theory,
C
32
H
38
N
6 0 3 (554.7) EKA mass spectrum: 555 289 278 Example 139 1-Methyl-2- (4-amidino-2-chloro-phenyl) -aminomethyl] acid-N-phenyl-N- (2ethoxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 25d from l-methyl-2--[N-(4cyano-2-chloro-phenyl) -aminomethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 82 t of theory,
C
28
H
2 qC1N 6 0 3 (533.1) EKA mass spectrum: 533/5 278/9 0 140 Exampnle 140 1-Methyl-2- (n-octyloxycarbonylamidino)phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl (2 -ethoxycarbonyl ethyl) -amide -hydrochloride and n-octyl chloroformate.
Yield: 34 15 of theory,
C
37
H
46
N
6 0 5 (654.8) Rf value: 0. 15 (silica gel; di chloromethane /ethanol 19: 1) EKA mass spectrum: 655 339 677 Example 141 l-Methyl-2- (4-amidino-2-ethyl-phenyl) -aminomethyl] acid-N-phenyl-N- (2ethoxycarbonylethyl) -amide -hydrochloride Prepared analogously to Example 25d from l-methyl-2-[N-(4cyano-2-ethyl-phenyl) -aminomethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 61 of theory
C
30
H
34
N
6 0 3 (526.6) EKA mass spectrum: 527 275 264 141 Example 142 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-benzylamide-hydrochloride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-benzylamide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 63 *1 of theory,
C
24
H
24
N
6 0 (412,'5) Rf value: 0. 76 (silica gel; di chioromethane /ethanol 4: 1) EKA mass spectrum: 413 Example 143 1-Methyl-2- (2-ethoxyethoxy)ethyloxy) carbonylamidino) -phenyl] -aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide Prepared analogously to Example 90 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and diethyleneglycolmonoethylether chioroformate.
Yield: 43 t of theory,
C
34
H
41
N
7 0 7 (659.8) Rf value: 0.56 (silica gel; dichloromethane /methanol 9:1) EKA mass spectrum: 660 341.7 142 Example 144 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N- (l-methylpyrazol-4-yl) (2ethoxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and amnmonium carbonate.
Yield: 60 of theory,
C
26 11 30
N
8 0 3 (502.6) Rf value: 0.13 (silica gel; dichioromethane/ethanol 4:1) EKA mass spectrum: 503 263 252 Example 145 3-Methyl-2- [(4-amidinophenyl) -thiomethyl] -imidazo 5-b] pyridin-6-yl-carboxylic acid-N-phenyl-N- (2ethoxycarbonylethyl) -amide-hydrochloride Prepared analogously to Example 1 from 3-methyl-2-[(4cyanophenyl) thiomethyl] -imidazo 5-b] pyridin-6-ylcarboxylic acid-N-phenyl-N- (2-methoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 88 of theory,
C
27
H
28
N
6 0 3 S (516.63) Rf value: 0.23 (silica gel; ethyl acetate/ethanol/ammonia= 50:45:5) EKA mass spectrum: 517 270 -143 Example 146 3-Methyl-2- (4-amidinophenyl) -aminomethyl] imidazo[4,5-blpyridin-6-yl-carboxylic acid-N-phenyl-N- (2 -ethoxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 1 from 3-methyl-2-[N-(4cyanophenyl) -aminomethyl] -imidazo pyridin-6-ylcarboxylic acid-N-phenyl-N- (2-methoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 82 *1 of theory,
C
27
H
29
N
7 0 3 (499.58) Rf value: 0.20 (silica gel; ethyl acetate /ethanol /ammonia 50:45:5) EKA mass spectrum: 500 261.7 Example 147 3-Methyl-2- [(4-amidinophenyl) -thiomethyl] imidazo 5-blpyridin-6-yl-carboxylic acid-N-phenyl-N- (2 -hydroxycarbonylethyl) -amide-hydrochloride Prepared analogously to Example 2 from 3-methyl-2-[(4amidinophenyl) -thiomethyl] -imidazo pyridin-6-ylcarboxylic acid-N-phenyl-N- (2 -ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 88 t of theory,
C
25
H
24
N
6 0 3 S (488.56) Rf value: 0.21 (silica gel; ethyl acetate /ethanol /ammonia= 50:45:5) EKA mass spectrum: 489 511 -144 Example 148 3-Methyl-2- (4-amidinophenyl) -aminomethyl] imidazo pyridin-6-yl-carboxylic acid-N-phenyl-N- (2 -hydroxycarbonylethyl) -amide -hydrochloride Prepared analogously to Example 2 from 3-methyl-2-[N-(4amidinophenyl) -aminomethyl] -imidazo pyridin-6-ylcarboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 80 of theory,
C
25
H
25
N
7 0 3 (471.52) Rf value: 0. 19 (silica gel; ethyl ace tate/ethanol /ammonia 50:45:5) EKA mass spectrum: 472 494 258.6 Example 149 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-phenyl-N- (2-ethoxycarbonylethyl) amide-hydrochloride a) 1-Methyl-2 rN- (4-cyanophenyl) -aminomethyll -benzimidazolacid-N-p~henvl-N- (2-ethoxvcarbonylethyl) amide 2.54 g (6,2 mMol) of 3-nitro-4-methylamino-benzenesulphonic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide were hydrogenated at room temperature under 5 bar hydrogen pressure over palladium/charcoal (100k) in a mixture of ml of ethanol and 75 ml of dichioromethane. The resulting crude 3 -amino-4-methylamino-benzenesulphoflic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide was taken up 7Z ZN in 30 ml of phosphorus oxychloride, without purification, 145 then 1.1 g (6,2 mMol) of N-(4-cyanophenyl)-glycine were added and the mixture was refluxed for two hours. After cooling to room temperature the reaction mixture was added to about 70 ml of water with cooling and in this way the excess phosphorus oxychloride was destroyed. The resulting solution was neutralised with solid sodium carbonate and extracted three times with 30 ml of ethyl acetate. After evaporation of the solvent the crude product was purified by column chromatography (100 g silica gel; eluant: cyclohexane/ethyl acetate 2:3).
Yield: 860 mg ('26.8 of theory), Melting point: 188-191 0
C
C
27
H
27
N
5 0 3 S (517.6) Rf value: 0.52 (silica gel; dichloromethane/methanol 9:1) EKA mass spectrum: (M+H) 518 540 b) l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]acid-N-phenyl-N- (2-ethoxycarbonylethyl)-amide-hydrochloride Prepared analogously to Example 25d from l-methyl-2-[N-(4acid- N-phenyl-N-(2-ethoxycarbonylethyl)-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 87 of theory,
C
27
H
30
N
6 0 4 S (534.6) Rf value: 0.13 (silica gel; dichloromethane/ethanol 9:1) EKA mass spectrum: 535 279 Example 150 l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazolacid-N-(l-methylpyrazol-4-yl)- N-(2-ethoxycarbonylethyl)-amide-hydrochloride 146 Prepared analogously to Example 25d from l-methyl-2-[N-(4cyanophenyl) -aminomethyl] -benzimidazol-5-yl-sulphonic acid- N- (1-methylpyrazol-4-yl) (2-ethoxycarbonylethyl) -amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 38 of theory,
C
25
H
30
N
8 0 4 S (538.6) Rf value: 0.09 (silica gel; dichioromethane/ethanol =9:1) EKA mass spectrum: 539 Example 151 1-Methyl-2- (4-amidinophenyl) -aminomethyl] 3-dihydroindol-l-yl-sulphonyl) -benzimidazolehydrochloride Prepared analogously to Example 25d from l-methyl-2- [N- (4-cyanophenyl) -aminomethyl] 3-dihydroindol-1-ylsulphonyl)-benzimidazole and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 15 of theory, Rf value: 0.36 (silica gel; dichloromethane/methanol 4:1)
C
24
H
24
N
6 0 2 S (460.6) EKA mass spectrum: 461 147 Example 152 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazoleacid-N-phenyl-N-(2-hydroxycarbonylethyl)amide Prepared analogously to Example 26 from 1-methyl- 2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-ylsulphonic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amidehydrochloride and sodium hydroxide solution.
Yield: 24 of theory, Rf value: 0.55 (Reverse-Phase RP-18 silica gel; saline solution 3:2)
C
25
H
26
N
6 0 4 S (506.6) EKA mass spectrum: 507 529 276 Example 153 l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-(isoindolin- 2-yl-sulphonyl)-benzimidazol-hydrochloride Prepared analogously to Example 25d from 1-methyl- 2-[N-(4-cyanophenyl)-aminomethyl]-5- (isoindolin-2-ylsulphonyl)-benzimidazole and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 33 of theory, Rf value: 0.32 (silica gel; dichloromethane/methanol 4:1)
C
24
H
24
N
6 0 2 S (460.6) EKA mass spectrum: (M+H) 461 148 Example 154 2-[2-(4-Amidinophenyl)-ethyl]-quinazolin-7-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride a. Ethyl 4-methyl-3-nitro-benzoate To a solution of 3 ml of concentrated hydrochloric acid and 4 ml of concentrated sulphuric acid, 4.9 g (0.03 mol) of ethyl p-tolylate were added dropwise with stirring at 5 0
C
and stirred for 1 hour whilst cooling in an ice-bath. After heating to ambient temperature the mixture was poured onto ice-water and extracted with ethyl acetate. The organic extracts were washed with sodium hydrogen carbonate solution, dried and evaporated down.
Yield: 5.7 g (90 of theory), Rf value: 0.81 (silica gel, ethyl acetate/cyclohexane 1:1) b. Methyl 4-(2-dimethylaminovinyl)-3-nitro-benzoate 1.0 g (4.8 mmol) of ethyl 4-methyl-3-nitro-benzoate, 0.74 g (6.2 mmol) of dimethylformamide dimethylacetal and 2 ml of dimethylformamide were heated to 140 0 C with stirring for 3 hours. Then the solvent was distilled off and the crude product thus obtained was reacted without any further purification.
Yield: 1.2 g (100 of theory), Rf value: 0.54 (silica gel, ethyl acetate/cyclohexane 1:1) c. Methyl 4-formyl-3-nitro-benzoate 1.2 g (4.8 mmol) of methyl 4-(2-dimethylaminovinyl)-3nitro-benzoate were dissolved in 120 ml of tetrahydrofuran/water and after the addition of 3.0 g (14.3 mmol) of sodium metaperiodate the mixture was stirred for 20 hours at ambient temperature. The suspension was then diluted with water and methylene chloride and extracted with methylene chloride. The combined organic 0 149 extracts were washed with sodium hydrogen carbonate solution, dried and evaporated down. The residue was chromatographed on silica gel and eluted with ethyl acetate/cyclohexane Yield: 0.6 g (63 of theory), Rf value: 0.63 (silica gel, ethyl acetate/cyclohexane 1:1) d. Methyl 3-Amino-4-formyl-benzoate To a solution of 25 ml of ethanol/glacial acetic acid/water were added 0.6 g (2.9 mmol) of methyl 4-formyl-3nitro-benzoate, 1.2 g (21.4 mmol) of iron powder and 0.01 ml of concentrated hydrochloric acid and the mixture was refluxed with stirring for 15 minutes. Then the iron was separated off, the solution was diluted with water and extracted with methylene chloride. The combined organic extracts were washed with water, dried and evaporated down.
Yield: 0.3 g (58 of theory), Rf value: 0.74 (silica gel, methylene chloride/methanol 9.5:0.5) e. Methyl 3-[3-(4-cyanophenyl)-propionylamino]-4-formylbenzoate 1.0 g (5.6 mmol) of methyl 3-amino-4-formyl-benzoate and 1.1 g (5.6 mmol) of 4-cyanophenylpropionic acid chloride were dissolved in 50 ml of methylene chloride and after the addition of 0.7 g (5.6 mmol) of N-ethyl-diisopropylamine the mixture was stirred for 24 hours at ambient temperature. Then it was extracted with sodium hydrogen carbonate solution, the combined organic extracts were dried and evaporated down. The residue was chromatographed on silica gel and eluted with ethyl acetate/cyclohexane Yield: 0.6 g (32 of theory), Rf value: 0.60 (silica gel, ethyl acetate/cyclohexane 1:1) 150 f. Methyl 2-[2-(4-cyanophenyl)-ethyl]-quinazoline-7carboxylate 0.6 g (1.8 mmol) of ethyl 3-[3-(4-cyanophenyl)propionylamino]-4-formyl-benzoate and 10 ml of methanolic ammonia solution were agitated in a pressure vessel for 36 hours. Then the solvent was distilled off, the residue was chromatographed on silica gel and eluted with methylene chloride containing 0 to 1 methanol.
Yield: 0.35 g (62 of theory), Rf value: 0.38 (silica gel, ethyl acetate/cyclohexane 1:1) g. 2-[2-(4-Cyanophenyl)-ethyl]-quinazolin-7-carboxylic acid 0.3 g (0.94 mmol) of methyl 2-[2-(4-cyanophenyl)-ethyl]quinazoline-7-carboxylate were dissolved in 4.7 ml of IN lithium hydroxide solution and 4 ml of tetrahydrofuran and stirred for 3 hours at ambient temperature. Then 4.7 ml of 1N hydrochloric acid were added and the mixture was stirred for 30 minutes. The product precipitated was suction filtered, washed with water and dried.
Yield: 0.30 g (100 of theory), Rf value: 0.1 (silica gel, ethyl acetate/cyclohexane 1:1) h. 2-[2-(4-Cyanophenyl)-ethyl]-quinazolin-7-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide 0.4 g (1.3 mmol) of 2-[2-(4-cyanophenyl)-ethyl]quinazoline-7-carboxylic acid and 5 ml of thionyl chloride were stirred for 60 minutes at 50 0 C. Then the thionyl chloride was distilled off, the residue was dissolved in methylene chloride, mixed with 0.24 g (1.3 mmol) of methyl 3-(N-phenylamino)-propionate and 0.22 ml of (1.3 mmol) of N-ethyldiisopropylamine and stirred for 18 hours at ambient temperature. After evaporation of the solvent in vacuo the 151 residue was chromatographed on silica gel and eluted with methylene chloride containing 1 methanol.
Yield: 230 mg (37 of theory), Rf value: 0.64 (silica gel, methylene chloride/methanol 9:1) i. 2-[2-(4-Amidinophenyl)-ethyl]-quinazolin-7-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride 230 mg (0.5 mmol) of 2-[2-(4-cyanophenyl)-ethyl]quinazolin-7-yl-carboxylic acid-N-phenyl- N-(2-methoxycarbonylethyl)-amide were stirred in 30 ml of saturated ethanolic hydrochloric acid for 8 hours at ambient temperature. Then the mixture was evaporated to dryness in vacuo, the residue was taken up in 20 ml of ethanol, combined with 0.5 g (5.0 mmol) of ammonium carbonate and stirred overnight at ambient temperature.
After evaporation of the solvent the crude product was chromatographed on silica gel and eluted with methylene chloride/ethanol Yield: 100 mg (39 of theory), Rf value: 0.5 (silica gel, methylene chloride/ethanol 4:1)
C
2 9
H
2 9
N
5 0 3 (495.59) Mass spectrum: 496 Example 155 l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol- 5-yl-sulphonic acid-N-(l-methylpyrazol-4-yl)-N-(2hydroxycarbonylethyl)-amide Prepared analogously to Example 26 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (1-methylpyrazol-4-yl)-N-(2-ethoxycarbonylethyl) amide-hydrochloride and sodium hydroxide solution.
152 Yield: 95 of theory,
C
23
H
26
N
8 0 4 S (510.6) Rf value: 0.53 (Reversed Phase silica gel RP-18, methanol saline solution) EKA mass spectrum: 511 533 278 Example 156 l-Methyl-2- [N-(3-amidino-pyridin-6-yl)-aminomethyl] acid-N-(2-pyridyl)- N-(2-ethoxycarbonylethyl)-amide-hydrochloride a) 3- (N-tert.Butoxycarbonyl-amino)acetylamino] 4-methylamino-benzoic acid-N-(2-pyridyl)- N-(2-ethoxycarbonylethyl)-amide 19.2 g (0.11 mol) of N-tert.butyloxycarbonylglycine were dissolved in 175 ml of dimethylformamide, mixed with 35.2 g (0.11 mol) of O-benzotriazol-l-yl)-N,N,N',N'tetramethyluronium tetrafluoroborate, 11.0 g of triethylamine and 34.2 g (0.10 mol) of 3-amino-4-methylamino-benzoic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide and stirred for 2.5 hours at ambient temperature.
Then the reaction solution was mixed with 5 1 of ice water and stirred for 2 hours. The grey precipitate formed was filtered off, washed with water, dried and recrystallised from ethyl acetate with the addition of activated charcoal.
Yield: 39.85 g (80 of theory),
C
2 5
H
3 3
N
5 0 6 (499.6) Rf value: 0.55 (silica gel; methylene chloride/ethanol 19:1) 153 b) l-Methyl-2-(N-tert.butoxycarbonyl-aminomethyl)acid-N-(2-pyridyl)- N-(2-ethoxycarbonylethyl)-amide 10.0 g (0.02 mol) of 3-[(N-tert.butoxycarbonylamino)acetylamino]-4-methylamino-benzoic acid- N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide were dissolved in 50 ml of glacial acetic acid and refluxed for one hour. Then the solvent was distilled off, the residue was mixed with ice water and adjusted to pH 8 by the addition of 2N ammonia. After extraction three times with ethyl acetate the combined organic phases were washed with saline solution and dried over sodium sulphate. After evaporation of the solvent the crude product was chromatographed on silica gel, eluting first with methylene chloride, then with methylene chloride/ethanol (50:1) and The desired fractions were combined and evaporated down.
Yield: 5.85 g (61 of theory),
C
25
H
31
N
5 0 5 (481.6) Rf value: 0.70 (silica gel; methylene chloride/ethanol 9:1) c) acid-N-(2-pyridyl)-N-(2-ethoxvcarbonylethyl)-amidetrifluoracetate 4.81 g (0.10 mol) of 1-methyl-2-(N-tert.butoxycarbonylacid- N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide were dissolved in 25 ml of methylene chloride, mixed with 5 ml of trifluoroacetic acid and stirred for 5 hours at ambient temperature. Then the solvent was evaporated off and the residue was stirred with ether. The crystals thus formed were filtered off, washed with ether and dried.
Yield: 3.15 g (68 of theory),
C
20
H
23
N
5 0 3 (381.4) Rf value: 0.18 (silica gel; methylene chloride/ethanol tN 9:1) 154 d) l-Methyl-2-[N-(3-cyano-pyridin-6-vl)-aminomethyllacid-N-(2-pyridyl)- N-(2-ethoxycarbonylethyl)-amide g (3.25 mmol) of l-methyl-2-aminomethyl-benzimidazolacid-N-(2-pyridyl)- N-(2-ethoxycarbonylethyl)-amide-trifluoracetate were stirred into 10 ml of N-ethyl-diisopropylamine and heated to 100 0 C for 15 minutes. After the addition of 720 mg (5.25 mmol) of. 2-chloro-5-cyano-pyridine the reaction mixture was heated to 125 0 C for 2 hours. After cooling to ambient temperature and stirring with about 20 ml of water, the pH was adjusted to 4 by the addition of lN hydrochloric acid and the mixture was extracted 3 times with ethyl acetate. The combined organic phases were washed with saline solution and dried over sodium sulphate. After evaporation of the solvent the crude product was chromatographed on silica gel, eluting first with methylene chloride, later with methylene chloride/ethanol (25:1) and The desired fractions were combined and evaporated down.
Yield: 1.05 g (67 of theory),
C
2 6
H
2 5
N
7 0 (483.6) Mass spectrum: (M+H) 484 e) 1-Methyl-2-[N-(3-amidino-pyridin-6-yl)-aminomethyl]acid-N-(2-pyridyl)- N-(2-ethoxycarbonvlethyl)-amide-hydrochloride Prepared analogously to Example 25d from 1-Methyl-2-[N-(3carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 38 of theory, 1 C 28
H
28
N
8 0 3 (500.6) 155 Mass spectrum: (M+H) 501 Example 157 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-indol-5-ylcarboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amidehydroiodide a) 4-Nitro-benzoic acid-N-phenyl-N-(2methoxycarbonylethyl)amide 16.7 g (0.1 mol) of 4-nitrobenzoic acid were refluxed in ml of thionyl chloride and 3 drops of dimethylformamide for 1 hour. After the solvent had been distilled off in vacuo the crude product was dissolved in 150 ml of tetrahydrofuran and added dropwise to a solution of 18 g (0.1 mol) of N-(2-methoxycarbonylethyl)aniline in 250 ml of tetrahydrofuran and 42 ml 0.3 mol) of triethylamine.
After being stirred for one hour at ambient temperature the reaction mixture was diluted with 250 ml of ethyl acetate and washed 2x with 200 ml of 14% saline solution. After the solvent had been distilled off and the residue chromatographed (silica gel; methylene chloride) a yellow oil was obtained which slowly solidified.
Yield: 32.6 g (100 of theory), Rf value: 0.37 (silica gel; methylene chloride/methanol 50:1) b) 4-Amino-benzoic acid-N-phenyl-N-(2methoxycarbonylethyl)amide 22 g (67 mmol) of 4-nitro-benzoic acid-N-phenyl-N-(2methoxycarbonylethyl)-amide were hydrogenated in 500 ml of methanol with 2 g of 10% palladium on charcoal at 3 bar hydrogen pressure for 3 hours. After filtration and distillation of the solvent the reaction mixture was washed with 100 ml of ether and the white crystalline product was further reacted directly.
156 Yield: 18.6 g (94 of theory), Rf value: 0.70 (silica gel; methylene chloride/ethanol 19:1) c) 2-Methyl-3-thiomethyl-indol-5-yl-carboxylic acid-Nphenyl-N-(2-methoxycarbonylethyl)-amide 26.8 g (91 mmol) of 4-amino-benzoic acid-N-phenyl-N-(2methoxycarbonylethyl)amide were dissolved in 500 ml of methylene chloride, cooled to -70 0 C and mixed within minutes with freshly prepared tert.butylhypochlorite J.
Mintz et al., Organic Synthesis, Coll. Vol. 5, page 184).
The mixture was stirred for 2 hours at -700C, then 9.46 g (91 mmol) of methylthioacetone in 40 ml of methylene chloride were added dropwise within 10 minutes and stirring was continued for a further 1.5 hours. Then 12.7 ml (9.1 g, 91 mmol) of triethylamine in 25 ml of methylene chloride were added. The mixture was left for 30 minutes at -780C and then slowly warmed to ambient temperature overnight.
After washing twice with 50 ml of water the organic phase was separated off and dried with sodium sulphate. After removal of the solvent in vacuo a white amorphous substance is obtained after purification by chromatography (silica gel; ethyl acetate/petroleum ether 2:8 to 3:7) Yield: 24.1 g (69 of theory), Rf value: 0.58 (silica gel; ethyl acetate/petroleum ether 1:1)
C
21
H
22
N
2 0 3 S (382.49) Mass spectrum: (M) 382 S- 157 d) acid-N-phenvl-N-(2-methoxycarbonylethyl)-amide 8.9 g (23 mmol) of 2-Methyl-3-thiomethyl-indol-5-ylcarboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide were dissolved in 600 ml of ethanol, mixed with about 150 mg of Raney nickel and stirred for 2 hours at ambient temperature (analogously to P.G. Gassman et al., Organic Synthesis Coll. Vol. 6, page 601). Then the mixture was filtered and the solvent eliminated in vacuo. The crude product thus obtained (8 g) was dissolved in 200 ml of absolute tetrahydrofuran, mixed with 150 mg of dimethylaminopyridine and 6.84 g (32 mmol) of di-tert.butyl pyrocarbonate and stirred for 2.5 hours at 50 0 C. Then the solvent was distilled off in vacuo and the crude product was purified by chromatography (silica gel, ethyl acetate/petroleum ether 1:4).
Yield: 10.0 g (98 of theory), Rf value: 0.40 (silica gel; ethyl acetate/petroleum ether =3:7) e) 2-[N-(4-Cyanophenyl)aminomethyll-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxvcarbonvlethyl)-amide g (8 mmol) of 1-tert.butoxycarbonyl-2-methyl-indol-5yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)amide were dissolved in 80 ml of carbon tetrachloride, mixed with 1.5 g (8.4 mmol) of N-bromo-succinimide and mg of azobisisobutyronitrile and refluxed for 2.5 hours.
Then the still warm solution was filtered, the filtrate obtained was washed with saturated sodium hydrogen carbonate solution and dried with sodium sulphate. After distillation of the solvent the crude product was dissolved in 30 ml of N-ethyl-diisopropylamine, mixed with 1.0 g (8 mmol) of 4-aminobenzonitrile and refluxed for 2.5 hours.
The solvent was distilled off in vacuo and the residue obtained was purified by chromatography (silica gel; ethyl acetate/petroleum ether 1:4 to 1:1).
158 Yield: 1.1 g (30 of theory), Rf value: 0.21 (silica gel; ethyl acetate/petroleum ether 1:1) f. 1-Methyl-2-[N-(4-thiocarbamoyl-phenyl)aminomethyllacid-N-phenyl-N-(2methoxycarbonylethyl)-amide g (3.3 mmol) of 2-[N-(4-cyanophenyl)aminomethyl]-indolacid-N-phenyl-N-(2-methoxycarbonylethyl)amide were dissolved in 60 ml of xylene, mixed with 0.45 g (3.3 mmol) of -potassium carbonate and 0.5 ml of (3.3 mmol) of methyl p-toluenesulphonate and refluxed for 4 hours.
Then the same amounts of potassium carbonate and methyl toluenesulphonate were added a second time and the mixture was refluxed overnight. It was filtered and washed with acetone. After concentration of the filtrate thus obtained, the residue obtained was purified by chromatography (silica gel; ethyl acetate/petroleum ether 1:4 to The N-methylated indole obtained (yield: 0.64 g, 41 of theory) was dissolved in 20 ml of pyridine and mixed with 0.67 ml (1.37 mmol) of triethylamine. Then hydrogen sulphide gas was introduced into the solution thus obtained. After 4.5 days nitrogen was passed through the reaction solution for 30 minutes, the solvent was distilled off and the residue obtained was purified by chromatography (silica gel; methylene chloride/ethanol 99:1 to 98:2).
Yield: 0.30 g (43 of theory),
C
28
H
28
N
4 0 3 S (500.62) EKA mass spectrum: (M+H) 501 523 g) l-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-indol-5-vlcarboxylic acid-N-phenyl-N-(2-methoxvcarbonylethyl)-amidehydroiodide 0.30 g (0.60 mmol) of l-methyl-2-[N-(4-thiocarbamoyl)acid-N-phenyl- N-(2-methoxycarbonylethyl)-amide were dissolved in 20 ml of 159 acetone together with 0.75 ml (12 mmol) of methyl iodide and stirred for 2 hours at ambient temperature. Then the solvent was distilled off and the crude product was stirred together with 1.0 g of ammonium acetate in 12 ml of ethanol and 5 ml of methylene chloride for 20 hours at 400C. The solvent was distilled off in vacuo and the residue obtained was purified by chromatography (silica gel; methylene chloride/ethanol 9:1 to 4:1).
Yield: 55 of theory,
C
28
H
29
N
5 0 3 (483.58) Rf value: 0.20 (silica gel; methylene chloride/ethanol 4:1 1 drop of acetic acid) EKA mass spectrum: (M+H) 484 Example 158 l-Methyl-2-[N-(4-amidinophenyl)aminomethyl]thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide-hydrochloride a) Iminoethyl methoxyacetate hydrochloride A solution of 35.5 g (0.50 mol) of methoxyacetonitrile in 29 ml (23 g, 0.50 mol) of ethanol and 30 ml of absolute diethylether was cooled to 0°C and over 1 hour 22.5 g (0.62 mol) of hydrogen chloride gas was introduced, whilst towards the end of the introduction of gas the reaction product crystallised out. To complete the precipitation 130 ml of diethylether were added and the colourless needles were filtered off.
Yield: 66.4 g (86 of theory), Melting point: 117-1180C.
b) 4-Hydroxvmethvl-2-methoxymethyl-imidazole A mixture of 30.6 g (0.20 mol) of iminoethyl methoxyacetate-hydrochloride, 18 g (0.20 mol) of 1.3dihydroxyacetone and 200 ml of liquid ammonia was heated to 68 0 C for 3 hours in a stirred autoclave at a pressure of 27 S- 160 bar (analogously to: P. Dziuron et al. Arch. Pharm. 307, 1974, p.470). Then the ammonia was eliminated and 200 ml of methylene chloride were added. The white precipitate formed was filtered off and washed with methylene chloride. The filtrate was evaporated down and the residue obtained was purified by chromatography (aluminium oxide; methylene chloride/ethanol 90:10 to 85:15).
Yield: 26.7 g (94 of theory), Rf value: 0.43 (silica gel; methylene chloride/ethanol 9:1)
C
6
H
10
N
2 0 2 (142.-20) Mass spectrum: (M) 142 c) 4-Hydroxymethyl-2-methoxymethyl-l-methyl-imidazole as a 1:1 mixture with 5-hydroxvmethvl-2-methoxymethyl-l-methvlimidazole A mixture of 7.1 g (50 mmol) of 4-hydroxymethyl-2methoxymethylimidazole, 3.0 g (53 mmol) of powdered potassium hydroxide and 3.4 ml (0.55 mmol) of methyl iodide was heated to 50 0 C in 100 ml of dimethylformamide for 4 hours (analogously to I. Sinclair et al., J. Med. Chem., 29, 1986, 261). Then the solvent was distilled off in vacuo and the crude product purified by column chromatography (aluminium oxide; methylene chloride/ethanol 99:1 to 95:5).
Yield: 6.1 g (78 of theory; 1:1 mixture of the two regioisomers) Rf value: 0.32 (silica gel; methylene chloride/ethanol 19:1) d) 5-Chloro-4-hvdroxymethyl-2-methoxymethyl-l-methylimidazole A 1:1 mixture of 7.7 g (49 mmol) of 4-hydroxymethyl- 2-methoxymethyl-1-methyl-imidazole and 2-methoxymethyl-1-methyl-imidazole and 7.3 g (55 mmol) of N-chloro-succinimide was heated to 50 0 C in 48 ml of s ethylene glycol monoethylether and 70 ml of dioxan for 9 161 hours. Then the solvent was distilled off in vacuo and the crude product purified by chromatography (silica gel; methylene chloride/ethanol 99.:1 to 90:10) to obtain the isomerically pure title compound.
Yield: 3.4 g (36 of theory), Rf value: 0.40 (silica gel; methylene chloride/ethanol 19:1) e) 5-chloro-4-formyl-2-methoxvmethyl-l-methyl-imidazole 3.4 g (18 mmol) of 5-chloro-4-hydroxymethyl-2methoxymethyl-l-methyl-imidazole were dissolved in 100 ml of methylene chloride and at two-hour intervals manganese dioxide was added (2 x 6.0 g, a total of 0.14 mol). After 4 hours the inorganic component was filtered off, the solvent was eliminated and the crude product obtained was further reacted without any further purification.
Yield: 3.0 g (89 of theory), Rf value: 0.44 (silica gel; methylene chloride/ethanol 50:1) 162 f) Ethyl l-methyl-2-methoxymethyl-thieno[2.3-d]imidazol-5yl-carboxylate To a freshly prepared sodium ethoxide solution (from 391 mg, 17 mMol of sodium) in 15 ml of ethanol were added dropwise 1.9 ml (2.1 g, 17 mmol) of ethyl thioglycolate.
After 1 hour stirring at ambient temperature 1.6 g mmol) of 5-chloro-4-formyl-2-methoxymethyl-l-methylimidazole in 20 ml of absolute ethanol were added and the mixture was heated to 80 0 C (analogously to B. Iddon et al., J. Chem. Soc. Perkin Trans. I, 1987, 1457). After 5 hours the solvent was distilled off, the residue was taken up in ml of methylene chloride and washed with 20 ml of water.
The aqueous phase was washed again with 20 ml of methylene chloride and then the combined organic phases were dried with sodium sulphate. After removal of the solvent in vacuo the crude product obtained was purified by column chromatography (aluminium oxide; methylene chloride).
Yield: 1.0 g (46 of theory), Rf value: 0.48 (silica gel; methylene chloride/ethanol 50:1)
C
11 H1 4
N
2 0 3 S (254.31) EKA mass spectrum: (M+H) 255 277 g) l-Methyl-2-methoxymethyl-thieno[2.3-d]imidazol-5-ylcarboxylic acid To a solution of 0.90 g (3.54 mmol) of ethyl l-methyl-2methoxymethyl-thieno[2.3-d]imidazol-5-yl-carboxylate in ml of ethanol were added dropwise 5 ml of 2 N sodium hydroxide solution and the mixture was stirred for 2 hours at ambient temperature. Then the solvent was distilled off in vacuo, the residue was taken up in 5 ml of water and washed with 10 ml of diethylether. The aqueous phase was acidified with 6 ml of 2N hydrochloric acid, cooled to 0 C and the precipitated crystals are filtered off.
9. Yield: 0.50 g (63% of theory) 163 Rf value: 0.21 (silica gel; methylene chloride/ethanol 9:1 a few drops of acetic acid)
C
9
H
1 0
N
2 0 3 S (226.26) Mass spectrum: 226 h) l-Methyl-2-methoxymethyl-thieno[2.3-d]imidazol-5-ylcarboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide A suspension of 0.50 g (2.2 mmol) of l-methyl-2methoxymethyl-thieno[2.3-d]imidazol-5-yl-carboxylic acid in 20 ml of methylene chloride was mixed with 2.0 ml (3.2 g, 27 mmol) of thionyl chloride and refluxed for 60 minutes, during which time the solid gradually dissolved. After distillation of the liquid components the crude product was taken up twice more in methylene chloride. After the solvent had been eliminated once more the crude acid chloride was taken up in 20 ml of tetrahydrofuran and added dropwise to a mixture of 0.42 g (2.3 mmol) of N-(2-methoxycarbonylethyl)aniline and 0.92 ml (6.6 mmol) of triethylamine in 30 ml of tetrahydrofuran. After 16 hours' stirring at 50 0 C the solvent was eliminated and the crude product obtained was purified by chromatography (silica gel; methylene chloride/ethanol 100:1).
Yield: 0.66 g (77% of theory), Rf value: 0.47 (silica gel; methylene chloride/ethanol 19:1) i) l-Methyl-2-(N-4-cyanophenylaminomethyl)thieno[2.3-dlimidazol-5-yl-carboxylic acid-N-phenyl-N-(2methoxvcarbonvlethvl)-amide To a solution of 0.73 g (1.88 mmol) of l-methyl-2methoxymethyl-thieno[2.3-d]imidazol-5-yl-carboxylic acid-Nphenyl-N-(2-methoxycarbonylethyl)-amide in 30 ml of methylene chloride were added dropwise at 50C 2.9 ml (2.9 mmol) of a 1-molar solution of boron tribromide in methylene chloride. After 16 hours' stirring at ambient temperature the mixture was washed with 20 ml of saturated sodium hydrogen carbonate solution, the organic phase was 164 separated off, dried with sodium sulphate and filtered. The filtrate was mixed with 14 ml of N-ethyl-diisopropylamine and 0.43 g (3.64 mmol) of 4-aminobenzonitrile. Then the methylene chloride was distilled off in vacuo, the residue obtained was heated to 50 0 C for 1 hour and then the residual solvent was distilled off in vacuo. After chromatography (silica gel; methylene chloride/ethanol 99:1 to 97:3) a yellow oil was obtained which slowly solidified.
Yield: 0.37 g (42% of theory), Rf value: 0.29 (silica gel; methylene chloride/ethanol 50:1 a few drops of ammonia j) 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl] thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2ethoxycarbonylethyl)-amide-hydrochloride 0.38 g (0.80 mmol) of l-methyl-2-(N-4cyanophenylaminomethyl)-thieno[2.3-d] carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide were stirred in 40 ml of ethanol saturated with hydrogen chloride for 5 hours first at 0°C, then later at ambient temperature until no more starting material could be detected by thin layer chromatography. Then the solvent was distilled off at a maximum 28 0 C bath temperature, the oily residue was taken up in 40 ml of absolute ethanol and mixed with 1.1 g of ammonium carbonate. After 18 hours the solvent was distilled off in vacuo and the crude product was purified by chromatography (silica gel; methylene chloride/ethanol 9:1 to 4:1).
Yield 57 of theory
C
26
H
28
N
6 0 3 S (504.62) Rf value: 0.21 (silica gel; methylene chloride/ethanol 4:1 a few drops of acetic acid) EKA mass spectrum: 505 (M+H+Na) 264 0 -165 Example 159 1-Methyl-2- (4-amidinophenyl)aminomethyl] thieno[2.3-d] imidazol-5-yl-carboxylic acid-N-phenyl-N- (2hydroxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 2 from 1-methyl-2-[N-(4amidinophenyl) aminomethyl] -thieno 3-d] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 85 15 of-theory,
C
24
H
24
N
6 0 3 S (476.56) Rf value: 0.36 (Reversed Phase silica gel RP-8; methanol 5 saline solution) EKA mass spectrum: 477 499 250 Example 160 1-Methyl-3- (4-amidinophenyl) thiomethyll -quinoxalin-2-on- 6-yl-carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) amide -hydrochloride a) 1-Methvl-3- (4-cyanophenvl) thiomethvll -cuinoxalin-2on-6-vl-carboxvylic acid-N-phenvl-N- (2methoxvcarbonylethvl) -amide A solution of 2.5 g (7.6 mmol) of 3-amino-4-methylaminobenzoic acid-N-phenyl-N- (2-methoxycarbonylethyl) -amide and 2.4 g (9.6 mmol) of ethyl 3-(4-cyanophenyl)thio-2-oxopropionate were heated to boiling in 50 ml of ethanol for minutes. After removal of the solvent the crude product obtained was purified by chromatography (silica gel; methylene chloride).
Yield: 1.6 g (40 1; of theory), Rf value: 0.63 (silica gel; Et0Ac/EtOH/ammonia 90:10:1) 166 b) l-Methyl-3- (4-amidinophenyl) thiomethyl] -quinoxalin-2on-6-yl-carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) amide -hydrochloride Prepared analogously to Example 1 from l,-methyl-3-[N-(4cyanophenyl) thiomethyl] -quinoxalin-2-on-6-yl-carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 23 of theory,
C
28
H
27
N
5 0 4 S (543.64) Rf value: 0.25 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: 544 566 Examiple 161 3-Methyl-2- (4-amidinophenyl)ethyl] imidazo [1.2-alpyridin-7-yl-carboxylic acid-N-phenyl-N- (2ethoxycarbonylethyl) -amide-hydrochloride a) 3-methvl-2- (4-cyanophenvl)ethvll imidazorl.2-alpvridin-7-vl-carboxvlic acid-N-phenyl-N- (2ethoxvcarbonylethyl) -amide 1.4 g (4.6 mmol) of 3-methyl-2-[2-(4-cyanophenyl)ethyl]imidazo [1.2-alpyridin-7-yl-carboxylic acid (prepared from 4-bromo-l- (4-cyanophenyl) -l-penten-3-one and methyl 2aminopyridine-4-carboxylate analogously to Y. Katsura et al. Chem. Pharm. Bull. 1992, 40, 1424-1438) were suspended in 15 ml of thionyl chloride and heated to boiling for 1 hour until fully dissolved. After the thionyl chloride had been distilled off the acid chloride was dissolved in 15 ml of pyridine without any further purification and at 0 0
C
mixed with 1.0 g (5.2 mmol) of N-(2-ethoxycarbonylethyl)aniline. After 1 hour the solvent was distilled off, the residue was taken up in 30 ml of methylene chloride, washed with 15 ml of 1N hydrochloric acid and dried with sodium 167 sulphate. After distillation of the solvent and chromatography (silica gel; methylene chloride/ethanol 0 to 2 a brown oil was obtained.
Yield: 1.48 g (64 of theory), Rf value: 0.73 (silica gel; ethyl acetate/ethanol/ammonia 90:10:1) b) 3-Methyl-2-[2-(4-amidinophenyl)ethyl imidazo[l.2-a]pyridin-7-vl-carboxylic acid-N-phenvl-N-(2ethoxycarbonylethyl)- amide-hvdrochloride Prepared analogously to Example 1 from 3-methyl-2-[2-(4cyanophenyl)ethyl -imidazo[1.2-a] pyridin-7-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 62 of theory,
C
2 9
H
3 1
N
5 0 3 (497.60) Rf value: 0.23 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: 498 Example 162 3-Methyl-2-[2-(4-amidinophenyl)ethyl]imidazo[1.2-a]pyridin-7-yl-carboxylic acid-N-phenyl-N-(2hydroxycarbonylethyl)-amide-hydrochloride Prepared analogously to Example 2 from 3-methyl-2-[2-(4amidinophenyl)ethyl]-imidazo [.2-a]pyridin-7-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl) -amide-hydrochloride and sodium hydroxide solution.
Yield: 92 of theory,
C
2 7H2 7
N
5 0 3 (469.55) Rf value: 0.19 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: 470 492 168 235.7 246.7 257.7 Example 163 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-phenyl-N- [(N-ethoxycarbonylethyl-Nmethyl) -2 -aminoethyl] -amide-dihydrochioride Prepared analogously to Example 25d from l-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N-phenyl-N- [(N-ethoxycarbonylethyl-N-methyl) -2aminoethyl] -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 80 t of theory,
C
31
H
37
N
7 0 3 (555.7) Rf value: 0.24 (silica gel; dichloromethane/methanol 4:1) EKA mass spectrum: 556 289.8 278.8 Example 164 l-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-phenyl-N- [(N-hydroxycarbonylethyl-Nmethyl) aminoethyl] -amide -hydrochloride Prepared analogously to Example 26 from i-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl-N- [(N-ethoxycarbonylethyl-N-methyl) -2aminoethyl] -amide-dihydrochioride and sodium hydroxide solution.
Yield: 79 of theory,
C
29 11 33
N
7 0 3 (527.6) 0 -169 Rf value: 0.43 (Reversed Phase silica gel RP-18; aqueous saline solution 6:4) EKA mass spectrum: 528 275.6 264.6 Example 165 1-Methyl--2- (4-amidinophenyl) -aminomethyl] -benzimidazol- 5-yl-carboxylic acid-N--phenyl-N- (3-hydroxy-n-propyl) -amidehydrochloride Prepared from l-methyl-2- (4-amidinophenyl) -aminomethyl] acid-N-phenyl-N- (3-benzyloxyn-propyl) -amide -hydrochloride by hydrogenation over palladium/charcoal at 5 bar hydrogen pressure and at ambient temperature.
Yield: 61 of theory,
C
26
H
28
N
6 0 2 (456.6) Rf value: 0.70 (Reversed Phase silica gel RP-18; aqueous saline solution 9:1) EKA mass spectrum: 457 (M+H+Na) 240 170 Example 166 l-Methyl-2 (4 (N-n-hexyloxycarbonylamidino) phenyl] aminomethyll -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl-2-[N-[4- (N-n-hexyloxycarbonylamidino) phenyl] -aminomethyl] acid-N- (2-pyridyl) (2ethoxycarbonylethyl)-amide and sodium hydroxide solution.
Yield: 97 t of theory,
C
32 11 37
N
7 0 5 (599.7) Rf value: 0.22 (silica gel; dichioromethane /methanol 9:1) EKA mass spectrum: 600 311.7 300.8 322.8 Example 167 l-Methyl-2- (N-n-hexyloxycarbonylamidino) phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (3 -hydroxy-n-propyl) -amide Prepared analogously to Example 165 from l-methyl-2-[N-[4- (N-n-hexyloxycarbonylamidino) phenyl] -aminomethyl] ic acid-N-phenyl-N- (3-benzyloxyn-propyl)-amide by catalytic debenzylation.
Yield: 26 t of theory,
C
33
H
40
N
6 0 4 (584.7) Rf value: 0.39 (silica gel; dichiorornethane /ethanol 9:1 EKA mass spectrum: 585 304 607 171- Example 168 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazolacid-N-(3-fluorophenyl)-N-(2ethoxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 25d from 1-methyl-2-[N-(4acid-N-(3-fluorophenyl)-N-(2-ethoxycarbonylethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 42 of theory,
C
2 8
H
2 9
FN
6 0 3 (516.6) Rf value: 0.31 (silica gel; dichloromethane/methanol 5:1) EKA mass spectrum: 517 270 Example 169 l-Methyl-2- (4-amidinophenyl) -aminomethyll -benzimidazolacid-N-(4-fluorophenyl)-N-(2ethoxycarbonylethyl)-amide-hydrochloride Prepared analogously to Example 25d from l-methyl-2-[N-(4cyanophenyl) -aminomethyl] acid-N-(4-fluorophenyl)-N-(2-ethoxycarbonylethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 90 of theory,
C
28
H
29
FN
6 0 3 (516.6) Rf value: 0.29 (silica gel; dichioromethane/methanol 5:1) EKA mass spectrum: 517 270 -172 Example 170 1-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N- (3-f luorophenyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (3-f luorophenyl) (2-ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 97 t of theory,
C
26
H
25
FN
6 0 3 (488.5) Rf value: 0.13 (silica gel; dichioromethane/ethanol 4:1) EKA mass spectrum: 489 511 267 Example 171 1-Methyl-2- (4-amidinophenyl) -aminomethyl) -benzimidazolacid-N- (4-f luorophenyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (4-f luorophenyl) (2-ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 89 t of theory,
C
26 11 25
FN
6 0 3 (488.5) Rf value: 0.15 (silica gel; dichloromethane/ethanol 4:1) EKA mass spectrum: 489 (M-iNa)+ 511 =.267 173 Example 172 1-Methyl-2- (4-amidino-2-methoxy-phenyl) -aminomethyl] benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2ethoxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyano-2-methoxy-phenyl) -aminomethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 89 of theory,
C
29
H
32
N
6 0 4 (528.6) Rf value: 0.13 (silica gel; dichloromethane/ethanol =4:1) EKA mass spectrum: 529 (M+H+Na) 276 265 Example 173 l-Methyl-2- (N-4-ethylbenzoylamidino)phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and 4-ethylbenzoylchloride.
Yield: 64 of theory,
C
36 11 37
N
7 0 4 (631.7) Rf value: 0.78 (silica gel; dichioromethane/methanol 9:1) EKA mass spectrum: 632 327.8 (M+Na) 654 174 Example 174 1-Methyl-2- (N-benzyloxycarbonylamidino)phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amidehydrochloride and benzyl chioroformate.
Yield: 64 of theory,
C
35
H
35
N
7 0 5 (633.6) Rf value: 0.60 (silica gel; dichioromethane/methanol 9:1) EKA mass spectrum: 634 (M-iH+Na) 328.8 656 Example 175 1-Methyl-2- (4-amidino-2-methoxy-phenyl) -aminomethyl] acid-N-phenyl-N- (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl-2-[N-(4amidino-2-methoxy-phenyl) -aminornethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amidehydrochloride and sodium hydroxide solution.
Yield: 71 of theory,
C
27
H
2 8
N
6 0 4 (500.6) Rf value: 0.15 (silica gel; dichioromethane/ethanol 4:1) EKA mass spectrum: 501 523 273 175 Example 176 l-Methyl-2- (4-amidino-2-methoxy-phenyl) -aminomethyl] acid-N- (2-pyridyl) (2ethoxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 25d from 1-methyl-2-[N-(4cyano-2-methoxy-phenyl) -aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 67 -15 of theory,
C
28
H
31
N
7 0 4 (529.6) Rf value: 0.16 (silica gel; dichioromethane/ethanol 4:1) EKA mass spectrum: 530 0- -176 Example 177 l-Methyl-2- (4-amidino-2-methoxy-phenyl) -aminomethyl] acid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from l-methyl-2-[N-(4amidino-2-methoxy-phenyl) -aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide-hydrochioride and sodium hydroxide solution.
Yield: 78 %o of theory,
C
26
H
27
N
7 0 4 (501.6) Rf value: 0.12 (silica gel; dichioromethane/ethanol 4:1) EKA mass spectrum: 502 Example 178 l-Methyl-2- (N-benzyloxycarbonylamidino) phenyl] -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -N- (2-hydroxycarbonylethyl) -amide Prepared analogously to Example 104 from l-methyl-2-[N-[4- (N-benzyloxycarbonylamidino) phenyl] -aminomethyl] acid-N- (2-pyridyl) (2ethoxycarbonylethyl)-amide and sodium hydroxide solution.
Yield: 62 of theory,
C
33
H
31
N
7 0 5 (605.7) Rf value: 0.26 (silica gel; dichloromethane/methanol 9:1) EKA mass spectrum: 606 628 (M-H+2Na)+ 650 303.8 314.8 325.7 177 Example 179 l-Methyl-2- (4-amidinophenyl) -aminomethyl] -benzimidazolacid-N-phenyl-N- (3-benzyloxy-n-propyl) amide-hydrochioride Prepared analogously to Example 25 from l-methyl-2-[N-(4cyanophenyl) -aminomethyll acid-N-phenyl-N- (3-benzyloxy-n-propyl) -amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 61 of theory,
C
33
H
34
N
6 0 2 (546.7) Rf value: 0.19 (silica gel; dichioromethane/ethanol 4:1) EKA mass spectrum: 547 (M+H+Na) 285 Example 180 l-Methyl-2- (N-n-hexyloxycarbonylamidino)phenYl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (3-benzyloxy-n-propyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidinophenyl) -aminomethyl] acid-N-phenyl-N- (3-benzyloxy-n-propyl) -amide-hydrochloride and n-hexyl chloroformate.
Yield: 73 of theory,
C
40
H
46
N
6 0 4 (674.9) Rf value: 0.46 (silica gel; dichioromethane/ethanol 9:1) EKA mass spectrum: 675 349 697 713 178 Example 181 3-Methyl-2- (4-amidinophenyl) ethyl] imidazo[1.2-alpyridin-7-yl-carboxylic acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -amide-hydrochioride Prepared analogously to Example 1 from 3-methyl-2-[2-(4cyanophenyl) ethyl] -imidazo pyridin-7-yl-carboxylic acid-N- (2-pyridyl) (2-methoxycarbonylethyl) -amidehydrochloride and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 53 -01 of theory,
C
28
H
30
N
6 0 3 (498.59) Rf value: 0.42 (silica gel; ethyl acetate/ethanol/ammonia 50:45:5) EKA mass spectrum: 499 272 261 250 Example 182 1-Methyl-2- (3-amidino-pyridin-6-yl) -aminomethyl] acid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl- 2- (3-cyanopyridin-6-yl) -aminomethyl] carboxylic acid-N- (2-pyridyl) (2-hydroxycarbonylethyl) amide and sodium hydroxide solution.
Yield: 40 of theory,
C
24
H
24
N
8 0 3 (472.9) Rf value: 0.67 (Reversed Phase silica gel RP-8; saline solution i:1) EKA mass spectrum: 473 179 Example 183 1-Methyl-2-[N-[4-(N-hydroxylamidino)phenyl]-aminomethyl]acid-N-(2-pyridyl)-N-[2- (methansulphonylaminocarbonyl)-ethyl]-amide a. l-Methvl-2-[N-(4-cyanophenvl)-aminomethyl]-benzimidazolacid-N-(2-pyridvl)-N-[2- (methanesulphonylaminocarbonvl) -ethyll-amide 2.0 g (4.5 mmol) of l-methyl-2-[N-(4-cyanophenyl)acid- N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide and 0.73 g (4.7 mmol) of carbonyldiimidazole were dissolved in 80 ml of tetrahydrofuran and 5 ml of dimethylformamide and stirred for 30 minutes at ambient temperature and for 2 hours at 900C. In parallel 0.55 g (5.8 mmol) of methansulphonic acid amide and 0.28 g (5.8 mmol) of sodium hydride were suspended in 15 ml of dimethylformamide and stirred for 2 hours at ambient temperature. Then this suspension was added at ambient temperature to the tetrahydrofuran solution. After 12 hours at ambient temperature 50 ml of water were added and the pH value was adjusted to 6.8. The solution was extracted 4x with methylene chloride, the combined organic phases were dried over sodium sulphate and evaporated down. The crude product was chromatographed on silica gel (methylene chloride/ethanol The.desired fractions were combined and evaporated down. Yield:.1.05 g (44 of theory),
C
2 6
H
2 5
N
7 0 4 S (531.6) Rf value: 0.72 (silica gel; dichloromethane/methanol 9:1) 0 180 b. l-Methvl-2- f4- (N-hvdroxvlamidino)phenvll aminomethyl] -benzimidazol-5-vl-carboxylic acid- N- (2-rwridvl) (methansulphonvlaninocarbonyl) -ethyll amide Prepared analogously to Example 96 from 1-methyl- 2- (4-cyanophenyl) -aminomethyl] carboxylic acid-N- (2-pyridyl) [2- (methanesuiphonylaminocarbonyl) -ethyl] -amide and hydroxylamine.
Yield: 270- of theory,
C
26
H
28
N
8 0 5 S (564.6) Rf value: 0.75 (silica gel; dichioromethane/ethanol 7:3 1% glacial acetic acid) EKA mass spectrum: 565 587 Example 184 l-Methyl-2- (5-amidino-thiazol-2-yl) -aminomethyl] acid-N- (2-pyridyl) (2ethoxycarbonylethyl) -amide-hydrochloride Prepared analogously to Example 25d from 1-methyl- 2- (5-cyano-thiazol-2-yl) -aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Examiple 185 1-Methyl-2- (5-amidino-thiazol-2-yl) -aminomethyl] acid-N- (2-pyridyl) (2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl- 2- (5-amidino-thiazol-2-yl) -aminomethyl] -benzimidazol- 181 acid-N-(2-pyridyl)-N-(2ethoxycarbonylethyl)-amide-hydrochioride and sodium hydroxide solution.
Example 186 1-Methyl-2-[N-(2-amidino-pyrazin-5-yl)-aminomethyl]acid-N- (2-pyridyl) ethoxycarbonylethyl)-amide-hydrochioride Prepared analogously to Example 25d from 1-methyl- 2-[N-(2-cyano-pyrazin-5-yl)-aminomethyl]-benzimidazol-5-ylcarboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.
Yield: 19 of theory,
C
25
H
2 7
N
9 0 3 (501.6) Rf value: 0.28 (silica gel; dichloromethane/methanol 4:1 1% glacial acetic acid) EKA mass spectrum: 502 262.5 Example 187 l-Methyl-2- (2-amidino-pyrazin-5-yl) -aminomethyl acid-N-(2-pyridyl)-N-(2hydroxycarbonylethyl) -amide Prepared analogously to Example 26 from 1-methyl- 2- (2-amidino-pyrazin-5-yl) -aminomethyl] -benzimidazolacid-N-(2-pyridyl)-N-(2ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.
Yield: 11 of theory,
C
2 3
H
23
N
9 0 3 (473.5) 0 -182 Rf value: 0.55 (Reversed Phase silica gel RP-8; 511 saline solution/methanol 6:4) EKA mass spectrum: 474 496.6 Example 188 l-Methyl-2- (N-n-hexyloxycarbonylamidino)phenyl] ethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- [2- (lH--tetrazol-5-yl) -ethyl] -amide Prepared analogously to Example 90 from 1-methyl-2-[2-(4amidinophenyl) -ethyl] -benzimidazol-5-yl-carboxylic acid- N-phenyl-N- (lH-tetrazol-5-yl) -ethyl] -amide and n-hexyl chloroformate.
Examiple 189 l-Methyl-2- (2-methoxy-4-n-pentoxycarbonylamidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic acid-Nphenyl (2 -ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidino-2-methoXy-phenyl) -aminomethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amidehydrochloride and n-pentyl chloroformate.
Yield: 53 t of theory,
C
35
H
42
N
6 0 6 (642.7) Rf value: 0.54 (silica gel; dichioromethane/ethanol 9:1) EKA mass spectrum: 643 (M+H+Na) 333.4 -183 Example 190 l-Methyl-2- (4-n-heptyloxycarbonylamidino-2-methoxyphenyl) -aminomethyl] -benzimidazol -5-yl-carboxylic acid-Nphenyl (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidino-2-methoxy-phenyl) -aminomethyl] carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amidehydrochloride and n-heptyl chioroformate.
Yield: 68 5* of theory,
C
37
H
46
N
6 0 6 (670.8) Rf value: 0.56 (silica gel; dichioromethane/ethanol 9:1 EKA mass spectrum: 671 347.4 Example 191 l-Methyl-2- (4-ethoxycarbonylamidilo-2-mfethoxy-phenyl) aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2pyridyl) (2-ethoxycarbonylethyl) -arnide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidino-2-methoxy-phenyl) -aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide-hydrochloride and ethyl chioroformate.
Yield: 43 0- of theory,
C
31
H
35
N
7 0 6 (601.7) Rf value: 0.44 (silica gel; dichioromethane/ethanol 9:1) EKA mass spectrum: 602 (M-iH+Na) 312.8 0 -184 Example 192 l-Methyl-2- (2-methoxy-4-n-pentoxycarbonylamidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidino-2-methoxy-phenyl) -aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide-hydrochloride and n-pentyl chloroformate.
Yield: 72 of 'theory,
C
34
H
41
N
7 0 6 (643.7) Rf value: 0.49 (silica gel; dichioromethane/ethanol 9:1) EKA mass spectrum: 644 (M+H+Na) 333.9 Example 193 l-Methyl-2- (2-methoxy-4-n-heptyloxycarbonylamidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) -amide Prepared analogously to Example 90 from l-methyl-2-[N-(4amidino-2-methoxy-phenyl) -aminomethyl] carboxylic acid-N- (2-pyridyl) (2-ethoxycarbonylethyl) amide-hydrochloride and n-heptyl chioroformate.
Yield: 55 of theory,
C
36
H
45
N
7 0 6 (671.8) Rf value: 0.54 (silica gel; dichioromethane/ethanol 9:1) EKA mass spectrum: 672 347.9 S- 185 Example 194 Dry ampoule containing 75 mg of active substance per 10 ml Composition: Active substance Mannitol water for injections 75.0 mg 50.0 mg ad 10.0 ml Preparation: Active substance and mannitol are dissolved in water.
After packaging the solution is freeze-dried. To produce the solution ready for use, the product is dissolved in water for injections.
0 186 Example 195 Dry ampoule containing 35 mg of active substance per 2 ml Composition: Active substance Mannitol water for injections 35.0 mg 100.0 mg ad 2.0 ml Preparation: Active substance and mannitol are dissolved in water. After packaging, the solution is freeze-dried.
To produce the solution ready for use, the product is dissolved in water for injections.
Example 196 Tablet containing 50 mg of active substance Composition: Active substance Lactose Maize starch Polyvinylpyrrolidone Magnesium stearate 50.0 mg 98.0 mg 50.0 mg 15.0 mg 2.0 mq 215.0 mg Preparation: and are mixed together and granulated with an aqueous solution of is added to the dried granulated material. From this mixture tablets are pressed, 0 187 biplanar, faceted on both sides and with a dividing notch on one side.
Diameter of the tablets: 9 mm.
Example 197 Tablet containing 350 mg of active substance Preparation: Active substance Lactose Maize starch Polyvinylpyrrolidone Magnesium stearate 350.0 mg 136.0 mg 80.0 mg 30.0 mg 4.0 mg 600.0 mg and are mixed together and granulated with an aqueous solution of is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.
Diameter of the tablets: 12 mm.
Example 198 Capsules containing 50 mg of active substance Composition: Active substance Dried maize starch Powdered lactose Magnesium stearate 50.0 mg 58.0 mg 50.0 mg 2.0 mq 160.0 mg 188 Preparation: is triturated with This trituration is added to the mixture of and with vigorous mixing.
This powder mixture is packed into size 3 hard gelatin capsules in a capsule filling machine.
Example 199 Capsules containing 350 mg of active substance Composition: Active substance Dried maize starch Powdered lactose Magnesium stearate 350.0 mg 46.0 mg 30.0 mg 4.0 mq 430.0 mg Preparation: is triturated with This trituration is added to the mixture of and with vigorous mixing.
This powder mixture is packed into size 0 hard gelatin capsules in a capsule filling machine.
Example 200 Suppositories containing 100 mg of active substance 1 suppository contains: Active substance 100.0 mg Polyethyleneglycol 1500) 600.0 mg Polyethyleneglycol 6000) 460.0 mg Polyethylenesorbitan monostearate 840.0 mq 2,000.0 mg

Claims (15)

1. Disubstituted bicyclic heterocycles of general formula Ra A Het B Ar E wherein A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R, group, B denotes an ethylene group, wherein a methylene group, linked either to the group Het or Ar, may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, carbonyl or -NR, group, wherein R 1 denotes a hydrogen atom or a C 1 _,-alkyl group, E denotes a cyano or RbNH-C(=NH)- group wherein Rb denotes a hydrogen atom, a hydroxy group, a C1-3-alkyl group or a group which may be cleaved in vivo, Ar denotes a phenylene or naphthylene group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C,_--alkyl or C 1 3 -alkoxy group, a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted in the carbon skeleton by a C 1 3 -alkyl group, Het denotes a bicyclic heterocycle of formula 190 X Y ,wherein X is a nitrogen atom and Y is an oxygen or sulphur atom or a nitrogen atom optionally substituted by a C._,-alkyl or C 37 -cycloalkyl group, whilst additionally one or two non-angular methyne groups in the phenyl moiety of the above-mentioned bicyclic heterocycle may each be replaced by a nitrogen atom, or X denotes a methyne group optionally substituted by the group wherein R 1 is as hereinbefore defined, and Y denotes a nitrogen atom optionally substituted by a C 1 6 -alkyl or C 3 7 -cycloalkyl group, or Het denotes a group of the formula N R 1 I SQN 191 R 1 z fV G or R 1 N N, N R 1 R, is as hereinbefore defined, Z denotes an oxygen or sulphur atom, one of the groups D or G denotes a nitrogen atom and the other group D or G denotes a methyne group, and Ra denotes a C 1 6 -alkyl group, a C 3 _,-cycloalkyl group optionally substituted by a C-, 3 -alkyl group, wherein the C 1 _-alkyl group may additionally be substituted by a carboxyl group or by a group which may be converted in vivo into a carboxy group, or an R 2 NR 3 group wherein R 2 denotes a C 1 ,,-alkyl group, which may be substituted by a carboxy, C_. 6 -alkyloxycarbonyl, benzyloxycarbonyl, C_3-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, trifluorosulphonylamino, trifluorosulphonylaminocarbonyl or 1H-tetrazolyl group, 192 a C 2 _4-alkyl group substituted by a hydroxy, phenyl- CI.3-alkoxy, carboxy-C 1 3 -alkylamino, alkoxycarbonyl-C_ 3-alkylamino, N- (C, 3 -alkyl) -carboxy- C 1 _3-alkylamino or N-(C 1 _3-alkyl)-C 1 _3-alkoxycarbonyl-C 1 3 alkylamino group, whilst in the abovementioned groups the carbon atom in the a-position relative to the adjacent nitrogen atom may not be substituted, or a piperidinyl group optionally substituted by a C 1 3 -alkyl group and R 3 denotes a hydrogen atom, a CI_ 6 -alkyl group, a C 3 7 cycloalkyl group optionally substituted by a C 1 -3-alkyl group, a C 3 6 -alkenyl or alkynyl group, wherein the 15 unsaturated part may not be linked directly to the nitrogen atom of the R 2 NR 3 group, a phenyl group Soptionally substituted by a fluorine, chlorine or bromine atom or by a Ci_ 3 -alkyl or C 1 3 -alkoxy group, a benzyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 20 pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, piperidinyl or imidazolyl group optionally Ssubstituted by a C 1 i 3 -alkyl group or R 2 and R 3 together with the nitrogen atom between them 25 denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxy or C 1 4 -alkoxycarbonyl group, onto which a phenyl ring may additionally be fused, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof.
2. Disubstituted bicyclic heterocycles of general formula I according to claim 1, wherein A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno 193 moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R 1 group, B denotes an ethylene group, in which a methylene group, linked either to the group Het or Ar, may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, carbonyl or group, wherein RI denotes a hydrogen atom or a C 1 _s-alkyl group, E denotes an RbNH-C(=NH)- group wherein Rb denotes a hydrogen atom, a hydroxy group, a C._ 3 -alkyl group or a group which may be cleaved in vivo, Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, Cl_ 3 -alkyl or C 1 3 -alkoxy group, a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted in the carbon skeleton by a C 1 3 -alkyl group, Het denotes a bicyclic heterocycle of formula I wherein X is a nitrogen atom and Y is an oxygen or sulphur atom or a nitrogen atom optionally substituted by a C_.,-alkyl or C 3 _.-cycloalkyl group, whilst additionally one or two non-angular methyne groups in the phenyl moiety of the 194 above-mentioned bicyclic heterocycle may each be replaced by a nitrogen atom, or X denotes a methyne group optionally substituted by the group wherein R, is as hereinbefore defined, and Y denotes a nitrogen atom optionally substituted by a C, _-alkyl or C 3 7 -cycloalkyl group, or Het denotes.a group of the formulae _a N :C t 1 N SRQ R 1 -195- wherein R1 wherein R 1 is as hereinbefore defined, Z denotes an oxygen or sulphur atom one of the groups D or G denotes a nitrogen atom and the other group D or G denotes a methyne group, and Ra denotes a C,- 6 -alkyl group, a C 3 _,-cycloalkyl group optionally substituted by a C 1 3 -alkyl group, wherein the C 1 3 -alkyl group may additionally be substituted by a carboxyl group or by a group which may be converted in vivo into a carboxy group, or a RNR 3 group wherein R, denotes a C 14 -alkyl group, which may be substituted by a carboxy, C,-a-alkyloxycarbonyl, benzyloxycarbonyl, Cl- 3 -alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, trifluorosulphonylamino, trifluorosulphonylaminocarbonyl or 1H-tetrazolyl group, a C 24 -alkyl group substituted by a hydroxy, phenyl- C 1 3 alkoxy, carboxy-C 1 3 -alkylamino, C1-- alkoxycarbonyl-C. -alkylamino, N-(C_ 3 -alkyl)-carboxy- C 1 3 -alkylamino or 3 -alkyl)-Cl_--alkoxycarbonyl-Cl- 3 alkylamino group, whilst in the abovementioned groups the carbon atom in the a-position relative to the adjacent nitrogen atom may not be substituted, or 196 a piperidinyl group optionally substituted by a Cl 3-alkyl group and R 3 denotes a hydrogen atom, a CI_ -alkyl group, a C 3 7 -cycloalkyl group optionally substituted by a C, 3-alkyl group, a C 3 6 -alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R 2 NR 3 group, a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a C 1 i 3 -alkyl or Ci-3-alkoxy group, a benzyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, piperidinyl 15 or imidazolyl group optionally substituted by a Ci-3- alkyl group or SR 2 and R 3 together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, 20 optionally substituted by a carboxy or C1-4- alkoxycarbonyl group, onto which a phenyl ring may additionally be fused, the tautomers, the stereoisomers and the salts thereof.
3. Disubstituted bicyclic heterocycles of general formula I according to claim 1, wherein A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R, group, B denotes an ethylene group in which the methylene group linked to the group Ar may be replaced by an oxygen or sulphur atom or by an group, wherein 197 R. denotes a hydrogen atom or a C,-,-alkyl group, E denotes an RbNH--C(=NH)- group wherein Rb denotes a hydrogen atom, a hydroxy, Cl- 9 -alkoxycarbonyl, cyclohexyloxycarbonyl, phenyl C 1 3 -alkoxycarbonyl, benzoyl., p-Cl 1 3 -alkyl-benzoyl or pyridinoyl group, whilst the ethoxy moiety in the 2-position of the abovementioned C 1 alkoxycarbonyl group may additionally be substituted by a C 1 3 -alkyl- sulfonyl or 2- (Cl 1 3 -alkoxy) -ethyl group, Ar denotes a 1,4-phenylene group optionally substituted by a chlorine atom or by a methyl, ethyl or methoxy group or it denotes a 2,5-thienylene group, Het denotes a 1- (C 1 3 -alkyl) -2,5-benzimidazolylene, 1- cyclopropyl-2, 5-benzimidazolylene, 2, 1-(C 1 3 -alkyl)-2,5-indolylene, i-(C 1 3 -alkyl)- 2,5-imidazo[4,5-b]pyridinylene, 3- (C 1 3 -alkyl) 2,7-imidazo[1,2-alpyridinylene or 1- (C 1 3 -alkyl) 2, 5-thieno 3-dI imidazolylene group and R. denotes an R 2 NR 3 group wherein R 2 is a C 1 4 -alkyl group substituted by a carboxy, C 1 -6 -alkyloxycarbonyl, benzyloxycarbonyl, Cl.. 3 -alkylsulphonylaminocarbonyl or group, a C 2 4 -alkyl group substituted by a hydroxy, benzyloxy, carboxy-Cl- 3 -alkylamnino, C 1 3 -alkoxycarbonyl- C 1 l 3 -alkylamino, N- (C 1 3 -alkyl) -carboxy-Cl-. 3 -alkylamino 0 198 or N-(C1- 3 -alkyl)-C 1 3 -alkoxycarbonyl-C 1 3 -alkylamino group, whilst in the abovementioned groups the carbon atom in the a-position to the adjacent nitrogen atom may not be substituted, R 3 denotes a C3_ 7 -cycloalkyl group, a propargyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R 2 NR 3 group, a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, a pyrazolyl, py- ridazolyl or pyridinyl group optionally substituted by a methyl group or R 2 and R 3 together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxy or C1- 4 -alk- oxycarbonyl group, to which a phenyl ring may additionally be fused, the tautomers, the stereoisomers and the salts thereof.
4. Disubstituted bicyclic heterocycles of general formula I according to claim 1, wherein A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R, group, B denotes an ethylene group in which the methylene group linked to the group Ar may be replaced by an oxygen or sulphur atom or by an group, wherein Ri denotes a hydrogen atom or a methyl group, E denotes an RbNH-C(=NH)- group, wherein S -199 Rb denotes a hydrogen atom or a hydroxy, C 19 ,-alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, p-C 1 3 -alkylbenzoyl or nicotinoyl group, whilst the ethoxy moiety in the 2- position of the abovementioned C,- 9 -alkoxycarbonyl group may additionally be substituted by a C- alkylsulphonyl or 2- (C 13 -alkoxy) -ethyl group, Ar denotes a 1,4-phenylene group optionally substituted by a chlorine atom or by a methyl, ethyl or methoxy group, or it denotes a 2,5-thienylene group, Het denotes a 1-methyl-2,5-benzimidazolylene, 1- cyclopropyl-2, 5-benzimidazolylene, 2, l-methyl-2, 5-indolylene, i-methyl- 2, 5-imidazo pyridinylene, 3-methyl- 2,7-imidazo[1,2-alpyridinylene or 1-methyl- 2, 5-thieno 3-d] imidazolylene group and Ra denotes a R 2 NR 3 group wherein R 2 denotes a C 1 3 -alkyl group which may be substituted by a carboxy, C 1 6 -alkyloxycarbonyl, benzyloxycarbonyl, methylsulphonylaminocarbonyl or 1H-tetrazol-5-yi group, a C 2 3 -alkyl group substituted by a hydroxy, benzyloxy, carboxy-Cl- 3 -alkylamino, Cl 1 3 -alkoxycarbonyl- C 1 3 -alkylamino, N- (Cl.. 3 -alkyl) -carboxy-C 1 3 -alkylamino or N- (C 1 3 -alkyl) -C 1 3 -alkoxycarbonyl-Cl- 3 -alkylamino group, whilst in the abovementioned groups the carbon atom in the x-position to the adjacent nitrogen atom may not be substituted, and 0 200 R 3 denotes a propargyl group, wherein the unsaturated moiety may not be linked directly to the nitrogen atom of the R 2 NR 3 group, a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group or it denotes a pyridinyl group, the tautomers, the stereoisomers and the salts thereof.
5. Disubstituted bicyclic heterocycles of general formula I according toclaim 1, wherein A denotes a carbonyl group linked to the benzo or thieno moiety of the group Het, B denotes an ethylene group wherein the methylene group attached to the group Ar may be replaced by an -NR 1 group, whilst R 1 denotes a hydrogen atom or a methyl group, E denotes an RbNH-C(=NH)- group wherein Rb is a hydrogen atom, a hydroxy, Cl_9-alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, p-C 1 3 -alkyl-benzoyl or nicotinoyl group, whilst the ethoxy moiety in the 2-position of the abovementioned C 1 _9-alkoxycarbonyl group may additionally be substituted by a methylsulfonyl or 2-ethoxy-ethyl group, Ar denotes a 1,4-phenylene group optionally substituted by a methoxy group or it denotes a 2,5-thienylene group, -201 Het denotes a 1-methyl-2,5-benzimidazolylene, 2, 5-benzothiazolylene, i-methyl-2, 5-indolylene or 1-methyl- 2, 5-thieno 3-d] imidazolylene group and Ra denotes an R 2 NR 3 group wherein R 2 denotes a 3 -alkyl group which may be substituted by a carboxy, C 1 6 -alkyloxycarbonyl, benzyloxycarbonyl, methylsulfonylaminocarbonyl or 1H-tetrazol-5-yl group, a C 2 3 -alkyl group substituted by a hydroxy, benzyloxy, carboxy-Cl 3 -alkylamino, Cl.. 3 -alkoxycarbonyl- Cl 1 3 -alkylamino, N- (Cl 1 3 -alkyl) -carboxy-Cl- 3 -alkylamino or N- (Cl 1 3 -alkyl) -Cl 1 3 -alkoxycarbonyl-Cl- 3 -alkylamino group, whilst in the abovementioned groups the carbon atom in the ax-position to the adjacent nitrogen atom may not be substituted, and R 3 denotes a phenyl group optionally substituted by a fluorine atom, or it denotes a 2-pyridinyl group, the tautomers, stereoisomers and the salts thereof.
6. The following compounds of general formula I: 2- (4-amidinophenyl) -aminomethyl] -benzthiazole- acid-N-phenyl-N- (2-carboxyethyl) -amide, 2- (4-midinophenyl) -N-methyl-aminomethyl] acid-N-phenyl-N- (2- hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2- hydroxycarbonylethyl) -amide, 0 202 1-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N-phenyl- N- (3-hydroxycarbonyipropyl) -amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N- (2-pyridyl) N- (hydroxycarbonylmethyl) -amide, 1-Methyl-2-[2-(2-amidinothiophen-5-yl)ethyl]- acid-N- (2-pyridyl) (2- hydroxycarbonylethyl) -amide, l-Methyl-2- (4-amidinophenyl) -aminomethyl] benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (2- hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) ethyl] -benzimidazol-S- yl-carboxylic acid-N- (2-pyridyl) (2- hydroxycarbonylethyl) -amide, Wi 1-Methyl-2- (4-amidinophenyl) ethyl] yl-carboxylic acid-N-phenyl-N- (2-hydroxycarbonylethyl) amide, l-Methyl-2- (4-amidinophenyl) ethyl] yl-carboxylic acid-N-phenyl-N- (lH-tetrazol-5-yl) ethyl] amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N-phenyl-N- (11- ethyl] -arnide, 1-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) (2- hydroxycarbonylethyl) -amide, 0 203 (in) 1-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] acid-N- (3-pyridyl) (2- hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) -N-methyl-aminomethyl] acid-N-phenyl-N- (2- hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] benzimidazol-5-yl-carboxylic acid-N-phenyl-N- hydroxycarbonylethyl-N-methyl) -2-aminoethyl] -amide, 1-Methyl-2- (4-amidinophenyl) -aminomethyl] acid-N- (3-f luorophenyl) (2- hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) -aminornethyl] acid-N- (4-f luorophenyl) (2- hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidino-2-methoxy-phelyl) aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2 -hydroxycarbonylethyl) -arnide, 1-Methyl-2- (4-amidino-2-methoxy-phenyl) aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2- pyridyl) (2-hydroxycarbonylethyl) -amide, 1-Methyl-2- (4-amidinophenyl) aminomethyl] carboxylic acid-N-phenyl-N- (2-methoxycarbonylethyl) -amide and 1-Methyl-2- (4-amidinophenyl) aminomethyl] thieno[2.3-d] imidazol-5-yl-carboxylic acid-N-phenyl-N- (2- hydroxycarbonylethyl) -arnide, 204 the tautomers, prodrugs, double prodrugs, stereoisomers and the salts thereof.
7. 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]- benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2- hydroxycarbonylethyl)-amide, the prodrugs, double prodrugs and the salts thereof.
8. l-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]- benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2- hydroxycarbonylmethyl)-amide, the prodrugs, double prodrugs and the salts thereof.
9. l-Methyl-2-[N- (4-amidino-2-methoxy-phenyl) -aminomethyl] 15 benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)- N- 2 -hydroxycarbonylethyl)-amide, the prodrugs, double prodrugs and the salts thereof.
10. 1-Methyl-2- [4-(N-n-hexyloxycarbonylamidino)phenyl- 20 aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2- pyridyl)-N-(ethoxycarbonylethyl) -amide and the salts thereof.
11. Physiologically acceptable salts of the compounds according to claims 1 to 10, wherein E denotes an RbNH-C(=NH)- group.
12. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 10,.wherein E denotes an RbNH-C(=NH)- group, or a salt according to claim 11, optionally together with one or more inert carriers and/or diluents.
13. Use of a compound according to at least one of claims 1 to 10, wherein E denotes an RbNH-C(=NH)- group, or a salt according to claim 11, for preparing a pharmaceutical composition having the effect of prolonging the thrombin 205 time, a thrombin-inhibiting effect and an inhibiting effect on related serine proteases.
14. Process for preparing a pharmaceutical composition according to claim 12, characterised in that a compound according to at least one of claims 1 to 10, wherein E denotes an RbNH-C(=NH)- group, or a salt according to claim 11, is incorporated in one or more inert carriers and/or diluents by a non-chemical method. Process for preparing compounds according to claims 1 to 11, characterised in that a. in order to prepare a compound of general formula I, 15 wherein E denotes an RbNH-C(=NH)- group, wherein Rb is a hydrogen atom or a hydroxy or C- 3 -alkyl group, a compound of general formula Ra A Het B Ar C(=NH) Z (II) optionally formed in the reaction mixture, wherein A, B, Ar, Het and Ra are defined as in claims 1 to 10 and Z 1 denotes an alkoxy, aralkoxy, alkylthio or aralkylthio group, is reacted with an amine of general formula H 2 N Rb ,(III) wherein Rb' denotes a hydrogen atom, a hydroxy or C 1 3 -alkyl group, or b. in order to prepare a compound of general formula I, wherein the Ra-A- group and E are defined as in claims 1 to with the proviso that the Ra-A- group contains a 206 carboxy group and E is defined as in claims 1 to 10 or the Ra-A- group is defined as in claims 1 to 10 and E denotes an NH 2 group, or the Ra-A- group contains a carboxy group and E denotes an NH 2 group, a compound of general formula Ra' A Het B Ar C E' ,(IV) wherein A, B, Ar and Het are defined as in claims 1 to 10 and the R group and E' have the meanings given for the Ra-A- group and E in claims 1 to 10, with the proviso that the R' group contains a group which can be converted into a carboxyl group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis and E is defined as in claims 1 to 10 or E' denotes a group which may be converted into an NH 2 group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis and the Ra'-A- group has the meanings given for the Ra-A- group in claims 1 to 10, or the Ra'-A- group contains a group which may be converted into a carboxyl group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis and E' denotes a group which may be converted into an group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis, is converted, by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis, into a compound of general formula I, wherein the Ra-A- group and E are defined as in claims 1 to 10, with the proviso that the Ra-A- group contains a carboxy group and E is defined as in claims 1 to 10 or the Ra-A- group has the meanings given in claims 1 to 10 and E denotes an NH 2 group or the group contains a carboxy group and E denotes an NH 2 group, or 207 c. in order to prepare a compound of general formula I wherein the group contains one of the ester groups mentioned in the definition of the Ra-A- group in claims 1 to 10, a compound of general formula Ra" A Het B Ar E (V) wherein B, E, Ar and Het are defined as in claims 1 to 10 and Ra"-A- group has the meanings given for the Ra-A- group in claims 1 to 10, with the proviso that the group contains a carboxyl group or a group which may be converted o by means of an alcohol into a corresponding ester group, is reacted with an alcohol of general formula HO R7 (VI) S: wherein R, denotes the alkyl moiety of one of the groups which may be cleaved in vivo mentioned in claims 1 to 10, with the exception of the R 4 -CO-O-(R 5 CR 6 group for a carboxyl 20 group, or with the formamide acetals thereof or with a compound of general formula Z2 R 8 (VII) wherein R, denotes the alkyl moiety of one of the groups which may be cleaved in vivo mentioned in claims 1 to 10, with the exception of the R 4 -CO-O-(RsCR) group for a carboxyl group and Z 2 denotes a leaving group, or d. in order to prepare a compound of general formula I wherein Rb denotes a group which may be cleaved in vivo, a compound of general formula Ra A Het B Ar C(=NH) NH 2 (VIII) if
208- wherein Ra, A, Het, B and Ar are defined as in claims 1 to 10, is reacted with a compound of general formula Z 2 R 7 ,(IX) wherein R 7 denotes a group which may be cleaved in vivo and Z 2 denotes a nucleofugic leaving group, or e. in order to prepare a compound of general formula I wherein B denotes an ethylene group wherein a methylene group is replaced by a sulphinyl or sulphonyl group, a compound of general formula R a A Het B' Ar E (X) wherein A, E, Ar, Het and Ra are defined as in claims 1 to 10 and 20 B' denotes an ethylene group, in which a methylene group is replaced by a sulphenyl or sulphinyl group, is oxidised or e 0 f. in order to prepare a compound of general formula I, wherein E denotes a cyano group and B is an ethylene group, in which a methylene group, linked either to the group Het o or Ar, is replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, carbonyl or group, a compound of general formula Ra A- Het U ,(XI) 30 is reacted with a compound of general formula V Ar CN (XII) wherein 1 209 Ra, A, Ar and Het are defined as in claims 1 to one of the groups U or V denotes an HO-, HS-, HOSO-, HOSO or HNRi- group and the other group denotes a Z 3 CH 2 group, wherein R, is defined as in claims 1 to 10 and Z 3 denotes a nucleofugic leaving group, or g. in order to prepare a compound of general formula I, wherein E is a cyano group and Ra denotes an R 2 NR 3 group, a compound of general formula H A Het B Ar CN (XIII) wherein A, B, Het and Ar are defined as in claims 1 to 10, is reacted with an amine of general formula /R2 H N ,(XIV) R 3 wherein R 2 and R 3 are defined as in claims 1 to 10, or with the reactive derivatives thereof, or h. in order to prepare a benzimidazolyl, benzothiazolyl or benzoxazolyl compound of general formula I, wherein B denotes an ethylene group, a compound of general formula NH Ra A (XV) YH wherein Ra, A and Y are defined as in claims 1 to 10, is reacted with a compound of general formula HO-CO CH 2 CH 2 Ar E ,(XVI) 2A\Z. Z wherein 210 Ar and E are defined as in claims 1 to 10, or with the reactive derivatives thereof and i. in order to prepare a quinoxalin-2-one compound of the general formula: a compound of general formula NH 2 Ra A 2, (XVII) NR 1 H wherein Ra, R 1 and A are defined as in claims 1 to 10, is reacted with a compound of general formula HO-CO COCH 2 Ar E ,(XVIII) wherein Ar and E are defined as in claims 1 to 10, or with the reactive derivatives thereof, or j. in order to prepare a compound of general formula I wherein R 2 denotes a C 1 _4-alkyl group substituted by an alkylsulphonylaminocarbonyl group: a compound of general formula R2 N A Het B Ar E ,(IXX) R wherein R 3 A, B, E, and Het are defined as in claims 1 to 10 and R 2 denotes a C 1 _4-alkyl group substituted by a carboxy group, or the reactive derivatives thereof, Q^ is reacted with a salt of a compound of general formula P:\OPERMKR\SPECI\2197823 esdoc-12 November. 21)1 -211- C 1 3 -Alkyl-S0 2 -NH 2 (XX) and, if necessary, a protecting group used during the reactions in order to protect reactive groups is cleaved and/or subsequently, if desired, a compound of general formula I thus obtained is resolved into the stereoisomers thereof and/or a compound of general formula I thus obtained is converted into the salts thereof, more particularly for pharmaceutical use into the physiologically acceptable salts thereof with an inorganic or organic acid or base. 16. l-methyl-2-[N-(4-amidinophenyl)-aminomethyl]- benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2- hydroxycarbonylethyl)-amide. 20 17. A method of treatment of a venous or arterial thrombotic disease, of providing antithrombotic support in thrombolytic treatment, of preventing long-term restenosis after PT(C)A, of preventing metastasis and growth of clot- dependent tumours or fibrin-dependent inflammatory processes 25 which involves administering to a patient in need of such treatment an effective amount of a compound according to any S* one of claims 1 to 10, wherein E denotes an RbNH-C(=NH)- group, or a salt according to claim 11. 18. Use of a compound according to any one of claims 1 to where E denotes an RbNH-C(=NH)- group, or a salt according to claim 11 in preparation of a pharmaceutical I- composition for treatment of a venous or arterial thrombotic disease, of providing antithrombotic support in thrombolytic a,,(1 P:\OPERUMKR\SPECIU2197823 rs.doc-12 November. 2001 -212- treatment, of preventing long-term restenosis after PT(C)A, of preventing metastasis and growth of clot-dependent tumours or fibrin-dependent inflammatory processes which involves administering to a patient in need of such treatment an effective amount of a compound according to any one of claims 1 to 10, wherein E denotes an RbNH-C(=NH)- group, or a salt according to claim 11. 19. A compound according to any one of claims 1 to 10 substantially as herein before described with reference to the Examples. S S Eth S* DATED this 12 th day of November, 2001 S S ****BOEHRINGER INGELHEIM PHARMA KG by its Patent Attorneys *DVe C DAVIES COLLISON CAVE S* S S sh* o ooo o o go o•• oooo o ••go•
AU63991/98A 1997-02-18 1998-02-16 Disubstituted bicyclic heterocycles, their production and use as medicaments Expired AU742593C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19706229A DE19706229A1 (en) 1997-02-18 1997-02-18 New aryl-substituted bi:cyclic heterocyclic compounds
DE19706229 1997-02-18
DE1997151939 DE19751939A1 (en) 1997-11-24 1997-11-24 New aryl-substituted bi:cyclic heterocyclic compounds
DE19751939 1997-11-24
PCT/EP1998/000865 WO1998037075A1 (en) 1997-02-18 1998-02-16 Disubstituted bicyclic heterocycles, their production and use as medicaments

Publications (3)

Publication Number Publication Date
AU6399198A AU6399198A (en) 1998-09-09
AU742593B2 true AU742593B2 (en) 2002-01-10
AU742593C AU742593C (en) 2004-04-29

Family

ID=26034058

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63991/98A Expired AU742593C (en) 1997-02-18 1998-02-16 Disubstituted bicyclic heterocycles, their production and use as medicaments

Country Status (39)

Country Link
EP (1) EP0966454B1 (en)
JP (1) JP3343359B2 (en)
KR (1) KR100619458B1 (en)
CN (1) CN1088702C (en)
AR (1) AR010896A1 (en)
AT (1) ATE239712T1 (en)
AU (1) AU742593C (en)
BG (1) BG64558B1 (en)
BR (1) BR9807843B1 (en)
CA (1) CA2277949C (en)
CO (1) CO4920237A1 (en)
CZ (1) CZ297768B6 (en)
DE (2) DE122008000020I1 (en)
DK (1) DK0966454T3 (en)
EA (1) EA003697B1 (en)
EE (1) EE04716B1 (en)
EG (1) EG24144A (en)
ES (1) ES2199426T4 (en)
FR (1) FR08C0025I2 (en)
HK (1) HK1025096A1 (en)
HR (1) HRP980082B1 (en)
HU (1) HU223754B1 (en)
IL (1) IL130812A (en)
LT (1) LTC0966454I2 (en)
LU (1) LU91437I2 (en)
MY (1) MY129408A (en)
NL (1) NL300349I2 (en)
NO (3) NO313879B1 (en)
NZ (1) NZ337323A (en)
PE (1) PE121699A1 (en)
PL (1) PL195551B1 (en)
PT (1) PT966454E (en)
RS (1) RS49686B (en)
SA (1) SA98190047B1 (en)
SI (1) SI0966454T1 (en)
SK (1) SK285432B6 (en)
TR (1) TR199902017T2 (en)
TW (1) TW588047B (en)
WO (1) WO1998037075A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675276B2 (en) 2014-11-03 2020-06-09 Hangzhou Solipharma Co., Ltd. Dosing preparation of dabigatran etexilate or a salt thereof and a preparation method thereof

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1608399A (en) * 1997-11-26 1999-06-15 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
US6114532A (en) * 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
AU2720199A (en) * 1998-02-03 1999-08-23 Boehringer Ingelheim Pharma Kg Five-membered, benzo-condensed heterocycles used as antithrombotic agents
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
NZ506507A (en) * 1998-02-09 2003-08-29 Dimensional Pharm Inc Heteroaryl amidine, methylamidine or guanidine derivatives useful as urokinase inhibitors
TWI248435B (en) * 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
US6248770B1 (en) 1998-07-09 2001-06-19 Boehringer Ingelheim Pharma Kg Benzimidazoles having antithrombotic activity
JP2002536446A (en) * 1999-02-09 2002-10-29 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド Heteroarylamidines, methylamidines and guanidines as protease inhibitors
DE19907813A1 (en) * 1999-02-24 2000-08-31 Boehringer Ingelheim Pharma Substituted bicyclic heterocycles, their preparation and their use as pharmaceuticals
AR023510A1 (en) 1999-04-21 2002-09-04 Astrazeneca Ab A TEAM OF PARTS, PHARMACEUTICAL FORMULATION AND USE OF A THROMBIN INHIBITOR.
DE19939463A1 (en) * 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides
US6512000B1 (en) 1999-08-20 2003-01-28 Boehringer Ingelheim Pharma Kg Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity
DE19945787A1 (en) 1999-09-24 2001-03-29 Boehringer Ingelheim Pharma New 2-(amidino- or aminomethyl-phenethyl)-5-sulfonylamino-benzimidazoles, are tryptase inhibitors useful e.g. for treating inflammatory or allergic disease such as asthma, urticaria or arthritis
US6413990B1 (en) 1999-09-24 2002-07-02 Boehringer Ingelheim Pharma Kg Arylsulphonamide-substituted benzimidazoles having tryptase-inhibiting activity
DE19945810A1 (en) * 1999-09-24 2001-03-29 Boehringer Ingelheim Pharma Substituted benzimidazole derivatives, process for their preparation and their use as medicaments
WO2001023360A1 (en) * 1999-09-24 2001-04-05 Boehringer Ingelheim Pharma Kg Aryl sulfonamide-substituted benzimidazol derivatives thereof as tryptase inhibitors
US6407130B1 (en) 1999-11-10 2002-06-18 Boehringer Ingelheim Pharma Kg Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity
US6451832B2 (en) 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2002085855A1 (en) 2001-04-19 2002-10-31 Eisai Co., Ltd. 2-iminopyrrolidine derivatives
DE10133786A1 (en) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Use of thrombin inhibitors for the treatment of arthritis
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CA2476054C (en) * 2002-03-07 2011-11-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
DE10235639A1 (en) 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New prodrugs of benzimidazole-5-carboxamide derivative thrombin inhibitor, useful for treating or preventing thrombotic diseases, are well tolerated on subcutaneous injection
AU2003265398A1 (en) 2002-08-09 2004-02-25 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
PE20040804A1 (en) * 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma CARBOXAMID DERIVATIVES AS INHIBITORS OF THE Xa FACTOR
DE10260730A1 (en) * 2002-12-23 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted nitrogen-containing heterobicyclene, their preparation and their use as pharmaceuticals
US7429597B2 (en) 2002-12-23 2008-09-30 Boehringer Ingelheim Pharma Gmbh & Co., Kg Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
EP2444393A1 (en) 2003-02-19 2012-04-25 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
DE10310278A1 (en) * 2003-03-10 2004-09-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg New N-(benzazinyl)-(hetero)aralkylamine derivatives, are inhibitors of factor Xa and/or related serine proteases, useful e.g. as antithrombotic agents and intermediates
EP2062580A1 (en) * 2003-04-24 2009-05-27 Boehringer Ingelheim International GmbH Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of trombin receptors
WO2005014534A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
CN1832920A (en) 2003-08-08 2006-09-13 特兰斯泰克制药公司 Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
DE10337697A1 (en) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
DE10339862A1 (en) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis
DE10341043A1 (en) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg New Oral Dosage Form for 3 - [(2 - {[4-hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] Propionic acid ethyl ester and its salts
EP1609784A1 (en) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Process for the preparation of 4-(benzimidazolylmethylamino)-benzamidines
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (en) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New hexyloxycarbonylamino-imino-methyl-phenylamino-methyl-benzimidazole-pyridine-propionic acid-ethyl ester salts such as hydrochloride useful for the prophylaxis of vein thrombosis and stroke
DE102005025728A1 (en) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester
DE602006017694D1 (en) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR SUITABLE FOR THE TREATMENT OF THROMBOTIC SUFFERING
DE102005061623A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts
DE102005061624A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamidines
US8044242B2 (en) 2006-03-09 2011-10-25 Bristol-Myers Squibb Company 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants
WO2007146719A2 (en) 2006-06-08 2007-12-21 Bristol-Myers Squibb Company 2-aminocarbonylphenylamino-2-phenylacetamides as factor viia inhibitors useful as anticoagulants
AR061996A1 (en) * 2006-07-17 2008-08-10 Boehringer Ingelheim Int INDICATIONS FOR DIRECT THROMBIN INHIBITORS IN THE CARDIOVASCULAR FIELD
CA2657269A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
WO2008076805A2 (en) 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (en) 2006-12-20 2008-12-18 Bristol Myers Squibb Co MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
EP1956018A1 (en) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Method of preparing a derivative of benzimidazole
MX2009011089A (en) 2007-04-23 2009-10-30 Sanofi Aventis Quinoline-carboxamide derivatives as p2y12 antagonists.
EP2178849A1 (en) * 2007-07-31 2010-04-28 Mallinckrodt Inc. Integrated photoactive agents and uses thereof
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
CZ305085B6 (en) * 2008-03-14 2015-04-29 Zentiva, K.S. Process for preparing dabigatran
CN102099012A (en) 2008-07-14 2011-06-15 贝林格尔.英格海姆国际有限公司 Method for manufacturing medicinal compounds containing dabigatran
US20110190352A1 (en) * 2008-08-19 2011-08-04 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
CZ2008669A3 (en) * 2008-10-24 2010-05-05 Zentiva, A. S. Process for preparing dabigatran and intermediates thereof
PL2391893T3 (en) * 2009-02-02 2015-03-31 Boehringer Ingelheim Int Lyophilised dabigatran
EP2647375A1 (en) 2009-05-14 2013-10-09 Boehringer Ingelheim International Gmbh Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases
KR20120050457A (en) 2009-08-24 2012-05-18 베링거 인겔하임 인터내셔날 게엠베하 Emergency interventions of active charcoal with dabigatran etexilate overdosing
CN102050814B (en) * 2009-11-06 2014-05-28 北京美倍他药物研究有限公司 Ester derivatives of dabigatran
CN102050815B (en) * 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 Dabigatran ester derivatives as prodrug
US8399678B2 (en) 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate
TWI513466B (en) 2010-01-20 2015-12-21 Boehringer Ingelheim Int Anticoagulant antidotes
HUP1000069A2 (en) 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
EA020528B1 (en) 2010-02-11 2014-11-28 Бристол-Майерс Сквибб Компани Macrocycles as factor xia inhibitors
WO2011107427A1 (en) 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
JP2013521318A (en) 2010-03-08 2013-06-10 ラティオファルム ゲー・エム・ベー・ハー Pharmaceutical composition containing dabigatran etexilate
EA022969B1 (en) 2010-07-01 2016-03-31 Крка, Товарна Здравил, Д.Д., Ново Место Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
EP2937343A1 (en) 2010-07-09 2015-10-28 Esteve Química, S.A. Process of preparing a thrombin specific inhibitor
MX2013000294A (en) 2010-07-09 2013-04-03 Esteve Quimica Sa Intermediates and process for preparing a thrombin specific inhibitor.
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
EP2691156A1 (en) 2011-03-30 2014-02-05 Boehringer Ingelheim International GmbH Anticoagulant antidotes
HUP1100244A2 (en) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Pharmaceutical intermediates and process for their production
CN102250099B (en) * 2011-05-16 2013-10-16 中国药科大学 Non-peptide thrombin inhibitors as well as preparation method and medical application thereof
CN102838588B (en) * 2011-06-24 2014-03-19 中国药科大学 Oral thrombin inhibitors, preparation methods and medical uses thereof
EP2550966B1 (en) * 2011-07-25 2016-10-19 Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG Amidoxime carboxylic acid esters of dabigatran as prodrugs and their use as medicament
TW201311689A (en) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 Novel macrocycles as factor XIa inhibitors
TW201319068A (en) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 Cyclic P1 linkers as factor XIa inhibitors
WO2013024394A1 (en) * 2011-08-12 2013-02-21 Alembic Pharmaceuticals Limited Novel reference markers of dabigatran etexilate
CN102993175B (en) * 2011-09-08 2014-08-13 天津药物研究院 Dabigatran derivatives, and preparation method and application thereof
CN102993174A (en) * 2011-09-08 2013-03-27 天津药物研究院 Dabigatran etexilate derivative as a prodrug
ES2572908T3 (en) 2011-10-14 2016-06-03 Bristol-Myers Squibb Company Tetrahydroisoquinoline compounds substituted as factor XIa inhibitors
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
RS56168B1 (en) 2011-10-14 2017-11-30 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN103998024A (en) 2011-12-22 2014-08-20 勃林格殷格翰国际有限公司 Immediate release multi unit pellet system
US9212166B2 (en) 2012-01-20 2015-12-15 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
EP2806858A1 (en) 2012-01-24 2014-12-03 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
CN104114158A (en) 2012-02-21 2014-10-22 埃斯特韦实验室有限公司 Oral pharmaceutical compositions of dabigatran etexilate
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
EP2834224B1 (en) 2012-04-02 2018-06-06 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
CN103387566B (en) * 2012-05-09 2015-09-09 上海医药工业研究院 Prepare the method for 3-[[[2-[[(4-cyano-phenyl) is amino] methyl]-1-methyl isophthalic acid H-benzoglyoxaline-5-base] carbonyl] (pyridine-2-base) is amino] ethyl propionate
CN103420980A (en) * 2012-05-22 2013-12-04 北京美倍他药物研究有限公司 Dabigatran derivatives
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
US9365544B2 (en) * 2012-07-16 2016-06-14 Interquim, S.A. Process for the preparation of intermediates for the synthesis of Dabigatran Etexilate, and crystalline forms of said intermediates
CN102766134B (en) * 2012-07-19 2014-06-25 北京普禄德医药科技有限公司 Dabigatran etexilate derivative and preparation method and application thereof
EP2881394B1 (en) * 2012-07-31 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Condensed ring heterocyclic compound
DK2880026T3 (en) 2012-08-03 2017-06-06 Bristol Myers Squibb Co DIHYDROPYRIDON-P1 AS A FACTOR XIA INHIBITORS
SI2882734T1 (en) 2012-08-03 2017-01-31 Bristol-Myers Squibb Company Dihydropyridone as factor xia inhibitors
WO2014041559A2 (en) * 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of dabigatran etexilate and intermediates thereof
EP2722033A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
WO2014060561A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
US9533971B2 (en) 2012-10-29 2017-01-03 Biophore India Pharmaceuticals Pvt. Ltd Process for the synthesis of dabigatran and its intermediates
US10077251B2 (en) 2012-10-29 2018-09-18 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of Dabigatran Etexilate and its intermediates
CN102977077A (en) * 2012-11-28 2013-03-20 浙江燎原药业有限公司 Method for preparing dabigatran etexilate intermediate
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103044404A (en) * 2013-01-14 2013-04-17 中国药科大学 Dabigatran derivatives, and preparation method and application thereof in antithrombosis
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
CN103224469A (en) * 2013-05-16 2013-07-31 上海应用技术学院 Pradaxa analogue with fluorine-containing group modified benzene ring as center and synthesis method thereof
UY35592A (en) 2013-06-03 2014-12-31 Bayer Pharma AG BENZOXAZOLES REPLACED
WO2014195230A1 (en) 2013-06-03 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted benzoxazoles
CN103288744A (en) * 2013-06-04 2013-09-11 上海应用技术学院 Fluorine group-containing-modified dabigatran etexilate analogue and synthetic method thereof
EP2853260A1 (en) 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
NO2760821T3 (en) 2014-01-31 2018-03-10
ES2784841T3 (en) 2014-01-31 2020-10-01 Bristol Myers Squibb Co Macrocycles with P2 'aromatic groups as factor XIa inhibitors
WO2015128875A2 (en) 2014-02-26 2015-09-03 Megafine Pharma (P) Ltd. A process for preparation of dabigatran etexilate mesylate and intermediates thereof
WO2015137680A1 (en) * 2014-03-10 2015-09-17 동아에스티 주식회사 Pharmaceutical composition for treating or preventing stroke and systemic embolism
IN2014MU01042A (en) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2929884A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
CN104230888A (en) * 2014-06-03 2014-12-24 长春工业大学 Preparation method of benzimidazole compound
CN105218519A (en) * 2014-06-04 2016-01-06 天津药物研究院 A kind of preparation method of dabigatran etexilate intermediate
CN104003977B (en) * 2014-06-05 2016-04-13 雅本化学股份有限公司 The preparation method of N-(2-chloromethyl-1-methyl isophthalic acid H-benzoglyoxaline-5-acyl group)-N-(pyridine-2-base)-3-alanine ethyl ester
DE102014108210A1 (en) 2014-06-11 2015-12-17 Dietrich Gulba rodenticide
CN104045628B (en) * 2014-06-13 2019-04-09 深圳翰宇药业股份有限公司 The purification process of benzimidizole derivatives
CN105315257A (en) * 2014-06-24 2016-02-10 华仁药业股份有限公司 Synthetic and purifying method of dabigatran etexilate
WO2016019849A1 (en) * 2014-08-06 2016-02-11 四川海思科制药有限公司 Dabigatran carboalkoxy derivative, preparation method therefor, and pharmaceutical use thereof
WO2016019848A1 (en) * 2014-08-06 2016-02-11 四川海思科制药有限公司 Dabigatran thioester derivative, preparation method therefor, and pharmaceutical use thereof
NO2721243T3 (en) 2014-10-01 2018-10-20
CN104592204B (en) * 2014-12-26 2017-05-17 华润赛科药业有限责任公司 Dabigatran derivatives as well as preparation method and application thereof
CN104650037A (en) * 2014-12-30 2015-05-27 青岛黄海制药有限责任公司 Synthesis method of dabigatran etexilate
TR201502223A2 (en) 2015-02-25 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dronedarone and dabigatran
CN104628733A (en) * 2015-03-02 2015-05-20 中国药科大学 Tetrahydrobenzo[4,5] imidazo[1,2-a] pyrazine thrombin inhibitors
JP6742348B2 (en) 2015-06-19 2020-08-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Diamide macrocycles as factor XIA inhibitors
CN104987323B (en) * 2015-07-10 2017-08-22 浙江美诺华药物化学有限公司 A kind of preparation method of dabigatran etcxilate
EP3324946A1 (en) 2015-07-20 2018-05-30 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical formulations of dabigatran free base
JP6816103B2 (en) 2015-07-29 2021-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Factor XIa inhibitor of novel macrocycle carrying non-aromatic P2'group
KR102697816B1 (en) 2015-08-05 2024-08-21 브리스톨-마이어스 스큅 컴퍼니 Novel substituted glycine-derived FXIA inhibitors
CN105294651A (en) * 2015-09-23 2016-02-03 烟台东诚药业集团股份有限公司 Method for synthesizing and preparing pradaxa formamidine intermediates
CN106866626A (en) * 2015-12-14 2017-06-20 天津药物研究院有限公司 A kind of preparation method of dabigatran etexilate intermediate
CN105481831B (en) * 2015-12-16 2018-06-12 开封明仁药业有限公司 A kind of method for preparing dabigatran etexilate intermediate
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
CN105566297A (en) * 2015-12-31 2016-05-11 哈药集团技术中心 Preparation method of dabigatran etexilate mesylate
EP3423458A1 (en) 2016-03-02 2019-01-09 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
CN105669651B (en) * 2016-03-07 2018-03-06 山东罗欣药业集团股份有限公司 A kind of preparation technology of dabigatran etexilate methanesulfonate
CN106397400A (en) * 2016-04-14 2017-02-15 江苏康缘药业股份有限公司 Preparation method for dabigatran etexilate
TR201606697A2 (en) 2016-05-20 2017-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi NEW ORAL PHARMACEUTICAL FORMULATIONS OF DABIGATRA
CN106349221A (en) * 2016-08-29 2017-01-25 常州市阳光药业有限公司 Preparation method of high-purity dabigatran etexilate
TR201617984A2 (en) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN
EP3332771A1 (en) 2016-12-07 2018-06-13 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayered tablet compositions of dabigatran
JP2018184375A (en) 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tablet comprising dabigatran etexilate or pharmaceutically acceptable salt thereof and method for producing the same
TR201706848A2 (en) 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING DABIGATRAN ETEXCLATE
WO2019004980A2 (en) 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate
CN109010249A (en) * 2017-06-08 2018-12-18 上海美悦生物科技发展有限公司 Injection dabigatran etcxilate pharmaceutical composition and its preparation method and application
KR20190036857A (en) 2017-09-28 2019-04-05 한미약품 주식회사 Composite capsule formulation comprising dabigatran etexilate
TR201722323A2 (en) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral pharmaceutical compositions of dabigatran
TR201722186A2 (en) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of dabigatran
TR201722630A2 (en) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
WO2019196111A1 (en) * 2018-04-13 2019-10-17 上海交通大学医学院附属瑞金医院 Anti-tumor multidrug resistance of heteroaryl amide compound, use in treatment of cancers and protein-drug molecular complex
CN108864047A (en) * 2018-07-02 2018-11-23 河南师范大学 A kind of preparation method of non-peptide batroxobin inhibitor dabigatran etcxilate
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
CN111606885A (en) * 2020-06-18 2020-09-01 安徽鼎旺医药有限公司 Dabigatran etexilate mesylate and preparation method thereof
CN113929661A (en) * 2020-06-29 2022-01-14 石药集团恩必普药业有限公司 Dabigatran etexilate intermediate and preparation method thereof
EP4070658A1 (en) 2021-04-06 2022-10-12 BIORoxx GmbH Use of anticoagulant active compounds as rodenticide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675405A (en) * 1984-09-21 1987-06-23 American Home Products Corporation Quinoline compounds as antiallergic and antithrombotic agents
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
CA2134192A1 (en) * 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675276B2 (en) 2014-11-03 2020-06-09 Hangzhou Solipharma Co., Ltd. Dosing preparation of dabigatran etexilate or a salt thereof and a preparation method thereof

Also Published As

Publication number Publication date
BR9807843A (en) 2001-06-19
EA003697B1 (en) 2003-08-28
NO313879B1 (en) 2002-12-16
NO2008012I1 (en) 2008-08-25
NL300349I1 (en) 2008-08-01
LU91437I9 (en) 2019-01-02
KR100619458B1 (en) 2006-09-08
AU6399198A (en) 1998-09-09
NO993945D0 (en) 1999-08-17
AU742593C (en) 2004-04-29
EE04716B1 (en) 2006-10-16
AR010896A1 (en) 2000-07-12
DE122008000020I1 (en) 2008-08-07
ES2199426T4 (en) 2007-08-16
IL130812A (en) 2005-12-18
ATE239712T1 (en) 2003-05-15
JP2001509815A (en) 2001-07-24
SK285432B6 (en) 2007-01-04
BR9807843B1 (en) 2010-06-29
CA2277949A1 (en) 1998-08-27
CZ297768B6 (en) 2007-03-28
SI0966454T1 (en) 2003-10-31
HUP0001116A3 (en) 2001-07-30
CN1088702C (en) 2002-08-07
NZ337323A (en) 2000-11-24
PL195551B1 (en) 2007-10-31
PT966454E (en) 2003-09-30
CZ291599A3 (en) 2000-06-14
WO1998037075A1 (en) 1998-08-27
NO2008012I2 (en) 2010-05-25
TW588047B (en) 2004-05-21
FR08C0025I2 (en) 2009-11-20
HRP980082A2 (en) 1998-10-31
CA2277949C (en) 2006-10-03
HU223754B1 (en) 2005-01-28
NO2021005I1 (en) 2021-02-05
PE121699A1 (en) 1999-12-08
HUP0001116A2 (en) 2001-05-28
SA98190047B1 (en) 2005-12-12
EG24144A (en) 2008-08-06
ES2199426T3 (en) 2004-02-16
CN1248251A (en) 2000-03-22
DK0966454T3 (en) 2003-09-01
KR20000071066A (en) 2000-11-25
EE9900359A (en) 2000-02-15
PL335154A1 (en) 2000-04-10
LTC0966454I2 (en) 2021-08-10
YU38799A (en) 2001-03-07
NO993945L (en) 1999-10-15
JP3343359B2 (en) 2002-11-11
FR08C0025I1 (en) 2008-07-18
HRP980082B1 (en) 2003-08-31
TR199902017T2 (en) 1999-10-21
BG64558B1 (en) 2005-07-29
EP0966454A1 (en) 1999-12-29
EP0966454B1 (en) 2003-05-07
RS49686B (en) 2007-12-31
BG103655A (en) 2000-02-29
CO4920237A1 (en) 2000-05-29
NL300349I2 (en) 2008-10-01
DE59808281D1 (en) 2003-06-12
MY129408A (en) 2007-03-30
IL130812A0 (en) 2001-01-28
SK112199A3 (en) 2000-05-16
EA199900746A1 (en) 2000-08-28
LTPA2008008I1 (en) 2021-02-25
LU91437I2 (en) 2008-07-14
HK1025096A1 (en) 2000-11-03

Similar Documents

Publication Publication Date Title
AU742593B2 (en) Disubstituted bicyclic heterocycles, their production and use as medicaments
US6469039B1 (en) Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions
US6414008B1 (en) Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
US6121308A (en) Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions
US7714009B2 (en) Nitrogen-containing fused heterocyclic compounds
US7189743B2 (en) Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide
AU4903399A (en) Benzimidazoles, production thereof and use thereof as medicaments
US6593355B2 (en) Benzimidazoles with antithrombotic activity
EP1244636A1 (en) Benzimidazoles, production thereof and the use thereof as antithrombotic
DE19751939A1 (en) New aryl-substituted bi:cyclic heterocyclic compounds
MXPA99007454A (en) Disubstituted bicyclic heterocycles, their production and use as medicaments
DE19706229A1 (en) New aryl-substituted bi:cyclic heterocyclic compounds
CZ200147A3 (en) Benzimidazoles, process of their preparation and use as medicaments
NZ538491A (en) Novel prodrugs of 1-methyl-2(4-amidinophenylaminomethyl)-benzimidazol-5-YL-carboxylic acid-(N-2-pyridil-N-2-hydroxycarbonylethyl)-amide, production and use thereof as medicaments

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20030704

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20031002